
<html lang="en"     class="pb-page"  data-request-id="9c79480f-7503-4a09-90cc-7791ff476e25"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/jm4003632;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2013.56.issue-11;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of 2-{3-[2-(1-Isopropyl-3-methyl-1H-1,2–4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): A β-Sparing Phosphoinositide 3-Kinase Inhibitor with High Unbound Exposure and Robust in Vivo Antitumor Activity" /></meta><meta name="dc.Creator" content="Chudi O.  Ndubaku" /></meta><meta name="dc.Creator" content="Timothy P.  Heffron" /></meta><meta name="dc.Creator" content="Steven T.  Staben" /></meta><meta name="dc.Creator" content="Matthew  Baumgardner" /></meta><meta name="dc.Creator" content="Nicole  Blaquiere" /></meta><meta name="dc.Creator" content="Erin  Bradley" /></meta><meta name="dc.Creator" content="Richard  Bull" /></meta><meta name="dc.Creator" content="Steven  Do" /></meta><meta name="dc.Creator" content="Jennafer  Dotson" /></meta><meta name="dc.Creator" content="Danette  Dudley" /></meta><meta name="dc.Creator" content="Kyle A.  Edgar" /></meta><meta name="dc.Creator" content="Lori S.  Friedman" /></meta><meta name="dc.Creator" content="Richard  Goldsmith" /></meta><meta name="dc.Creator" content="Robert A.  Heald" /></meta><meta name="dc.Creator" content="Aleksandr  Kolesnikov" /></meta><meta name="dc.Creator" content="Leslie  Lee" /></meta><meta name="dc.Creator" content="Cristina  Lewis" /></meta><meta name="dc.Creator" content="Michelle  Nannini" /></meta><meta name="dc.Creator" content="Jim  Nonomiya" /></meta><meta name="dc.Creator" content="Jodie  Pang" /></meta><meta name="dc.Creator" content="Steve  Price" /></meta><meta name="dc.Creator" content="Wei Wei  Prior" /></meta><meta name="dc.Creator" content="Laurent  Salphati" /></meta><meta name="dc.Creator" content="Steve  Sideris" /></meta><meta name="dc.Creator" content="Jeffery J.  Wallin" /></meta><meta name="dc.Creator" content="Lan  Wang" /></meta><meta name="dc.Creator" content="BinQing  Wei" /></meta><meta name="dc.Creator" content="Deepak  Sampath" /></meta><meta name="dc.Creator" content="Alan G.  Olivero" /></meta><meta name="dc.Description" content="Dysfunctional signaling through the phosphoinositide 3-kinase (PI3K)/AKT/mTOR pathway leads to uncontrolled tumor proliferation. In the course of the discovery of novel benzoxepin PI3K inhibitors, ..." /></meta><meta name="Description" content="Dysfunctional signaling through the phosphoinositide 3-kinase (PI3K)/AKT/mTOR pathway leads to uncontrolled tumor proliferation. In the course of the discovery of novel benzoxepin PI3K inhibitors, ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="June 3, 2013" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm4003632" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2013 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm4003632" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm4003632" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm4003632" /></link>
        
    
    

<title>Discovery of 2-{3-[2-(1-Isopropyl-3-methyl-1H-1,2–4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): A β-Sparing Phosphoinositide 3-Kinase Inhibitor with High Unbound Exposure and Robust in Vivo Antitumor Activity | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm4003632" /></meta><meta property="og:title" content="Discovery of 2-{3-[2-(1-Isopropyl-3-methyl-1H-1,2–4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): A β-Sparing Phosphoinositide 3-Kinase Inhibitor with High Unbound Exposure and Robust in Vivo Antitumor Activity" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/large/jm-2013-003632_0016.jpeg" /></meta><meta property="og:description" content="Dysfunctional signaling through the phosphoinositide 3-kinase (PI3K)/AKT/mTOR pathway leads to uncontrolled tumor proliferation. In the course of the discovery of novel benzoxepin PI3K inhibitors, we observed a strong dependency of in vivo antitumor activity on the free-drug exposure. By lowering the intrinsic clearance, we derived a set of imidazobenzoxazepin compounds that showed improved unbound drug exposure and effectively suppressed growth of tumors in a mouse xenograft model at low drug dose levels. One of these compounds, GDC-0032 (11l), was progressed to clinical trials and is currently under phase I evaluation as a potential treatment for human malignancies." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm4003632"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm4003632">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm4003632&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm4003632&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm4003632&amp;href=/doi/10.1021/jm4003632" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2013</span><span class="cit-fg-volume">, 56</span><span class="cit-fg-issue">, 11</span><span class="cit-fg-pageRange">, 4597-4610</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/56/11" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm400336x" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm400364h" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of 2-{3-[2-(1-Isopropyl-3-methyl-1<i>H</i>-1,2–4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-<i>d</i>][1,4]oxazepin-9-yl]-1<i>H</i>-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): A β-Sparing Phosphoinositide 3-Kinase Inhibitor with High Unbound Exposure and Robust in Vivo Antitumor Activity</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Chudi+O.++Ndubaku">Chudi O. Ndubaku</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Timothy+P.++Heffron">Timothy P. Heffron</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Steven+T.++Staben">Steven T. Staben</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Matthew++Baumgardner">Matthew Baumgardner</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Nicole++Blaquiere">Nicole Blaquiere</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Erin++Bradley">Erin Bradley</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Richard++Bull">Richard Bull</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Steven++Do">Steven Do</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jennafer++Dotson">Jennafer Dotson</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Danette++Dudley">Danette Dudley</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kyle+A.++Edgar">Kyle A. Edgar</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lori+S.++Friedman">Lori S. Friedman</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Richard++Goldsmith">Richard Goldsmith</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Robert+A.++Heald">Robert A. Heald</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Aleksandr++Kolesnikov">Aleksandr Kolesnikov</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Leslie++Lee">Leslie Lee</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Cristina++Lewis">Cristina Lewis</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michelle++Nannini">Michelle Nannini</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jim++Nonomiya">Jim Nonomiya</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jodie++Pang">Jodie Pang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Steve++Price">Steve Price</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Wei+Wei++Prior">Wei Wei Prior</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Laurent++Salphati">Laurent Salphati</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Steve++Sideris">Steve Sideris</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jeffery+J.++Wallin">Jeffery J. Wallin</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lan++Wang">Lan Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=BinQing++Wei">BinQing Wei</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Deepak++Sampath">Deepak Sampath</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Alan+G.++Olivero">Alan G. Olivero</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text"><sup>†</sup>Departments of Discovery Chemistry, <sup>‡</sup>Drug Metabolism and Pharmacokinetics, <sup>§</sup>Translational Oncology, and <sup>∥</sup>Biochemical Pharmacology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">⊥</span> <span class="aff-text">Argenta Discovery, 8-9 Spire Green Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United Kingdom</span></div><div class="corresp-info"><strong>*</strong>Phone: 650-225-2923 (C.O.N.); +1-(650)-467-3214 (T.P.H.). E-mail: <a href="/cdn-cgi/l/email-protection#24474c51404d4a6443414a410a474b49"><span class="__cf_email__" data-cfemail="a7c4cfd2c3cec9e7c0c2c9c289c4c8ca">[email protected]</span></a> (C.O.N.); <a href="/cdn-cgi/l/email-protection#304458555656425f5e7057555e551e535f5d"><span class="__cf_email__" data-cfemail="790d111c1f1f0b1617391e1c171c571a1614">[email protected]</span></a> (T.P.H.).</div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm4003632&amp;href=/doi/10.1021%2Fjm4003632" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2013</span></span><span class="cit-volume">, 56</span><span class="cit-issue">, 11</span><span class="cit-pageRange">, 4597–4610</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">May 10, 2013</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>11 March 2013</li><li><span class="item_label"><b>Published</b> online</span>3 June 2013</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 13 June 2013</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm4003632" title="DOI URL">https://doi.org/10.1021/jm4003632</a></div><div class="article_header-article-copyright"><strong>Copyright © 2013 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D4597%26pageCount%3D14%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DChudi%2BO.%2BNdubaku%252C%2BTimothy%2BP.%2BHeffron%252C%2BSteven%2BT.%2BStaben%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D56%26issueNum%3D11%26contentID%3Djm4003632%26title%3DDiscovery%2Bof%2B2-%257B3-%255B2-%25281-Isopropyl-3-methyl-1H-1%252C2%25E2%2580%25934-triazol-5-yl%2529-5%252C6-dihydrobenzo%255Bf%255Dimidazo%255B1%252C2-d%255D%255B1%252C4%255Doxazepin-9-yl%255D-1H-pyrazol-1-yl%257D-2-methylpropanamide%2B%2528GDC-0032%2529%253A%2BA%2B%25CE%25B2-Sparing%2BPhosphoinositide%2B3-Kinase%2BInhibitor%2Bwith%2BHigh%2BUnbound%2BExposure%2Band%2BRobust%2Bin%2BVivo%2BAntitumor%2BActivity%26numPages%3D14%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D4610%26publicationDate%3DJune%2B2013">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm4003632"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">4909</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">117</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm4003632" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of 2-{3-[2-(1-Isopropyl-3-methyl-1H-1,2–4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): A β-Sparing Phosphoinositide 3-Kinase Inhibitor with High Unbound Exposure and Robust in Vivo Antitumor Activity&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Chudi&quot;,&quot;last_name&quot;:&quot;O. Ndubaku&quot;},{&quot;first_name&quot;:&quot;Timothy&quot;,&quot;last_name&quot;:&quot;P. Heffron&quot;},{&quot;first_name&quot;:&quot;Steven&quot;,&quot;last_name&quot;:&quot;T. Staben&quot;},{&quot;first_name&quot;:&quot;Matthew&quot;,&quot;last_name&quot;:&quot;Baumgardner&quot;},{&quot;first_name&quot;:&quot;Nicole&quot;,&quot;last_name&quot;:&quot;Blaquiere&quot;},{&quot;first_name&quot;:&quot;Erin&quot;,&quot;last_name&quot;:&quot;Bradley&quot;},{&quot;first_name&quot;:&quot;Richard&quot;,&quot;last_name&quot;:&quot;Bull&quot;},{&quot;first_name&quot;:&quot;Steven&quot;,&quot;last_name&quot;:&quot;Do&quot;},{&quot;first_name&quot;:&quot;Jennafer&quot;,&quot;last_name&quot;:&quot;Dotson&quot;},{&quot;first_name&quot;:&quot;Danette&quot;,&quot;last_name&quot;:&quot;Dudley&quot;},{&quot;first_name&quot;:&quot;Kyle&quot;,&quot;last_name&quot;:&quot;A. Edgar&quot;},{&quot;first_name&quot;:&quot;Lori&quot;,&quot;last_name&quot;:&quot;S. Friedman&quot;},{&quot;first_name&quot;:&quot;Richard&quot;,&quot;last_name&quot;:&quot;Goldsmith&quot;},{&quot;first_name&quot;:&quot;Robert&quot;,&quot;last_name&quot;:&quot;A. Heald&quot;},{&quot;first_name&quot;:&quot;Aleksandr&quot;,&quot;last_name&quot;:&quot;Kolesnikov&quot;},{&quot;first_name&quot;:&quot;Leslie&quot;,&quot;last_name&quot;:&quot;Lee&quot;},{&quot;first_name&quot;:&quot;Cristina&quot;,&quot;last_name&quot;:&quot;Lewis&quot;},{&quot;first_name&quot;:&quot;Michelle&quot;,&quot;last_name&quot;:&quot;Nannini&quot;},{&quot;first_name&quot;:&quot;Jim&quot;,&quot;last_name&quot;:&quot;Nonomiya&quot;},{&quot;first_name&quot;:&quot;Jodie&quot;,&quot;last_name&quot;:&quot;Pang&quot;},{&quot;first_name&quot;:&quot;Steve&quot;,&quot;last_name&quot;:&quot;Price&quot;},{&quot;first_name&quot;:&quot;Wei&quot;,&quot;last_name&quot;:&quot;Wei Prior&quot;},{&quot;first_name&quot;:&quot;Laurent&quot;,&quot;last_name&quot;:&quot;Salphati&quot;},{&quot;first_name&quot;:&quot;Steve&quot;,&quot;last_name&quot;:&quot;Sideris&quot;},{&quot;first_name&quot;:&quot;Jeffery&quot;,&quot;last_name&quot;:&quot;J. Wallin&quot;},{&quot;first_name&quot;:&quot;Lan&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;BinQing&quot;,&quot;last_name&quot;:&quot;Wei&quot;},{&quot;first_name&quot;:&quot;Deepak&quot;,&quot;last_name&quot;:&quot;Sampath&quot;},{&quot;first_name&quot;:&quot;Alan&quot;,&quot;last_name&quot;:&quot;G. Olivero&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2013&quot;,&quot;month&quot;:&quot;06&quot;,&quot;day&quot;:&quot;03&quot;,&quot;issue&quot;:&quot;11&quot;,&quot;volume&quot;:&quot;56&quot;,&quot;pages&quot;:&quot;4597-4610&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm4003632&quot;},&quot;abstract&quot;:&quot;Dysfunctional signaling through the phosphoinositide 3-kinase (PI3K)/AKT/mTOR pathway leads to uncontrolled tumor proliferation. In the course of the discovery of novel benzoxepin PI3K inhibitors, we observed a strong dependency of in vivo antitumor activity on the free-drug exposure. By lowering the intrinsic clearance, we derived a set of imidazobenzoxazepin compounds that showed improved unbound drug exposure and effectively suppressed growth of tumors in a mouse xenograft model at low drug dose levels. One of these compounds, GDC-0032 (11l), was progressed to clinical trials and is currently under phase I evaluation as a potential treatment for human malignancies.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm4003632&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm4003632" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm4003632&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm4003632" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm4003632&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm4003632" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm4003632&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm4003632&amp;href=/doi/10.1021/jm4003632" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm4003632" /></input><a href="/doi/pdf/10.1021/jm4003632" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm4003632&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm4003632%26sid%3Dliteratum%253Aachs%26pmid%3D23662903%26genre%3Darticle%26aulast%3DNdubaku%26date%3D2013%26atitle%3DDiscovery%2Bof%2B2-%257B3-%255B2-%25281-Isopropyl-3-methyl-1H-1%252C2%25E2%2580%25934-triazol-5-yl%2529-5%252C6-dihydrobenzo%255Bf%255Dimidazo%255B1%252C2-d%255D%255B1%252C4%255Doxazepin-9-yl%255D-1H-pyrazol-1-yl%257D-2-methylpropanamide%2B%2528GDC-0032%2529%253A%2BA%2B%25CE%25B2-Sparing%2BPhosphoinositide%2B3-Kinase%2BInhibitor%2Bwith%2BHigh%2BUnbound%2BExposure%2Band%2BRobust%2Bin%2BVivo%2BAntitumor%2BActivity%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D56%26issue%3D11%26spage%3D4597%26epage%3D4610%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292201" title="Scaffolds">Scaffolds</a>,</li><li><a href="/action/doSearch?ConceptID=290676" title="Substituents">Substituents</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292153" title="Tumors">Tumors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/56/11" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jmcmar.2013.56.issue-11/production/jmcmar.2013.56.issue-11.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/medium/jm-2013-003632_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/large/jm-2013-003632_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4003632&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Dysfunctional signaling through the phosphoinositide 3-kinase (PI3K)/AKT/mTOR pathway leads to uncontrolled tumor proliferation. In the course of the discovery of novel benzoxepin PI3K inhibitors, we observed a strong dependency of in vivo antitumor activity on the free-drug exposure. By lowering the intrinsic clearance, we derived a set of imidazobenzoxazepin compounds that showed improved unbound drug exposure and effectively suppressed growth of tumors in a mouse xenograft model at low drug dose levels. One of these compounds, GDC-0032 (<b>11l</b>), was progressed to clinical trials and is currently under phase I evaluation as a potential treatment for human malignancies.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51673" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51673" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The phosphoinositide 3-kinase (PI3K) enzymes are lipid kinases responsible for the conversion of membrane-bound 4,5-phosphatidylinositolbisphosphate (PIP2) into 3,4,5-phosphatidylinositoltrisphosphate (PIP3).<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1, 2)</a> This signaling event occurs in response to various extracellular triggers including activation of receptor tyrosine kinases (RTKs) and G-protein coupled receptors (GPCRs). Phosphorylation to PIP3 in turn promotes downstream activation of Akt and mTOR, which influence several functions important to cellular integrity including proliferation, evasion of apoptosis, metabolism, and angiogenesis. Not surprisingly, perturbations of this crucial pathway are highly associated with cancer. While there are four class I PI3K isoforms (α, β, δ, and γ) implicated in the signaling cascade, the aberration most common to cancer is the amplification or activating mutation of PI3Kα.<a onclick="showRef(event, 'ref3 ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref3 ref4 ref5">(3-5)</a> Moreover, inactivation or genetic deletion of the negative regulator of this pathway, phosphatase and tensin homologue (PTEN), is also common.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> As a result, small molecule inhibitors that target the PI3Ks have been intensely pursued as potential treatments for various types of cancers, and some of these have recently advanced into the clinic.<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7, 8)</a></div><div class="NLM_p">We recently introduced a novel class of PI3K inhibitors containing a central benzoxepin scaffold (e.g., compound <b>2</b>, Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>).<a onclick="showRef(event, 'ref9 ref10 ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref9 ref10 ref11 ref12">(9-12)</a> This class of inhibitors was originally discovered by structure-guided optimization of hits from high-throughput screening. Optimized compounds displayed good levels of potency toward the PI3Ks as well as high selectivity over off-targets. Strong structural rationale also exists to suggest why variations of the substituents on the benzoxepin scaffold lead to isoform selectivity for PI3Kα over PI3Kβ, an important aspect of mitigating potentially adverse effects on glucose metabolism.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Very recently, we showed that modifications to the heterocyclic central subunit as well as the peripheral substituents yielded druglike compounds such as <b>2</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>), which had sufficient exposure in vivo to achieve tumor growth inhibition (TGI) in a mouse xenograft study.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Despite potent in vitro activity, better even than the clinical compound <b>1</b> (GDC-0941, Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>),<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a><b>2</b> only achieved modest tumor growth inhibition in an MCF7-neo/HER2 xenograft breast cancer model even when dosed at its maximum absorbable dose due to solubility limitations (100 mg/kg, Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>A). In the graph showing the %TGI by drug dose, GDC-0941 achieves greater tumor growth inhibition at lower doses than <b>2</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>B). This outcome was evident despite <b>2</b> achieving significantly higher total area under the concentration–time curve (AUC<sub>tot</sub>) than <b>1</b> in vivo and being slightly more potent in the proliferation assay with the same cell line evaluated in the xenograft study (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). According to the free drug hypothesis, in the absence of active transport in vivo, only the steady-state unbound drug concentration available to engage the target of interest will have the ability to impart a pharmacological effect.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Our group had prior experience with this phenomenon during the discovery of PI3K/mTOR inhibitor GDC-0980.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> We therefore reasoned that the minimal antitumor activity observed for <b>2</b> was largely due to its low solubility and limited in vivo unbound exposure achieved. The objective was then to identify molecules with improved solubility and overall lower unbound clearance (CL<sub>u</sub>).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Comparison of Clinical Compound GDC-0941 (<b>1</b>) and Thiazolobenzoxepin (<b>2</b>)</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/medium/jm-2013-003632_0018.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" colspan="6" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">mouse PK @  100 mg/kg<a class="ref internalNav" href="#t1fn6" aria-label="f">f</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">PI3Kα IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">p-Akt (S473) IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">MCF7-neo/HER2 IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">cLogD<a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center">kinetic solubility (μM)<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a></th><th class="colsep0 rowsep0" align="center">AUC<sub>tot</sub>(μM·h, p.o.)</th><th class="colsep0 rowsep0" align="center">AUC<sub>u</sub>(μM·h, p.o.)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">3.0</td><td class="colsep0 rowsep0" align="left">0.007</td><td class="colsep0 rowsep0" align="left">0.290</td><td class="colsep0 rowsep0" align="left">2.1</td><td class="colsep0 rowsep0" align="left">37.0</td><td class="colsep0 rowsep0" align="left">80.3</td><td class="colsep0 rowsep0" align="left">3.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="left"><0.5</td><td class="colsep0 rowsep0" align="left">0.016</td><td class="colsep0 rowsep0" align="left">0.195</td><td class="colsep0 rowsep0" align="left">3.8 (3.9)<a class="ref internalNav" href="#t1fn7" aria-label="g">g</a></td><td class="colsep0 rowsep0" align="left">4.7</td><td class="colsep0 rowsep0" align="left">275</td><td class="colsep0 rowsep0" align="left">0.55</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">IC<sub>50</sub> data are an average of at least three independent experiments. Each value has a standard deviation of less than one geometric mean.</p></div><div class="footnote" id="t1fn2"><sup>b</sup><p class="last">Determined with ELISA assay.</p></div><div class="footnote" id="t1fn3"><sup>c</sup><p class="last">Cell proliferation inhibition over 72–96 h.</p></div><div class="footnote" id="t1fn4"><sup>d</sup><p class="last">Calculated using MoKa software.</p></div><div class="footnote" id="t1fn5"><sup>e</sup><p class="last">Measurements carried out in PBS pH 7.2 buffer (23 °C) with serial dilution and LC-CLND quantification.</p></div><div class="footnote" id="t1fn6"><sup>f</sup><p class="last">Adult female nude mice were administered with compound suspended in MCT via oral gavage.</p></div><div class="footnote" id="t1fn7"><sup>g</sup><p class="last">Measured logD value.</p></div></div></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/medium/jm-2013-003632_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/large/jm-2013-003632_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (A) Dose curves of tumor volume response of compound <b>2</b> against MCF7-neo/HER2 xenografts in mice relative to vehicle over the course of 21 days (0.5% methycellulose/0.2% Tween-80). (B) Comparison of % tumor growth inhibition of compounds <b>1</b> and <b>2</b> in MCF7-neo/HER2 xenografts at the four doses evaluated.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/large/jm-2013-003632_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4003632&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In order to achieve this end, we envisioned using physicochemical parameters to guide these optimizations. In particular, one property that we quickly deemed was most important was the calculated distribution coefficient (cLogD), a measure of molecular lipophilicity. While other factors such as acidity and molecular size and shape can influence properties such as in vitro protein binding and solubility, reducing cLogD has been shown to correlate with lower unbound clearance.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Therefore, reducing cLogD became a key strategy that we employed to increase unbound exposure in vivo. Specifically, the thiazole central subunit was targeted for modification in order to reduce overall lipophilicity.</div><div class="NLM_p">In a previous communication,<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> we described a set of novel benzoxepin scaffolds with potent activity against PI3Kα, wherein the thiazolobenzoxepin subseries was selected for further optimization (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>). All of the scaffolds described were designed to adopt similar binding topologies in their low energy conformation and make the same requisite polar and van der Waals interactions in the ligand binding site. It is important to note that, for the five scaffolds (<b>A</b>–<b>E</b>) examined, imidazobenzoxazepin (<b>E</b>) was determined to have the lowest inherent cLogD value in analogous cases (e.g., • = Me, Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>), albeit very similar to pyrazolobenzoxazepin (<b>C</b>).<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/medium/jm-2013-003632_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/large/jm-2013-003632_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Scaffold replacements to reduce lipophilic nature of thiazolobenzoxepin <b>B</b> (cLogD values are given for analogues terminated by methyl groups).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/large/jm-2013-003632_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4003632&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">On the basis of this singular factor, imidazobenzoxazepin (<b>E</b>) may be expected to have decreased unbound clearance and improved solubility. We targeted analogues within the imidazobenzoxazepin scaffold that were previously determined to be optimal for the thienobenzoxepin (<b>A</b>) and the thiazolobenzoxepin (<b>B</b>) series based upon prior structural knowledge.<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11, 12)</a> In particular, we selected to retain the pyrazole substituent at the 8-position and the triazole at the 2-position (based on the thienobenzoxepin numbering, Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>) because we were content with the benefits that they provided with regards to potency, selectivity, and pharmacokinetics.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05717" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05717" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Chemistry</h3><div class="NLM_p">The preparation of imidazobenzoxazepin compounds was carried out in a similar vein to the strategies described previously.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> One distinct feature of this scaffold is the presence of the bridgehead nitrogen in the fused tricycle. To fashion the tricyclic core, we subjected commercially available salicaldehyde <b>3</b> to a condensation reaction with glyoxal and two equivalents of ammonia to provide <b>4</b> (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>). Subsequently, <b>4</b> was subjected to 7-membered ring annulation with 1,2-dibromoethane in high dilution to minimize undesired bimolecular elimination (E2) byproduct. The corresponding imidazobenzoxazepin tricycle (<b>5</b>) was then functionalized at the C-4 position of the imidazole ring employing a two-step sequence. We originally observed that electrophilic aromatic halogenation occurred preferentially at C-5 at a rate faster than at C-4 in line with previous reports.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Thus, use of at least two equivalents of <i>N</i>-iodosuccinimide provided the di-iodo intermediate <b>6</b> in good yield, and no further iodination was observed beyond the diiodide. This compound was readily monodeiodinated with a Grignard reagent, taking advantage of the heightened reactivity at C-5 to adjust the functionality to the desired bromoiodide <b>7</b>.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/medium/jm-2013-003632_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/large/jm-2013-003632_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthetic Route to the Imidazobenzoxazepin Bromoiodide Core</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/large/jm-2013-003632_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4003632&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">At this point, the synthesis of the various analogues diverged. The compounds were assembled by carbonylative amidation of bromoiodide <b>7</b> selectively at the iodide to generate the primary amide <b>8</b> (Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>).<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Regioselective triazole formation can be carried out with a variety of hydrazines as previously described.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Finally, reaction of the bromide with a diversity of pyrazole boronic acids or esters under Suzuki conditions provided the compounds (<b>11a</b>–<b>l</b>) described in this manuscript.</div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/medium/jm-2013-003632_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/large/jm-2013-003632_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Elaboration of Bromoiodide <b>7</b> to PI3K Inhibitors (<b>11a</b>–<b>l</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/large/jm-2013-003632_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4003632&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> In Vitro Activity</h3><div class="NLM_p">Our initial investigations began with measuring the effect that changing the groups on the pyrazole and triazole substituents had on PI3Kα biochemical potency, selectivity over PI3Kβ and cell-based activity (p-Akt and MCF7-neo/HER2 proliferation). In addition, the mouse liver microsomal intrinsic clearance (CL<sub>int</sub>) and kinetic solubility were also determined (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). In general, it was noted that changes to the triazole substituents pointing toward the affinity pocket in PI3Kα, R<sup>2</sup> and R<sup>3</sup>, had the greatest impact to potency whereas the substituents on the pyrazole pointing out toward the solvent, R<sup>1</sup>, were used to tune PI3Kβ selectivity as well as physicochemical properties, particularly cLogD.<a onclick="showRef(event, 'ref10 ref12'); return false;" href="javascript:void(0);" class="ref ref10 ref12">(10, 12)</a> In the variations evaluated, careful effort was taken in the design process to avoid introduction of severe metabolic soft spots within the molecules.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. PI3Kα Biochemical Activity, β-Sparing Ratio, Cellular Activities, and Mouse Liver Microsome Intrinsic Clearance as a Function of Structural Changes<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/medium/jm-2013-003632_0005.gif" alt="" id="fx2" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/medium/jm-2013-003632_0006.gif" alt="" id="fx3" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">See Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a> for assay descriptions.</p></div><div class="footnote" id="t2fn2"><sup>Table b</sup><p class="last"><i>K</i><sub>i</sub> values are an average of three independent experiments. Each value has a standard deviation of less than one geometric mean.</p></div><div class="footnote" id="t2fn3"><sup>Table c</sup><p class="last">Ratio of PI3Kβ IC<sub>50</sub> over PI3Kα apparent <i>K</i><sub>i</sub>, x = fold.</p></div><div class="footnote" id="t2fn4"><sup>Table d</sup><p class="last">Compounds were incubated with mouse liver microsomes for 1 h, and % remaining was determined by LC-MS/MS analysis.</p></div><div class="footnote" id="t2fn5"><sup>Table e</sup><p class="last">Not tested, the compound was not evaluated in this assay.</p></div></div><div></div></div><div class="NLM_p last">We began our survey with the imidazobenzoxazepin <b>11a</b> bearing an isopropyl substituent on the triazole similar to the thiazolobenzoxepin <b>2</b>. Biochemical and cellular potencies were reasonable but intrinsic microsomal clearance was high at 550 mL/(min·kg). This rate of metabolic clearance was not tolerable. A simple substitution with a 1-methyl group on the pyrazole near the solvent-exposed region of the ligand and a 3-methyl group on the triazole helped to significantly improve mouse liver microsome (MLM) clearance (<b>11b</b>). However, the kinetic solubility of 2 μM remained unacceptably low. Placement of a polar substituent such as a hydroxyethyl tail on the pyrazole near the solvent-exposed front pocket was effective in reducing cLogD to 2.6 for <b>11c</b> while maintaining good biochemical activity. This change was well tolerated and resulted in a slight improvement of cell-based potency and metabolic clearance. Further reduction of cLogD by removing the isopropyl substituent on the triazole altogether and replacing with either the less lipophilic <i>N</i>-H (<b>11d</b>) and <i>N</i>-methyl (<b>11e</b>) led to 50-fold and 5-fold loss in potency, respectively. Reinsertion of the isopropyl group and removal of the 3-methyl group resulted in a compound with increased potency and microsomal clearance (<b>11f</b> vs <b>11c</b>). Further modifications to the triazole revealed that a 2,2,2-trifluoroethyl substituent in <b>11g</b> was an effective replacement of the isopropyl, with comparable biochemical and cellular activity. Metabolic clearance was also slightly improved with this replacement. Next, we investigated the substituents at the 1-position of the pyrazole to help improve kinetic solubility. As mentioned previously, this portion of the inhibitor extends toward the solvent, so we reasoned that various groups would be tolerated in this region. Therefore, a number of polar groups at this position were evaluated with all of the analogues showing effective kinase inhibition with sub-nanomolar activity against PI3Kα, good cell-based activity, and kinetic solubility (<b>11h</b>–<b>j</b>). Finally, the tertiary alcohol (<b>11k</b>) and the α-quaternary amide (<b>11l</b>) pyrazole substituents were also evaluated. These latter compounds possessed a favorable balance of all of the properties that we optimized for: enzymatic and cellular activity, microsomal clearance, and kinetic solubility. It is noteworthy that all the compounds described had desirable levels of selectivity over PI3Kβ, which was attributed to the pyrazole substitution that they shared in common.<a onclick="showRef(event, 'ref10 ref12'); return false;" href="javascript:void(0);" class="ref ref10 ref12">(10, 12)</a></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Pharmacokinetic Properties</h3><div class="NLM_p">From the data gathered thus far, <b>11c</b>, <b>11k</b>, and <b>11l</b> were selected for progression into in vivo pharmacokinetic (PK) profiling. A single dose of each compound was administered to adult female nude mice either intravenously at 1 mg/kg or orally at 25 mg/kg. The data for these three compounds are summarized in Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>. When compared to the original thiazolobenzoxepin inhibitor <b>2</b>, the imidazobenzoxazepin inhibitors (<b>11c</b>, <b>11k</b>, and <b>11l</b>) all showed improved antiproliferative cellular activity in the MCF7-neo/HER2 line (138, 81, and 25 nM, respectively). Additionally, in line with their low in vitro clearance, the mouse plasma clearance (CL<sub>p</sub>) values were also low for these optimized compounds. More importantly, in each case, both the unbound clearance (CL<sub>u</sub>) and correspondingly the unbound oral exposure (AUC<sub>u</sub>) were significantly (>10×) improved relative to thiazolobenzoxepin <b>2</b>. Compound <b>11l</b> provided the highest unbound exposure of the compounds tested (AUC<sub>u</sub> = 42 μM·h). On the basis of these results, we selected <b>11l</b> to evaluate in an in vivo tumor xenograft study in a head-to-head comparison with compound <b>1</b>.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Cellular Anti-proliferative Activity and Pharmacokinetic Profiles of Imidazobenzoxazepins (Compounds <b>11c</b>, <b>11k</b>, and <b>11l</b>) Compared to Thiazolobenzoxepin <b>2</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/medium/jm-2013-003632_0007.gif" alt="" id="fx4" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/medium/jm-2013-003632_0008.gif" alt="" id="fx5" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">%Plasma protein binding measured with equilibrium dialysis.</p></div><div class="footnote" id="t3fn2"><sup>Table b</sup><p class="last">CL<sub>u</sub> = CL<sub>p</sub>/<i>f</i><sub>u</sub>.</p></div><div class="footnote" id="t3fn3"><sup>Table c</sup><p class="last">AUC<sub>u</sub> = AUC<sub>tot</sub> × <i>f</i><sub>u</sub>; <i>f</i><sub>u</sub> = (100 – %PPB)/100.</p></div></div><div></div></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> In Vivo Efficacy and Pharmacodynamics</h3><div class="NLM_p">The in vivo efficacy of compound <b>11l</b> was compared to compound <b>1</b> in the MCF7-neo/Her2 xenograft model grown in nude mice. Daily, oral administration of compound <b>1</b> at 45 mg/kg resulted in 69% TGI when compared to vehicle-treated mice (purple curve, Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>). Daily administration of compound <b>11l</b> orally at 1.4, 2.8, 5.8, 11.25, or 22.5 mg/kg resulted in dose-dependent increase in TGI (19%, 76%, 95%, 103%, and 123%, respectively) and tumor regressions when compared to vehicle-treated mice. The increased potency and unbound concentration of compound <b>11l</b> resulted in comparable TGI (76%) to compound <b>1</b> (69%) at a dose that is approximately 16-fold lower (2.8 mg/kg versus 45 mg/kg). Treatment of both compounds <b>1</b> and <b>11l</b> were well tolerated with less than 10% body weight loss observed compared to vehicle controls (data not shown).</div><figure id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/medium/jm-2013-003632_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/large/jm-2013-003632_0009.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Dose–response curves of fitted tumor volumes in response to <b>1</b> and <b>11l</b> at the doses shown against MCF7-neo/HER2 xenografts in mice relative to vehicle (MCT; 0.5% methycellulose/0.2% Tween-80) after daily (QD) oral (PO) dosing for 20 days.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/large/jm-2013-003632_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4003632&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The relationship between pharmacokinetics (PK) and pharmacodynamics (PD) of compound <b>11l</b> relative to compound <b>1</b> was also investigated in the MCF7-neo/Her2 xenograft model (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>). The phosphorylation levels of Akt in MCF7-neo/HER2 tumors, as well as plasma drug concentrations of both compounds, were evaluated 1 h after a single dose of vehicle (MCT), compound <b>1</b> at 45 mg/kg, or compound <b>11l</b> at 1.4, 2.8, 5.8, 11.25, or 22.5 mg/kg. Compound <b>1</b> resulted in 58% decrease of phosphorylation of Akt (pAkt<sup>Ser473</sup>) levels while a 16-fold lower dose of compound <b>11l</b> at 2.8 mg/kg resulted in a similar decrease in Akt phosphorylation (59%). The comparable decreases in pAkt between these doses of compounds <b>11l</b> and <b>1</b> are likely due to similar unbound plasma drug concentrations that were achieved in mice after 1 h of dosing (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>).</div><figure id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/medium/jm-2013-003632_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/large/jm-2013-003632_0010.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Quantification of pAkt<sup>Ser473</sup> levels in MCF7-neo-Her2 tumor xenografts 1 h after a single dose of MCT vehicle (0.5% methycellulose/0.2% Tween-80), compound <b>1</b> at 45 mg/kg, or compound <b>11l</b> at 1.4, 2.8, 5.8, 11.125, or 22.5 mg/kg. Phosphorylated Akt (pAkt<sup>Ser473</sup>) and total Akt (tAkt) levels were measured by Mesoscale Discovery assay, and values are expressed as the ratio of pAkt/tAkt. Error bars represent SEM for tumor xenograft samples from four different animals. Corresponding plasma free-drug concentrations (closed diamonds) for each dose of compound <b>1</b> or compound <b>11l</b> are plotted on the right <i>y</i> axis.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/large/jm-2013-003632_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4003632&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To better understand the differences in pharmacokinetic properties between thiazolobenzoxepin (e.g., <b>2</b>) and imidazobenzoxazepin (e.g., <b>11l</b>) inhibitors, it is necessary to consider the impact of reducing cLogD had on metabolic clearance. This analysis can be applied to all five scaffolds (<b>A</b>–<b>E</b>) previously introduced in Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a> in order to generalize the observation (see Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>).</div><figure id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/medium/jm-2013-003632_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/large/jm-2013-003632_0011.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Pie charts of mouse liver microsomal clearance categories according to scaffolds <b>A</b>–<b>E</b>. Numbers above individual pie charts correspond to sample size. Green = stable, <27 mL/(min·kg); orange = moderate, 27–63 mL/(min·kg); and red = high, >63 mL/(min·kg).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/large/jm-2013-003632_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4003632&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">When compounds from each of the subseries were incubated with mouse liver microsomes (MLM), the imidazobenzoxazepin (<b>E</b>) had the greatest ratio of compounds (>75%) measured to be in the moderate or low clearance category (CL<sub>hep</sub> < 63 mL/(min·kg)). In contrast, the other scaffolds had more compounds fall in the high clearance category. This outcome can be attributed to two main factors: first, this series was the least lipophilic as determined by cLogD; second, and more important to our understanding, the oxidative potential of the α-methylene position varies depending on the adjacent heterocycle present in each core.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> By blocking this particular metabolic soft spot, we can effectively lower clearance rate, all else being equal. In silico, the degree to which this oxidation could occur was determined using the computational program MetaSite (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>).<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> The program indicated that the preferred site of oxidation on the core was at this soft spot for the compounds analyzed (shaded spheres). The oxidation at this site was severe for thienobenzoxepin <b>A</b> and thiazolobenzoxepin <b>B</b>. To a lesser degree, pyrazolobenzoxazepin <b>C</b> and pyrazolobenzoxepin <b>D</b> were also calculated to be mildly susceptible to oxidation. However, imidazobenzoxazepin <b>E</b> was calculated as not experiencing any such oxidation at this α-methylene position. One possible explanation for the attenuated reactivity at this site for <b>E</b> was that the nitrogen atom directly attached to the position in question was shielding it from cytochrome P450 enzymes. The polarization of this methylene group by the imidazole nitrogen can alter its susceptibility toward oxidation, thereby shifting metabolism on the molecule elsewhere. We confirmed that these calculations were relevant in a real setting by performing in vitro metabolite identification using compounds <b>2</b> and <b>11l</b> following incubation with human hepatocytes. Indeed, the formation of a substantial amount of the oxidation product corresponding to <b>oxo</b>-<b>2</b> was observed after 4 h (Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>a). Conversely, exposure of imidazobenzoxazepin <b>11l</b> to similar conditions yielded only minimal detectable quantity of the product corresponding to α-methylene oxidation (Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>b).<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></div><figure id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/medium/jm-2013-003632_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/large/jm-2013-003632_0012.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. MetaSite predictions for site of CYP-mediated oxidation of the α-methyl group adjacent to the heterocyclic subunit at the center of each scaffold <b>A</b>–<b>E</b>. Red spheres indicate severe magnitude of such oxidation while gray spheres indicate moderate oxidation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/large/jm-2013-003632_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4003632&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch3" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/medium/jm-2013-003632_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/large/jm-2013-003632_0013.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Thiazolobenzoxepin <b>2</b> Was Extensively Converted to the Oxidized Product when Incubated with Human Hepatocytes<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/large/jm-2013-003632_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4003632&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>The corresponding product is minimal when <b>11l</b> is subjected to similar conditions.</p></p></figure><div class="NLM_p">By masking a metabolic site, we managed to reduce both the in vivo clearance and (because we concomitantly increased the free fraction) the unbound clearance as well. To confirm that the improvement to the unbound plasma clearance was general for the imidazobenzoxazepin (<b>E</b>) scaffold relative to thiazolobenzoxepin (<b>B</b>), we plotted CL<sub>u</sub> for 10 matched-pair comparisons where compounds differed only by the composition of their central core, imidazole versus thiazole (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>). In all cases evaluated, <b>E</b> consistently showed lower CL<sub>u</sub> for each pair with direct analogues in both scaffolds. Ultimately, our strategy of transitioning to the imidazobenzoxazepin scaffold proved beneficial in generating well-behaved compounds that achieve high unbound exposures in vivo.</div><figure id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/medium/jm-2013-003632_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/large/jm-2013-003632_0014.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Two-dimensional plot of 10 matched-pair comparisons with unbound clearance (CL<sub>u</sub>) of imidazobenzoxazepins (<b>E</b>) on the <i>y</i> axis and thiazolobenzoxepins (<b>B</b>) on the <i>x</i> axis. The diagonal blue line represents the line of unity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/large/jm-2013-003632_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4003632&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Therapeutic Candidate Profile</h3><div class="NLM_p">Consequently, compound <b>11l</b> was extensively characterized to determine if it met our criteria for a therapeutic candidate for use in clinical trials (Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a>). Earlier, we established that it reached all expectations with regard to potency, PK/PD, and efficacy in human xenograft mouse models. Selectivity against the broader kinome was also determined by screening against Invitrogen’s SelectScreen panel of kinases. Out of 235 kinases that were screened with <b>11l</b> at 1 μM, we found that only five kinases were inhibited greater than 50%: PI3K-C2 beta, PI3Kα, PI3Kδ, PI3Kγ, and hVPS34 at 80.4%, 98.6%, 97.9%, 90.6%, and 69.9%, respectively. Notably, PI3Kβ was not included in the panel of kinases screened. Measurement of IC<sub>50</sub> values for potently inhibited kinases showed that we indeed maintained biochemical selectivity over the non-class I PI3Ks, with IC<sub>50</sub> values for PI3K-C2 beta and hVPS34 measuring 292 and 374 nM, respectively. Compared to the 290 pM activity against PI3Kα, we achieve a 1000-fold selectivity against these potential off-targets. The favorable pharmacokinetic profile evident in nude mice was also achieved in Sprague–Dawley rats. We observed low clearance (CL<sub>P</sub> = 1.8 mL/(min·kg)) and high oral bioavailability (<i>F</i> = 99%) consistent with in vitro experiments carried out in hepatocytes that suggested low metabolic clearance. Auspiciously, the clearance predicted by human hepatocytes is low, suggesting low plasma clearance could be achieved in vivo. After these and further analyses, which included toxicological and safety evaluation, we determined that <b>11l</b> had a satisfactory profile to progress into human clinical trials.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></div><figure id="fig8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/medium/jm-2013-003632_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/large/jm-2013-003632_0015.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Preclinical candidate profile of PI3K β-sparing inhibitor <b>11l</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/large/jm-2013-003632_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4003632&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72653" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72653" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, we discovered a novel class of compounds for the inhibition of PI3K-driven tumors. The key feature for optimization was improving unbound exposure (AUC<sub>u</sub>) by reducing cLogD as a design parameter. This improvement had profound effects on tumor growth inhibition in vivo. Relative to a closely related benzoxepin scaffold evaluated, imidazobenzoxazepin had better tumor growth inhibition at even lower drug doses. In line with the free drug hypothesis, reducing the intrinsic plasma clearance (in this case, a result of removing metabolic soft spots) and increasing free exposure resulted in more efficacious drugs. This approach was essential because we had access to a substantial set of data for comparing direct analogues in several closely related scaffolds. As a result, we quickly settled on a suitable scaffold to optimize in order to achieve the desired profile. Our optimization efforts led to the identification of <b>11l</b> (or GDC-0032), currently undergoing clinical development for use in PI3K-related cancers.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78558" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78558" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Computation</h3><div class="NLM_p last">Using MoKa software (version 1.1.0, Molecular Discovery) and a custom p<i>K</i><sub>a</sub> model augmented with Roche internal data, logarithm of the acid dissociation constant of most basic center (cp<i>K</i><sub>a_MB</sub>), logarithm of the partition coefficient (cLogP), and logarithm of the distribution coefficient at pH 7.4 (cLogD) were calculated. Metabolic soft spots were predicted using MetaSite. The program calculates a probability of CYP-based metabolism at certain sites of a molecule by considering both accessibility of the atoms to the reactive heme and their reactivity in the appropriate reaction mechanism.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Accessibility was derived by comparing GRID-based fingerprint representations of a CYP450 binding site and a three-dimensional structure of the substrate. Substrate reactivity was computed from a mixture of molecular orbital calculations and fragment recognition.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Chemistry. General Methods</h3><div class="NLM_p">All solvents and reagents were used as obtained. Reactions involving air- or moisture-sensitive reagents were carried out under nitrogen atmosphere. Microwave reactions were performed using CEM Discover and Biotage Initiator reactors. NMR spectra were recorded in a deuterated solvent with a Bruker Avance 400 or 500 MHz NMR spectrometer and referenced to trimethylsilane (TMS). Chemical shifts are expressed as δ units using TMS as the external standard (in NMR description, s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, and br = broad peak). All coupling constants (<i>J</i>) are reported in hertz. Mass spectra were measured with a Finnigan SSQ710C spectrometer using an electrospray ionization (ESI) source coupled to a Waters 600MS high-performance liquid chromatography (HPLC) system operating in reverse mode with an X-bridge phenyl column of dimensions 150 mm by 2.6 mm, with 5 μm sized particles. Analytical purity was greater than 95% unless stated otherwise. The following analytical method was used to determine chemical purity of final compounds unless otherwise stated: HPLC-Agilent 1200, water with 0.05% TFA, acetonitrile with 0.05% TFA, Agilent Zorbax SD-C18, 1.8 μM, 2.1 mm × 30 mm, 40 °C, 3–95% B in 8.5 min, 95% in 2.5 min, 400 μL/min, 220 and 254 nm, equipped with Agilent quadrupole 6140, ESI positive, 110–800 amu.</div><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> Ethyl 4-(3-Bromophenoxy)butanoate (<b>12</b>)</h4><div class="NLM_p last">Solid 3-bromophenol (10.0 g, 58 mmol) was added portion wise to a stirred suspension of K<sub>2</sub>CO<sub>3</sub> in acetone (100 mL) at room temperature. Sodium iodide (NaI, 1.0 g) was added, followed by ethyl-4-bromobutyrate (9.2 mL, 64 mmol). The reaction mixture was heated at 80 °C overnight, cooled to room temperature, diluted with water, and extracted with ethyl acetate to give ethyl 4-(3-bromophenoxy)butanoate (<b>12</b>).</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> 4-(3-Bromophenoxy)butanoic acid (<b>13</b>)</h4><div class="NLM_p last">Ethyl 4-(3-bromophenoxy)butanoate (<b>12</b>) was taken up in 100 mL of THF and 50 mL of water and treated with lithium hydroxide (hydrate, 4.9 g). The whole was heated at 50 °C for 2 days. The mixture was cooled to room temperature and acidified to pH 1 with 2 N HCl. The aqueous was extracted with ethylacetate. The combined organics were washed with brine and dried over sodium sulfate to give crude 4-(3-bromophenoxy)butanoic acid (<b>13</b>) as a sticky solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 500 MHz) 7.24 (m, 1H), 7.13 (m, 1H), 7.11 (m, 1H), 6.95 (m, 1H), 3.99 (m, 2H), 2.37 (m, 2H), 1.94 (m, 2H).</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> 8-Bromo-3,4-dihydrobenzo[b]oxepin-5(2H)-one (<b>14</b>)</h4><div class="NLM_p last">To a stirred suspension of polyphosphoric acid (PPA, ca. 60 g) and Celite (ca. 40 g) in 100 mL of toluene was added crude 4-(3-bromophenoxy)butanoic acid (<b>13</b>) (ca. 58 mmol) in one portion, followed by a 10 mL toluene rinse. The resultant suspension was heated at 110 °C for 5 h. The toluene was decanted through a plug of Celite, and the remaining slurry was washed repeatedly with toluene and ethylacetate. The eluent was concentrated and purified by flash column chromatography (4:1 hex/EtOAc) to give 8-bromo-3,4-dihydrobenzo[b]oxepin-5(2H)-one (7 g, ca. 50% yield). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 500 MHz) 7.55 (d, <i>J</i> = 8.5 Hz, 1H), 7.37 (d, <i>J</i> = 1.5 Hz, 1H), 7.35 (dd, <i>J</i> = 8.5, 1.5 Hz, 1H), 4.24 (t, <i>J</i> = 6.5 Hz, 2H), 2.79 (t, <i>J</i> = 7.0 Hz, 2H), 2.14 (m, 2H).</div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> 4,8-Dibromo-3,4-dihydrobenzo[<i>b</i>]oxepin-5(2<i>H</i>)-one (<b>15</b>)</h4><div class="NLM_p last">To a stirred solution of 8-bromo-3,4-dihydro-2<i>H</i>-benzo[<i>b</i>]oxepin-5-one (3.10 g, 12.8 mmol) in Et<sub>2</sub>O at 0 °C was added Br<sub>2</sub> (625 μL, 12.2 mmol), and the reaction mixture was allowed to warm to room temperature over 2 h. Volatiles were evaporated, and the residue was purified by flash column chromatography (0–20% EtOAc in hexanes) to give 4,8-dibromo-3,4-dihydrobenzo[<i>b</i>]oxepin-5(2<i>H</i>)-one (<b>15</b>) as a colorless solid (4.0 g, 96% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.18–7.21 (m, 2H), 7.55 (d, <i>J</i> = 8.0, 1H), 4.87 (app. t, <i>J</i> = 5.2, 2H), 4.33–4.39 (m, 1H), 4.09–4.16 (m, 1H), 2.78–2.91 (m, 1H), 2.40–2.49 (m, 1H).</div></div><div id="sec4_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> 8-Bromo-4,5-dihydro-6-oxa-3-thia-1-aza-benzo[<i>e</i>]azulene-2-carboxylic Acid Ethyl Ester (<b>16</b>)</h4><div class="NLM_p last">To a stirred solution of 4,8-dibromo-3,4-dihydrobenzo[<i>b</i>]oxepin-5(2<i>H</i>)-one (2.17 g, 6.8 mmol) in EtOH (70 mL) was added ethyl thiooxamate (2.72 g, 20.4 mmol), and the reaction mixture was heated at reflux temperature over 4 d. The reaction mixture was concentrated, and the residue was purified by flash column chromatography (0–20% EtOAc in hexanes) to give 8-bromo-4,5-dihydro-6-oxa-3-thia-1-aza-benzo[<i>e</i>]azulene-2-carboxylic acid ethyl ester (<b>16</b>) as a yellow solid (1.08 g, 45% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.36 (d, <i>J</i> = 8.4, 1H), 7.16–7.22 (m, 2H), 4.42 (q, <i>J</i> = 7.2, 2H), 4.31 (app. t, <i>J</i> = 5.2, 2H), 3.32 (app. t, <i>J</i> = 5.2, 2H), 1.38 (t, <i>J</i> = 7.2, 3H).</div></div><div id="sec4_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> 8-Bromo-4,5-dihydro-6-oxa-3-thia-1-aza-benzo[<i>e</i>]azulene-2-carboxylic Acid (<b>17</b>)</h4><div class="NLM_p last">To a stirred solution of 8-bromo-4,5-dihydro-6-oxa-3-thia-1-aza-benzo[<i>e</i>]azulene-2-carboxylic acid ethyl ester in THF (10 mL) and MeOH (5 mL) was added a solution of NaOH (117 mg, 2.9 mmol) in water (2 mL). The reaction mixture was stirred at room temperature for 2 h upon which time it was acidified with 2 M HCl. The aqueous was extracted with CH<sub>2</sub>Cl<sub>2</sub>, and the combined organics were dried (MgSO<sub>4</sub>) and concentrated to give 8-bromo-4,5-dihydro-6-oxa-3-thia-1-aza-benzo[<i>e</i>]azulene-2-carboxylic acid as a colorless solid (396 mg, 83%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.22 (d, <i>J</i> = 8.4, 1H), 7.19–7.24 (m, 2H), 4.33 (t, <i>J</i> = 5.2, 2H), 3.36 (t, <i>J</i> = 5.2, 2H).</div></div><div id="sec4_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> 2-{4-[2-(2-Isopropyl-2<i>H</i>-[1,2,4]triazol-3-yl)-4,5-dihydro-6-oxa-3-thia-1-aza-benzo[<i>e</i>]azulen-8-yl]-pyrazol-1-yl}-ethanol (<b>2</b>)<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a></h4><div class="NLM_p last">8-Bromo-2-(2-isopropyl-2<i>H</i>-[1,2,4]triazol-3-yl)-4,5-dihydro-6-oxa-3-thia-1-aza-benzo[<i>e</i>]azulene (<b>17</b>) was reacted with ethyl 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazol-1-yl)acetate under typical Suzuki coupling conditions (vide infra) to give {4-[2-(2-isopropyl-2<i>H</i>-[1,2,4]triazol-3-yl)-4,5-dihydro-6-oxa-3-thia-1-aza-benzo[<i>e</i>]azulen-8-yl]-pyrazol-1-yl}-acetic acid ethyl ester as a colorless solid. In a separate preparation, a solution of {4-[2-(2-isopropyl-2<i>H</i>-[1,2,4]triazol-3-yl)-4,5-dihydro-6-oxa-3-thia-1-aza-benzo[<i>e</i>]azulen-8-yl]-pyrazol-1-yl}-acetic acid ethyl ester in THF (200 mL) was cooled to 0 °C and treated dropwise with a solution of 1 M LiAlH<sub>4</sub> (in THF, 23 mL, 23 mmol, 2.5 equiv). After 1 h, liquid chromatography/mass spectrometry (LC/MS) indicated consumption of starting material. A solution of saturated sodium sulfate was added slowly until H<sub>2</sub> evolution ceased. Solid magnesium sulfate (∼30 g) was added, and the whole was stirred for 20 min. Filtration over Celite (EtOAc and DCM) followed by concentration of the filtrate gave a crude residue that was purified by rp-HPLC to give 1.4 g of <b>2</b> (43%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.36–8.29 (m, 1H), 8.23 (s, 1H), 8.11 (d, <i>J</i> = 1.7 Hz, 1H), 7.97 (s, 1H), 7.44 (dd, <i>J</i> = 8.3, 1.8 Hz, 1H), 7.31 (d, <i>J</i> = 1.8 Hz, 1H), 5.84 (hept, <i>J</i> = 6.6 Hz, 1H), 4.95 (t, <i>J</i> = 5.3 Hz, 1H), 4.39 (t, <i>J</i> = 5.0 Hz, 2H), 4.16 (dd, <i>J</i> = 7.1, 4.3 Hz, 2H), 3.77 (q, <i>J</i> = 5.6 Hz, 2H), 3.44 (t, <i>J</i> = 5.1 Hz, 2H), 1.56 (d, <i>J</i> = 6.5 Hz, 6H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 158.36, 152.50, 150.65, 148.05, 148.01, 145.40, 136.37, 134.51, 134.48, 133.85, 130.12, 128.05, 121.46, 120.50, 119.83, 116.65, 68.70, 59.94, 54.25, 51.58, 40.06, 39.97, 39.90, 39.80, 39.73, 39.63, 39.60, 39.47, 39.39, 39.30, 39.13, 38.97, 29.60, 22.02, 21.99. HRMS (ESI+): <i>m</i>/<i>z</i> (M + Na<sup>+</sup>) calcd: 445.1423, found: 445.1518. Melting point: 180 °C.</div></div><div id="sec4_2_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> 5-Bromo-2-(1<i>H</i>-imidazol-2-yl)phenol (<b>4</b>)</h4><div class="NLM_p last">4-Bromo-2-hydroxybenzaldehyde (1.0 g, 5 mmol), 40% aqueous solution of ethanedial (3.6 g, 24.9 mmol), and 50% aqueous ammonia (2.5 g) in methanol (20 mL) were stirred for 2 h or longer until the reaction was completed as determined by thin-layer chromatography. The solvent was removed under vacuum pressure, and the residue was partitioned between EtOAc and water. The mixture was then filtered to remove the precipitate. The solution pH was adjusted to 5–6 by careful addition of 1 N HCl. The aqueous layer was extracted with EtOAc three times. The combined organic portions were washed with water and brine and dried over MgSO<sub>4</sub>. The resulting residue was purified by ISCO chromatography (30% EtOAc/DCM) to provide 0.9 g (80% yield) of 5-bromo-2-(1<i>H</i>-imidazol-2-yl)phenol (<b>4</b>) as a yellow solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.13 (bs, 1H), 10.23 (s, 1H), 7.57 (d, <i>J</i> = 8.3 Hz, 1H), 7.21 (d, <i>J</i> = 1.8 Hz, 1H), 7.18–7.09 (m, 1H), 3.35 (bs, 1H).</div></div><div id="sec4_2_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> 9-Bromo-5,6-dihydrobenzo[<i>f</i>]imidazo[1,2-<i>d</i>][1,4]oxazepine (<b>5</b>)</h4><div class="NLM_p last">A mixture of 5-bromo-2-(1<i>H</i>-imidazol-2-yl)phenol (0.9 g, 4 mmol), 1,2-dibromoethane (1.3 mL, 15 mmol), and cesium carbonate (4.9 g, 15 mmol) in DMF (20 mL) was heated to 90 °C for 12 h. The mixture was partitioned between water and EtOAc. The organic layer was separated, washed with water and brine, and dried over MgSO<sub>4</sub>. It was concentrated in vacuo to yield the pure 9-bromo-5,6-dihydrobenzo[<i>f</i>]imidazo[1,2-<i>d</i>][1,4]oxazepine, 0.8 g (75% yield) (<b>5</b>). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.41 (d, <i>J</i> = 8.6 Hz, 1H), 7.31–7.21 (m, 3H), 7.19 (d, <i>J</i> = 1.1 Hz, 1H), 7.01 (d, <i>J</i> = 1.0 Hz, 1H), 4.59–4.26 (m, 4H).</div></div><div id="sec4_2_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> 9-Bromo-2,3-diiodo-5,6-dihydrobenzo[<i>f</i>]imidazo[1,2-<i>d</i>][1,4]oxazepine (<b>6</b>)</h4><div class="NLM_p last">A mixture of 9-bromo-5,6-dihydrobenzo[<i>f</i>]imidazo[1,2-<i>d</i>][1,4]oxazepine (0.8 g, 3 mmol) and <i>N</i>-iodosuccinimide (1.87 g, 8.3 mmol) in DMF was stirred at room temperature for 48 h. The mixture was diluted with EtOAc and washed with 5% sodium bicarbonate solution, 10% sodium thiosulfate, water, and brine, and the organic layer was dried over MgSO<sub>4</sub> and concentrated to a solid residue. Purification by ISCO chromatography (30% EtOAc/heptane) yielded 1.2 g (78% yield) of 9-bromo-2,3-diiodo-5,6-dihydrobenzo[<i>f</i>]imidazo[1,2-<i>d</i>][1,4]oxazepine (<b>6</b>). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.19 (d, <i>J</i> = 8.6 Hz, 1H), 7.35–7.18 (m, 2H), 4.58–4.24 (m, 4H).</div></div><div id="sec4_2_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> 9-Bromo-2-iodo-5,6-dihydrobenzo[<i>f</i>]imidazo[1,2-<i>d</i>][1,4]oxazepine (<b>7</b>)</h4><div class="NLM_p last">A 3.0 M solution of ethylmagnesium bromide in diethyl ether (1.1 mL, 3.3 mmol) was added dropwise to a cold suspension of 9-bromo-2,3-diiodo-5,6-dihydrobenzo[<i>f</i>]imidazo[1,2-<i>d</i>][1,4]oxazepine (1.1 g, 2.2 mmol) in THF at −15 °C. The mixture was stirred at cold temperature and monitored by LC/MS. After 1 h, full conversion was observed, and the reaction was poured into saturated ammonium chloride and extracted with EtOAc. The organic extracts were washed with water and brine, dried over MgSO<sub>4</sub>, and concentrated in vacuo. The crude residue was purified by flash column chromatography (EtOAc) to provide 0.7 g (81% yield) 9-bromo-2-iodo-5,6-dihydrobenzo[<i>f</i>]imidazo[1,2-<i>d</i>][1,4]oxazepine (<b>7</b>) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.22 (d, <i>J</i> = 8.5 Hz, 1H), 7.55 (s, 1H), 7.27 (dt, <i>J</i> = 5.5, 1.9 Hz, 2H), 4.43 (q, <i>J</i> = 6.1 Hz, 4H). <sup>13</sup>C NMR (75 MHz, DMSO) δ 155.9, 145.1, 131.4, 128.8, 125.8, 123.4, 122.4, 117.4, 83.7, 69.0, 49.8.</div></div><div id="sec4_2_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> 9-Bromo-5,6-dihydrobenzo[<i>f</i>]imidazo[1,2-<i>d</i>][1,4]oxazepine-2-carboxamide (<b>8</b>)</h4><div class="NLM_p last">9-Bromo-2-iodo-5,6-dihydrobenzo[<i>f</i>]imidazo[1,2-<i>d</i>][1,4]oxazepine (1.5 g, 3.8 mmol) was placed in a 100 mL round-bottomed flask, and bis(triphenylphosphine) palladium(II) chloride (142 mg, 0.202 mmol) was added followed by DMF (45 mL) and hexamethyldisilazane (4.34 mL, 20.6 mmol). The entire solution was purged with a CO balloon and sealed with the CO balloon attached. The reaction flask was heated at 70 °C for 2 h. LC/MS indicated clean conversion at the end of this period. The mixture was cooled to room temperature and poured into 1 N HCl (30 mL). The mixture was stirred for 5 min and neutralized with saturated aqueous NaHCO<sub>3</sub> solution. Then, it was extracted three times with EtOAc, dried over MgSO<sub>4</sub>, filtered, and concentrated in vacuo. It was triturated with IPA, and the solids were collected after filtration and EtOAc wash. This provided 734 mg (62% yield) of 9-bromo-5,6-dihydrobenzo[<i>f</i>]imidazo[1,2-<i>d</i>][1,4]oxazepine-2-carboxamide (<b>8</b>) as a tan solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.36 (d, <i>J</i> = 8.5, 1H), 7.63 (s, 1H), 7.24 (dd, <i>J</i> = 7.2, 4.2, 1H), 7.09–6.99 (m, 1H), 4.51–4.36 (m, 4H). LC/MS (ESI+): <i>m</i>/<i>z</i> 310 (M + H).</div></div><div id="sec4_2_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> 9-Bromo-2-(1-isopropyl-1<i>H</i>-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[<i>f</i>]imidazo[1,2-<i>d</i>][1,4]oxazepine (<b>9a</b>)</h4><div class="NLM_p last">9-Bromo-5,6-dihydrobenzo[<i>f</i>]imidazo[1,2-<i>d</i>][1,4]oxazepine-2-carboxamide (4.93 g, 16.0 mmol, a separate lot from previously) was taken up in 1,1-dimethoxy-<i>N</i>,<i>N</i>-dimethylmethanamine (25 mL, 0.18 mol) and 1,2-dimethoxyethane (66.5 mL, 0.640 mol). The heterogeneous mixture was stirred very vigorously and heated at 65 °C for 1 h. LC/MS showed complete consumption of starting material at the end of this period. The reaction mixture was concentrated in vacuo and carried on to the subsequent reaction with no further purification steps applied. The crude product from the previous reaction (5.8 g, 16.0 mmol) was suspended in glacial acetic acid (53.2 mL), and isopropylhydrazine hydrochloride (4.36 g, 39.4 mmol) was added. The mixture was heated at 100 °C for 2 h. The reaction vessel was cooled to room temperature, and the solvent was removed in vacuo. The resultant residue was dry loaded onto silica gel and purified by ISCO chromatography (120 g column, 100% EtOAc). Totally, 2.3 g (39% yield) of 9-bromo-2-(1-isopropyl-1<i>H</i>-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[<i>f</i>]imidazo[1,2-<i>d</i>][1,4]oxazepine (<b>9a</b>) was isolated over the two steps. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.34 (d, <i>J</i> = 8.6, 1H), 7.95 (s, 1H), 7.91 (s, 1H), 7.36 (dd, <i>J</i> = 8.7, 2.0, 1H), 7.30 (d, <i>J</i> = 2.0, 1H), 5.85 (dt, <i>J</i> = 13.3, 6.6, 1H), 4.55 (d, <i>J</i> = 15.5, 4H), 1.48 (d, <i>J</i> = 6.6, 6H). LC/MS (ESI+): <i>m</i>/<i>z</i> 376 (M + H).</div></div><div id="sec4_2_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 9-Bromo-2-(1-(2,2,2-trifluoroethyl)-1<i>H</i>-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[<i>f</i>]imidazo[1,2-<i>d</i>][1,4]oxazepine (<b>9b</b>)</h4><div class="NLM_p last">Following the procedure described above, 9-bromo-5,6-dihydrobenzo[<i>f</i>]imidazo[1,2-<i>d</i>][1,4]oxazepine-2-carboxamide and (2,2,2-trifluoroethyl)hydrazine were reacted to give 9-bromo-2-(1-(2,2,2-trifluoroethyl)-1<i>H</i>-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[<i>f</i>]imidazo[1,2-<i>d</i>][1,4]oxazepine (<b>9b</b>). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.28 (t, <i>J</i> = 21.9, 1H), 8.11 (t, <i>J</i> = 7.9, 2H), 7.51–7.35 (m, 1H), 7.32 (d, <i>J</i> = 2.0, 1H), 5.88 (q, <i>J</i> = 8.8, 2H), 4.76–4.29 (m, 4H). LC/MS (ESI+): <i>m</i>/<i>z</i> 413.9 (M + H).</div></div><div id="sec4_2_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 9-Bromo-2-(1-isopropyl-3-methyl-1<i>H</i>-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[<i>f</i>]imidazo[1,2-<i>d</i>][1,4]oxazepine (<b>9c</b>)</h4><div class="NLM_p last">9-Bromo-5,6-dihydrobenzo[<i>f</i>]imidazo[1,2-<i>d</i>][1,4]oxazepine-2-carboxamide (5.1 g, 16 mmol) was taken up in toluene (100 mL) and treated with dimethylacetamide-dimethylacetal (26.5 mL, 178 mmol). This mixture was heated 2 h at 120 °C in a sealed vessel. LC/MS indicated complete consumption of starting material and formation of the acylamidine intermediate together with the hydrolysis byproduct (40:60 mixture). This crude mixture was concentrated in vacuo to a yellow solid and combined with isopropylhydrazine hydrochloride (3.59 g, 32.4 mmol) in acetic acid (50 mL) and heated at 95 °C for 1 h. The reaction was observed to be completed as determined by LC/MS. The reaction vessel was subsequently cooled to room temperature, and the volatiles were evaporated. The solid was dry loaded onto an ISCO column and purified (120 g column, 10% MeOH/EtOAc) by flash column chromatography. This provided 5.9 g (95% yield) of 9-bromo-2-(1-isopropyl-3-methyl-1<i>H</i>-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[<i>f</i>]imidazo[1,2-<i>d</i>][1,4]oxazepine (<b>9c</b>) as a tan-colored solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.38 (d, <i>J</i> = 8.6, 1H), 7.63 (s, 1H), 7.31–7.20 (m, 5H), 5.94–5.76 (m, 1H), 5.30 (s, 1H), 4.46 (ddd, <i>J</i> = 7.9, 6.2, 3.6, 4H), 2.41 (s, 3H), 1.67–1.45 (m, 7H).</div></div><div id="sec4_2_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 1-[2-(Tetrahydro-pyran-2-yloxy)-ethyl]-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1<i>H</i>-pyrazole (<b>10f</b>)</h4><div class="NLM_p last">To a solution of 4-pyrazole boronic acid pinacol ester (2.0 g, 10.3 mmol) in anhydrous DMF (20 mL) was added cesium carbonate (4.03 g, 12.4 mmol), and the mixture was stirred at room temperature for 10 min. 2-(2-Bromoethoxy)tetrahydro-2<i>H</i>-pyran (1.87 mL, 12.4 mmol) was added in two portions, and the mixture was heated to 70 °C. After heating for 18 h, the mixture was allowed to cool to room temperature and partitioned between water (100 mL) and EtOAc (100 mL). The aqueous layer was washed with EtOAc (3 × 20 mL), and the combined organic layers were washed with water (3 × 100 mL) followed by brine, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated in vacuo. The resultant residue was purified by flash chromatography (SiO<sub>2</sub>, gradient 0–100% EtOAc in cyclohexane) to afford the title compound (2.15 g, 65%). LC/MS: <i>R</i><sub>T</sub> = 3.97 min, [M + Na]<sup>+</sup> = 345.</div></div><div id="sec4_2_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 2-Methyl-1-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-pyrazol-1-yl]-propan-2-ol (<b>10l</b>)</h4><div class="NLM_p last">To a solution of 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1<i>H</i>-pyrazole (500 mg, 2.58 mmol) in 2,2-dimethyl-oxirane (3 mL) was added cesium carbonate (130 mg, 0.40 mmol). The reaction was heated at 120 °C for 30 min using microwave irradiation. The reaction was cooled and then filtered through a plug of cotton wool, flushing with DCM. The filtrate was concentrated in vacuo giving 2-methyl-1-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-pyrazol-1-yl]-propan-2-ol as a beige solid (620 mg, 90%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.82 (1 H, d, <i>J</i> = 0.65 Hz), 7.69 (1 H, s), 4.07 (2 H, s), 1.32 (12 H, s), 1.15 (6 H, s). One exchangeable proton was not detectable.</div></div></div><div id="sec4_2_17_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> General Procedure for Suzuki Coupling of 8-Bromo Precursors</h3><div id="sec4_2_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> 2-{4-[2-(2-Isopropyl-2<i>H</i>-[1,2,4]triazol-3-yl)-4,5-dihydro-6-oxa-1,3<i>a</i>-diaza-benzo[<i>e</i>]azulen-8-yl]-pyrazol-1-yl}-ethanol (<b>11f</b>)</h4><div class="NLM_p">To a 10 mL microwave was added 9-bromo-2-(1-isopropyl-1<i>H</i>-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[<i>f</i>]imidazo[1,2-<i>d</i>][1,4]oxazepin (<b>9a</b>) (0.210 g, 0.56 mmol) and potassium acetate (0.17 g, 1.68 mmol), MeCN (1 mL), and water (2 mL). The mixture was thoroughly purged with N<sub>2</sub>. A solution of 1-(2-(tetrahydro-2<i>H</i>-pyran-2-yloxy)ethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole (<b>10f</b>) (0.271 g, 0.84 mmol) in MeCN (1 mL) was added, followed by tetrakis(triphenylphosphine) palladium (65 mg, 0.056 mmol), and the vial was sealed immediately. The mixture was irradiated with microwave at 120 °C for 20 min. Complete conversion was observed by LC/MS (a small amount of des-THP product was also evident). The reaction mixture was diluted with EtOAc and water and extracted three times with EtOAc. The organic phases were combined, dried with MgSO<sub>4</sub>, and concentrated. The residue was purified using ISCO chromatography eluting with 10% MeOH/EtOAc, which gave 170 mg, 0.35 mmol (62% yield) of a white foaming solid. This material was directly dissolved in DCM (2 mL) and treated with 4 M hydrogen chloride in 1,4-dioxane (0.35 mL). A white precipitate developed during the addition. The reaction was stirred at room temperature for 1 h, concentrated to dryness, and dissolved in DMF/H<sub>2</sub>O. The mixture was purified by rp-HPLC to provide 105 mg (74% yield) of 2-{4-[2-(2-isopropyl-2<i>H</i>-[1,2,4]triazol-3-yl)-4,5-dihydro-6-oxa-1,3<i>a</i>-diaza-benzo[<i>e</i>]azulen-8-yl]-pyrazol-1-yl}-ethanol (<b>11f</b>) as a white, partially crystalline solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.38 (d, <i>J</i> = 8.5 Hz, 1H), 8.24 (s, 1H), 7.97 (s, 1H), 7.92 (d, <i>J</i> = 1.9 Hz, 2H), 7.39 (dd, <i>J</i> = 8.3, 1.8 Hz, 1H), 7.28 (t, <i>J</i> = 1.9 Hz, 1H), 5.91 (hept, <i>J</i> = 6.6 Hz, 1H), 4.95 (t, <i>J</i> = 5.3 Hz, 1H), 4.53 (q, <i>J</i> = 5.9 Hz, 4H), 4.16 (t, <i>J</i> = 5.6 Hz, 2H), 3.77 (q, <i>J</i> = 5.5 Hz, 2H), 1.50 (d, <i>J</i> = 6.6 Hz, 6H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 155.88, 150.18, 147.10, 144.05, 136.45, 134.64, 130.14, 130.00, 128.18, 123.77, 120.32, 119.21, 116.00, 115.15, 68.31, 59.93, 54.27, 50.24, 49.69, 40.06, 39.97, 39.90, 39.80, 39.73, 39.63, 39.62, 39.47, 39.40, 39.30, 39.13, 38.97, 22.32. HRMS (ESI+): <i>m</i>/<i>z</i> (M + H<sup>+</sup>) calcd: 406.1991, found: 406.1972. Melting point: 216 °C.</div><div class="NLM_p last">The following nine compounds were prepared analogously to <b>11f</b> by replacement with the corresponding organoboron (<b>10</b>) coupling partner (yields 55–89%):</div></div><div id="sec4_2_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> 2-(2-Isopropyl-5-methyl-2<i>H</i>-[1,2,4]triazol-3-yl)-8-(1-methyl-1<i>H</i>-pyrazol-4-yl)-4,5-dihydro-6-oxa-1,3<i>a</i>-diaza-benzo[<i>e</i>]azulene (<b>11b</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.36 (d, <i>J</i> = 8.3 Hz, 1H), 8.22 (s, 1H), 7.94 (s, 1H), 7.88 (s, 1H), 7.37 (dd, <i>J</i> = 8.5, 1.7 Hz, 1H), 7.26 (d, <i>J</i> = 1.8 Hz, 1H), 5.93–5.76 (m, 1H), 4.57–4.44 (m, 4H), 3.87 (s, 3H), 2.26 (s, 3H), 1.47 (d, <i>J</i> = 6.7 Hz, 6H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 158.24, 155.85, 147.29, 143.91, 136.40, 134.48, 130.28, 129.99, 128.33, 123.63, 120.70, 119.22, 116.03, 115.23, 99.49, 68.30, 49.88, 49.67, 40.06, 39.97, 39.90, 39.80, 39.74, 39.64, 39.61, 39.47, 39.40, 39.30, 39.13, 38.97, 38.72, 22.35, 22.31, 13.82. HRMS (ESI+): <i>m</i>/<i>z</i> (M + Na<sup>+</sup>) calcd: 412.1862, found: 412.1892. Melting point: 230 °C.</div></div><div id="sec4_2_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> 2-{4-[2-(2-Isopropyl-5-methyl-2<i>H</i>-[1,2,4]triazol-3-yl)-4,5-dihydro-6-oxa-1,3<i>a</i>-diaza-benzo[<i>e</i>]azulen-8-yl]-pyrazol-1-yl}-ethanol (<b>11c</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.36 (d, <i>J</i> = 8.4 Hz, 1H), 8.23 (s, 1H), 7.96 (s, 1H), 7.88 (s, 1H), 7.39 (dd, <i>J</i> = 8.3, 1.8 Hz, 1H), 7.28 (d, <i>J</i> = 1.7 Hz, 1H), 5.95 – 5.76 (m, 1H), 4.95 (t, <i>J</i> = 5.3 Hz, 1H), 4.59–4.46 (m, 4H), 4.16 (t, <i>J</i> = 5.6 Hz, 2H), 3.77 (q, <i>J</i> = 5.5 Hz, 2H), 2.26 (s, 3H), 1.47 (d, <i>J</i> = 6.5 Hz, 6H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 158.24, 155.86, 147.31, 143.93, 136.45, 134.61, 130.27, 129.98, 128.17, 123.63, 120.33, 119.21, 116.00, 115.19, 99.48, 68.30, 59.93, 54.27, 49.88, 49.68, 40.06, 39.97, 39.90, 39.80, 39.73, 39.63, 39.57, 39.47, 39.39, 39.30, 39.13, 38.97, 35.69, 22.35, 22.32, 13.82. HRMS (ESI+): <i>m</i>/<i>z</i> (M + H<sup>+</sup>) calcd: 420.2148, found: 420.2141. Melting point: 247 °C.</div></div><div id="sec4_2_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> 2-{4-[2-(5-Methyl-2<i>H</i>-[1,2,4]triazol-3-yl)-4,5-dihydro-6-oxa-1,3<i>a</i>-diaza-benzo[<i>e</i>]azulen-8-yl]-pyrazol-1-yl}-ethanol (<b>11d</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.61 (d, <i>J</i> = 152.1 Hz, 1H), 8.43 (d, <i>J</i> = 20.4 Hz, 1H), 8.24 (s, 1H), 7.96 (s, 1H), 7.90–7.61 (m, 1H), 7.38 (d, <i>J</i> = 8.1 Hz, 1H), 7.27 (s, 1H), 4.95 (t, <i>J</i> = 5.2 Hz, 1H), 4.50 (s, 4H), 4.16 (dd, <i>J</i> = 7.1, 4.2 Hz, 2H), 3.77 (q, <i>J</i> = 5.4 Hz, 2H), 2.45 – 2.19 (m, 3H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 159.48, 155.74, 152.58, 150.26, 144.19, 138.36, 136.38, 134.57, 134.07, 130.28, 130.10, 128.15, 121.70, 120.36, 119.03, 115.92, 115.26, 104.70, 68.41, 60.13, 59.91, 54.27, 53.79, 49.61, 49.51, 40.06, 39.96, 39.89, 39.80, 39.73, 39.63, 39.47, 39.40, 39.29, 39.13, 38.96, 13.71, 11.55. HRMS (ESI+): <i>m</i>/<i>z</i> (M + H<sup>+</sup>) calcd: 378.1678, found: 378.1711. Melting point: 237 °C.</div></div><div id="sec4_2_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 2-{4-[2-(2,5-Dimethyl-2<i>H</i>-[1,2,4]triazol-3-yl)-4,5-dihydro-6-oxa-1,3<i>a</i>-diaza-benzo[<i>e</i>]azulen-8-yl]-pyrazol-1-yl}-ethanol (<b>11e</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.40 (d, <i>J</i> = 8.5 Hz, 1H), 8.24 (s, 1H), 7.96 (s, 1H), 7.90 (s, 1H), 7.37 (dd, <i>J</i> = 8.5, 1.7 Hz, 1H), 7.28 (d, <i>J</i> = 1.8 Hz, 1H), 4.95 (t, <i>J</i> = 5.3 Hz, 1H), 4.60–4.42 (m, 4H), 4.22 (s, 3H), 4.16 (t, <i>J</i> = 5.6 Hz, 2H), 3.77 (q, <i>J</i> = 5.5 Hz, 2H), 2.24 (s, 3H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 158.26, 155.85, 148.41, 144.00, 136.42, 134.63, 130.13, 128.19, 123.52, 120.30, 119.15, 115.99, 115.14, 99.50, 68.31, 59.93, 54.27, 49.68, 40.06, 39.97, 39.89, 39.80, 39.73, 39.63, 39.56, 39.47, 39.39, 39.30, 39.13, 38.97, 36.68, 13.48. HRMS (ESI+): <i>m</i>/<i>z</i> (M + H<sup>+</sup>) calcd: 392.1835, found: 392.1914.</div></div><div id="sec4_2_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> 2-(4-{2-[2-(2,2,2-Trifluoro-ethyl)-2<i>H</i>-[1,2,4]triazol-3-yl]-4,5-dihydro-6-oxa-1,3<i>a</i>-diaza-benzo[<i>e</i>]azulen-8-yl}-pyrazol-1-yl)-ethanol (<b>11g</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.34 (d, <i>J</i> = 8.3 Hz, 1H), 8.26 (s, 1H), 8.10 (s, 1H), 8.07 (s, 1H), 7.98 (s, 1H), 7.42 (dd, <i>J</i> = 8.3, 1.8 Hz, 1H), 7.29 (d, <i>J</i> = 1.7 Hz, 1H), 5.93 (q, <i>J</i> = 8.8 Hz, 2H), 4.95 (t, <i>J</i> = 5.3 Hz, 1H), 4.54 (td, <i>J</i> = 7.2, 1.7 Hz, 4H), 4.16 (t, <i>J</i> = 5.6 Hz, 2H), 3.77 (q, <i>J</i> = 5.6 Hz, 2H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 156.03, 151.65, 149.58, 144.36, 144.33, 136.49, 134.95, 134.93, 129.84, 129.11, 128.25, 126.98, 124.76, 124.51, 122.53, 120.25, 119.29, 116.02, 114.77, 99.49, 68.24, 59.91, 54.28, 49.80, 49.54, 49.27, 49.00, 40.06, 39.97, 39.90, 39.80, 39.73, 39.63, 39.61, 39.47, 39.40, 39.30, 39.13, 38.97. HRMS (ESI+): <i>m</i>/<i>z</i> (M + Na<sup>+</sup>) calcd: 468.1372, found: 468.1384. Melting point: 237 °C.</div></div><div id="sec4_2_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> 2-(3-{4-[2-(2-Isopropyl-5-methyl-2<i>H</i>-[1,2,4]triazol-3-yl)-4,5-dihydro-6-oxa-1,3<i>a</i>-diaza-benzo[<i>e</i>]azulen-8-yl]-pyrazol-1-yl}-azetidin-1-yl)-ethanol (<b>11h</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.45 (s, 1H), 8.37 (d, <i>J</i> = 8.5 Hz, 1H), 8.03 (s, 1H), 7.89 (s, 1H), 7.41 (dd, <i>J</i> = 8.5, 1.7 Hz, 1H), 7.32 (d, <i>J</i> = 1.8 Hz, 1H), 5.94 – 5.75 (m, 1H), 4.97 (p, <i>J</i> = 6.9 Hz, 1H), 4.54–4.49 (m, 4H), 4.47 (t, <i>J</i> = 5.5 Hz, 1H), 3.76–3.71 (m, 2H), 3.46–3.38 (m, 4H), 2.59 (t, <i>J</i> = 6.0 Hz, 2H), 2.50 (dt, <i>J</i> = 3.5, 1.7 Hz, 7H), 1.47 (d, <i>J</i> = 6.5 Hz, 6H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 158.24, 155.86, 147.30, 143.89, 136.76, 134.32, 130.28, 129.96, 126.91, 123.65, 120.82, 119.29, 116.18, 115.38, 99.48, 68.32, 61.10, 61.02, 59.42, 51.41, 49.88, 49.68, 40.07, 39.97, 39.90, 39.80, 39.73, 39.64, 39.57, 39.47, 39.44, 39.31, 39.14, 38.97, 22.34, 13.82. HRMS (ESI+): <i>m</i>/<i>z</i> (M + H<sup>+</sup>) calcd: 497.2389, found: 497.2419.</div></div><div id="sec4_2_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> (<i>S</i>)-2-Hydroxy-1-(3-{4-[2-(2-isopropyl-5-methyl-2<i>H</i>-[1,2,4]triazol-3-yl)-4,5-dihydro-6-oxa-1,3<i>a</i>-diaza-benzo[<i>e</i>]azulen-8-yl]-pyrazol-1-yl}-azetidin-1-yl)-propan-1-one (<b>11i</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.46 (d, <i>J</i> = 2.7 Hz, 1H), 8.38 (d, <i>J</i> = 8.4 Hz, 1H), 8.12 (s, 1H), 7.89 (s, 1H), 7.42 (dd, <i>J</i> = 8.5, 1.7 Hz, 1H), 7.32 (d, <i>J</i> = 1.8 Hz, 1H), 5.89–5.78 (m, 1H), 5.34–5.24 (m, 1H), 5.21 (t, <i>J</i> = 6.3 Hz, 1H), 4.75 (dt, <i>J</i> = 20.3, 8.9 Hz, 1H), 4.60–4.49 (m, 5H), 4.42–4.31 (m, 1H), 4.23–4.12 (m, 2H), 2.26 (s, 3H), 1.47 (d, <i>J</i> = 6.5 Hz, 6H), 1.22 (d, <i>J</i> = 6.8 Hz, 3H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 173.67, 173.54, 158.24, 155.85, 147.29, 143.86, 137.63, 137.60, 134.10, 130.29, 130.01, 127.68, 127.63, 123.68, 121.01, 119.33, 116.26, 115.49, 68.32, 65.88, 65.75, 58.08, 57.97, 55.09, 55.05, 50.17, 50.12, 49.89, 49.68, 40.06, 39.97, 39.89, 39.80, 39.73, 39.63, 39.56, 39.47, 39.40, 39.30, 39.13, 38.97, 22.38, 22.34, 22.33, 20.22, 13.82. HRMS (ESI+): <i>m</i>/<i>z</i> (M + H<sup>+</sup>) calcd: 503.2519, found: 503.2603. Melting point: 166 °C.</div></div><div id="sec4_2_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> 1-{4-[2-(2-Isopropyl-2<i>H</i>-[1,2,4]triazol-3-yl)-4,5-dihydro-6-oxa-1,3<i>a</i>-diaza-benzo[<i>e</i>]azulen-8-yl]-pyrazol-1-yl}-2-methyl-propan-2-ol (<b>11j</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.38 (d, <i>J</i> = 8.3 Hz, 1H), 8.17 (s, 1H), 7.96 (s, 1H), 7.92 (d, <i>J</i> = 2.8 Hz, 2H), 7.40 (dd, <i>J</i> = 8.4, 1.7 Hz, 1H), 7.29 (d, <i>J</i> = 1.8 Hz, 1H), 5.91 (hept, <i>J</i> = 6.6 Hz, 1H), 4.76 (s, 1H), 4.53 (q, <i>J</i> = 5.8 Hz, 4H), 4.04 (s, 2H), 1.50 (d, <i>J</i> = 6.7 Hz, 6H), 1.10 (s, 6H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 155.90, 150.19, 147.10, 144.05, 136.06, 134.62, 130.15, 130.01, 128.72, 123.78, 120.28, 119.27, 116.06, 115.20, 69.20, 68.32, 62.22, 50.24, 49.70, 40.06, 39.97, 39.90, 39.80, 39.73, 39.64, 39.56, 39.47, 39.40, 39.30, 39.13, 38.97, 27.23, 22.32. HRMS (ESI+): <i>m</i>/<i>z</i> (M + H<sup>+</sup>) calcd: 434.2304, found: 434.2325. Melting point: 241 °C.</div></div><div id="sec4_2_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> 1-{4-[2-(2-Isopropyl-5-methyl-2<i>H</i>-[1,2,4]triazol-3-yl)-4,5-dihydro-6-oxa-1,3<i>a</i>-diaza-benzo[<i>e</i>]azulen-8-yl]-pyrazol-1-yl}-2-methyl-propan-2-ol (<b>11k</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.36 (d, <i>J</i> = 8.4 Hz, 1H), 8.17 (s, 1H), 7.96 (s, 1H), 7.89 (s, 1H), 7.39 (dd, <i>J</i> = 8.4, 1.8 Hz, 1H), 7.28 (d, <i>J</i> = 1.8 Hz, 1H), 5.94–5.72 (m, 1H), 4.76 (s, 1H), 4.57–4.44 (m, 4H), 4.04 (s, 2H), 2.26 (s, 3H), 1.47 (d, <i>J</i> = 6.7 Hz, 6H), 1.09 (s, 6H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 158.24, 155.88, 147.30, 143.92, 136.05, 134.57, 130.27, 129.98, 128.71, 123.63, 120.28, 119.26, 116.05, 115.23, 99.49, 69.19, 68.31, 62.22, 49.87, 49.69, 40.06, 39.97, 39.90, 39.80, 39.73, 39.64, 39.60, 39.47, 39.40, 39.30, 39.13, 38.97, 27.23, 22.38, 22.35, 13.83. HRMS (ESI+): <i>m</i>/<i>z</i> (M + H<sup>+</sup>) calcd: 448.2461, found: 448.2541.</div></div><div id="sec4_2_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 2-{3-[2-(1-Isopropyl-3-methyl-1<i>H</i>-1,2–4-triazol-5-yl)-5,6-dihydrobenzo[<i>f</i>]imidazo[1,2-<i>d</i>][1,4]oxazepin-9-yl]-1<i>H</i>-pyrazol-1-yl}-2-methylpropanamide (<b>11l</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO) δ 8.42 (s, 1H), 8.37 (d, <i>J</i> = 8.3 Hz, 1H), 8.02 (s, 1H), 7.89 (s, 1H), 7.46 (dd, <i>J</i> = 8.3, 1.8 Hz, 1H), 7.36 (d, <i>J</i> = 1.8 Hz, 1H), 7.22 (s, 1H), 6.87 (s, 1H), 5.90–5.73 (m, 1H), 4.62–4.42 (m, 4H), 2.50 (dt, <i>J</i> = 3.6, 1.7 Hz, 5H), 2.26 (s, 3H), 1.74 (s, 6H), 1.47 (d, <i>J</i> = 6.5 Hz, 6H). <sup>13</sup>C NMR (126 MHz, DMSO) δ 173.78, 158.24, 155.88, 147.31, 143.94, 136.64, 134.60, 130.26, 129.88, 126.42, 123.62, 120.32, 119.31, 116.17, 115.26, 68.31, 64.48, 49.89, 49.70, 40.06, 39.97, 39.89, 39.80, 39.72, 39.63, 39.56, 39.47, 39.30, 39.13, 38.96, 25.47, 22.34, 13.82. HRMS (ESI+): <i>m</i>/<i>z</i> (M + H<sup>+</sup>) calcd: 461.2413, found: 461.2427. Melting point: 259 °C.</div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> Characterization of Biochemical and Cellular Activity in Vitro</h3><div class="NLM_p last">Enzymatic activity of the class I PI3K isoforms was measured using a fluorescence polarization assay that monitors formation of the product 3,4,5-inositoltriphosphate molecule as it competes with fluorescently labeled PIP3 for binding to the GRP-1 pleckstrin homology domain protein. An increase in phosphatidyl inositide-3-phosphate product results in a decrease in fluorescence polarization signal as the labeled fluorophore is displaced from the GRP-1 protein binding site. Class I PI3K isoforms were purchased from Perkin–Elmer or were expressed and purified as heterodimeric recombinant proteins. Tetramethylrhodamine-labeled PIP3 (TAMRA-PIP3), di-C8-PIP2, and PIP3 detection reagents were purchased from Echelon Biosciences. PI3Kα was assayed under initial rate conditions in the presence of 10 mM Tris (pH 7.5), 25 μM ATP, 9.75 μM PIP2, 5% glycerol, 4 mM MgCl<sub>2</sub>, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, and 2% (v/v) DMSO at 60 ng/mL. After assay for 30 min at 25 °C, reactions were terminated with a final concentration of 9 mM EDTA, 4.5 nM TAMRA-PIP3, and 4.2 μg/mL GRP-1 detector protein before reading fluorescence polarization on an Envision plate reader. IC<sub>50</sub> values were calculated from the fit of the dose–response curves to a 4-parameter equation. Each reported value is an average of three experiments, and all had a standard deviation less than one geometric mean.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> Analysis of Total and Phosphorylated Akt</h3><div class="NLM_p last">Tris lysis buffer containing 150 mM NaCl, 20 mM Tris pH 7.5, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, phosphatase inhibitor 1 (Sigma P2850), phosphatase inhibitor II (Sigma P5726), protease inhibitor (Sigma P8340), 1 mM NaF, and 1 mM PMSF was added to frozen tumor biopsies. Tumors were dissociated with a small pestle (Konte Glass Company 749521-1500), sonicated briefly on ice, and centrifuged at maximum rpm for 20 min at 4 °C. A 5–20 μg amount of protein from tumor lysates was used to determine phosphorylation status. Samples were assayed in duplicates per manufacturer’s protocol for pAkt/tAkt (MesoScale Discovery K11100D-2).</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> Proliferation Aassay with MCF7-neo/HER2 Cells</h3><div class="NLM_p last">Cell lines were obtained from the American Type Culture Collection (ATCC, Manassas, VA). MCF7-neo/HER2 ectopically expresses HER2 in the MCF7 parental cell line and was developed at Genentech.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Cell lines were cultured in RPMI supplemented with 10% fetal bovine serum, 100 units/mL penicillin, 100 μg/mL streptomycin, 10 mM HEPES, and 2 mM glutamine at 37 °C under 5% CO<sub>2</sub>. MCF7-neo/HER2 cells or PC3 cells were seeded in 384-well plates in media at 1000 cells/well or 3000 cells/well, respectively, and incubated overnight prior to the addition of compounds to a final DMSO concentration of 0.5% v/v. MCF7-neo/HER2 cells were incubated for 3 and 4 days, respectively, prior to the addition of CellTiter-Glo reagent (Promega) and reading of luminescence using an Analyst plate reader. For antiproliferative assays, a cytostatic agent such as aphidicolin and a cytotoxic agent such as staurosporine were included as controls. Dose–response curves were fit to a 4-parameter equation, and relative IC<sub>50</sub> values were calculated using Assay Explorer software.</div></div><div id="sec4_5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> Liver Microsomal Incubation</h3><div class="NLM_p">LMs (0.5 mL at 20 mg/mL) were premixed with alamethicin dissolved in methanol (100 μg/mg of LMs), G6P dehydrogenase (2.88 units/mg of LMs), and KPi buffer to a final volume of 5 mL. The cofactor mixture was prepared by adding NADP (3.33 mg/mL, 4 mM), UDPGA (12.92 mg/mL, 20 mM), G6P (6.8 mg/mL), and GSH (6.15 mg/mL, 20 mM) to 1 mL of 100 mM KPi incubation buffer. Equal volumes of cofactor solution and LMs solution (2 mg/mL) were added and preincubated for 5 min at 37 °C. The reaction was initiated by adding an equal volume of <b>3</b> (5 μM final concentration) in buffer for a final concentration of 0.5 mg/mL of LMs. Final concentrations were 5 mM for GSH and 1 mM for NADP. Following 1 h of incubation at 37 °C, the reaction was quenched by the addition of acetonitrile, followed by centrifugation at 3400<i>g</i> for 10 min. The supernatant was transferred and evaporated. The samples were reconstituted in 10% acetonitrile in water.</div><div class="NLM_p last">LC equipment consisted of a LC-10AD pump from Shimadzu Corporation (Columbia, MD), a HTS PAL autosampler from CTC Analytics (Carrboro, NC), a series 1100 model 1315 DAD UV detector (serial no. 11112915) from Agilent (Waldbronn, Germany), and a QTRAP4000 mass spectrometer equipped with a TurboIonSpray from Applied Biosystems (Foster City, CA). Various MS/MS functionalities were used for analysis, which included full scans, product-ion scans, and multiplereaction monitoring data-dependent ion (MRM ida) scans in positive-ion electrospray mode. The LC column was a Synergi Hydro-RP C18 (4 μm; 150 mm × 2.00 mm) from Phenomenex (Torrance, CA). Mobile phase A was 0.1% formic acid in water and mobile phase B was 0.1% formic acid in acetonitrile.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> In Vitro Hepatocyte Metabolite Identification Assays</h3><div class="NLM_p last">Cryopreserved hepatocytes from male Sprague–Dawley rat (RH; lot MTN) and male beagle dog (DH; lot OES) were purchased from Celsis/In Vitro Technologies (Baltimore, MD). Cryopreserved human hepatocytes (HH, pooled of 50 mixed gender; lot Hup 58 mix) were purchased from CellzDirect (Pittsboro, NC). Mobile phase solvents 0.1% formic acid in water (cat. no. 34673, lot 82630) and 0.1% formic acid in acetonitrile (cat. no. 34668, lot 82690) were purchased from Fluka (St. Louis, MO). InVitroGRO HT thawing medium (product no. Z99019, lot C01020C) was purchased from Celsis/In Vitro Technologies. DMEM medium (cat. no. 31053, lot 719700) was purchased from Invitrogen/Gibco (Grand Island, NY). Cryopreserved hepatocytes were thawed using prewarmed InVitroGRO HT thawing medium in 50 mL centrifuge tubes. The tubes were centrifuged for 5 min at 80<i>g</i>, and the supernatants were discarded. Cells were resuspended with 50 mL of prewarmed DMEM medium by gently inverting the tube several times. The tubes were centrifuged for 5 min at 80<i>g</i>, and the supernatants were discarded. Cells were brought up in 2.5 mL of prewarmed DMEM incubation medium. The total cell count and the number of viable cells were determined by the trypan blue exclusion method. Incubations were carried out in scintillation vials containing 0.5 mL of hepatocyte suspension (2.2–2.6 × 10<sup>6</sup> cells/mL) and 0.5 mL of DMEM media containing test article (20 μM). The scintillation vials were placed on an orbital shaker rotating at 16 rpm in a humidified incubator at 37 °C, 5% CO<sub>2</sub>. The reaction was quenched with 4 mL of acetonitrile at 0 and 3 h. Diclofenac (10 μM) was the positive control and was incubated with cryopreserved hepatocytes under the same conditions used for GDC-0032. The disappearance of diclofenac over 3 h was monitored, and the half-life of the compound was within expected values for each species.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> In Vivo Xenograft Studies</h3><div class="NLM_p">In vivo efficacy was evaluated in the MCF7-neo/Her2 xenograft model. Five million cells per mouse were resuspended in a 1:1 mixture of Hank’s buffered salt solution and matrigel basement membrane matrix (no. 356237, BD Biosciences, Santa Cruz, CA) and implanted into number 2/3 mammary fat pad of female athymic (nu/nu) nude mice obtained from Taconic (Hudson, NY). Prior to cell inoculation, 17-β-estradiol (0.36 mg/pellet, 60 day release, no. SE-121) obtained from Innovative Research of America (Sarasota, FL) was implanted into the dorsal shoulder blade area of each nude mouse. After implantation of cells, tumors were monitored until they reached a mean tumor volume of 250–350 mm<sup>3</sup> prior to initiating dosing. Test articles were dissolved in 0.5% methylcellulose with 0.2% Tween-80 (MCT) and administered daily via oral (PO) gavage.</div><div class="NLM_p">Tumor volumes were determined using digital calipers (Fred V. Fowler Company, Inc., Newton, MA) using the formula (L × W × W)/2. TGI was calculated as the percentage of the area under the fitted curve (AUC) for the respective dose group per day in relation to the vehicle, such that %TGI = 100(1 – (AUC<sub>treatment</sub>/day)/(AUC<sub>vehicle</sub>/day)). Curve fitting was applied to Log<sub>2</sub> transformed individual tumor volume data using a linear mixed-effects (LME) model with the R package nlme, version 3.1-97 in R v2.13.0 (R Development Core Team 2008; R Foundation for Statistical Computing; Vienna, Austria).<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Tumor sizes and body weights were recorded twice weekly over the course of the study. Mice with tumor volumes greater than or equal to 2000 mm<sup>3</sup> or with losses in body weight greater than or equal to 20% from their weight at the start of treatment were euthanized per IACUC guidelines.</div><div class="NLM_p last">For pharmacodynamic marker analysis, MCF7-neo/HER2 xenograft tumors were excised from animals and immediately snap frozen in dry ice.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/jm4003632" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22662" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22662" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chudi O. Ndubaku</span> - <span class="hlFld-Affiliation affiliation">†Departments
of Discovery Chemistry, ‡Drug Metabolism and Pharmacokinetics, §Translational Oncology, and ∥Biochemical
Pharmacology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Argenta Discovery, 8-9 Spire
Green Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United Kingdom</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#accfc4d9c8c5c2eccbc9c2c982cfc3c18cd8c4c9cacadec3c2eccbc9c2c982cfc3c1"><span class="__cf_email__" data-cfemail="fa99928f9e9394ba9d9f949fd4999597">[email protected]</span> <span class="__cf_email__" data-cfemail="35415d505353475a5b7552505b501b565a58">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Timothy P. Heffron</span> - <span class="hlFld-Affiliation affiliation">†Departments
of Discovery Chemistry, ‡Drug Metabolism and Pharmacokinetics, §Translational Oncology, and ∥Biochemical
Pharmacology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Argenta Discovery, 8-9 Spire
Green Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United Kingdom</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#6c0f04190805022c0b090209420f03014c1804090a0a1e03022c0b090209420f0301"><span class="__cf_email__" data-cfemail="93f0fbe6f7fafdd3f4f6fdf6bdf0fcfe">[email protected]</span> <span class="__cf_email__" data-cfemail="65110d000303170a0b2502000b004b060a08">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Steven T. Staben</span> - <span class="hlFld-Affiliation affiliation">†Departments
of Discovery Chemistry, ‡Drug Metabolism and Pharmacokinetics, §Translational Oncology, and ∥Biochemical
Pharmacology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Argenta Discovery, 8-9 Spire
Green Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matthew Baumgardner</span> - <span class="hlFld-Affiliation affiliation">†Departments
of Discovery Chemistry, ‡Drug Metabolism and Pharmacokinetics, §Translational Oncology, and ∥Biochemical
Pharmacology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Argenta Discovery, 8-9 Spire
Green Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nicole Blaquiere</span> - <span class="hlFld-Affiliation affiliation">†Departments
of Discovery Chemistry, ‡Drug Metabolism and Pharmacokinetics, §Translational Oncology, and ∥Biochemical
Pharmacology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Argenta Discovery, 8-9 Spire
Green Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Erin Bradley</span> - <span class="hlFld-Affiliation affiliation">†Departments
of Discovery Chemistry, ‡Drug Metabolism and Pharmacokinetics, §Translational Oncology, and ∥Biochemical
Pharmacology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Argenta Discovery, 8-9 Spire
Green Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Richard Bull</span> - <span class="hlFld-Affiliation affiliation">Argenta Discovery, 8-9 Spire
Green Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Steven Do</span> - <span class="hlFld-Affiliation affiliation">†Departments
of Discovery Chemistry, ‡Drug Metabolism and Pharmacokinetics, §Translational Oncology, and ∥Biochemical
Pharmacology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Argenta Discovery, 8-9 Spire
Green Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jennafer Dotson</span> - <span class="hlFld-Affiliation affiliation">†Departments
of Discovery Chemistry, ‡Drug Metabolism and Pharmacokinetics, §Translational Oncology, and ∥Biochemical
Pharmacology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Argenta Discovery, 8-9 Spire
Green Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Danette Dudley</span> - <span class="hlFld-Affiliation affiliation">†Departments
of Discovery Chemistry, ‡Drug Metabolism and Pharmacokinetics, §Translational Oncology, and ∥Biochemical
Pharmacology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Argenta Discovery, 8-9 Spire
Green Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kyle A. Edgar</span> - <span class="hlFld-Affiliation affiliation">†Departments
of Discovery Chemistry, ‡Drug Metabolism and Pharmacokinetics, §Translational Oncology, and ∥Biochemical
Pharmacology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Argenta Discovery, 8-9 Spire
Green Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lori S. Friedman</span> - <span class="hlFld-Affiliation affiliation">†Departments
of Discovery Chemistry, ‡Drug Metabolism and Pharmacokinetics, §Translational Oncology, and ∥Biochemical
Pharmacology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Argenta Discovery, 8-9 Spire
Green Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Richard Goldsmith</span> - <span class="hlFld-Affiliation affiliation">†Departments
of Discovery Chemistry, ‡Drug Metabolism and Pharmacokinetics, §Translational Oncology, and ∥Biochemical
Pharmacology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Argenta Discovery, 8-9 Spire
Green Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Robert A. Heald</span> - <span class="hlFld-Affiliation affiliation">Argenta Discovery, 8-9 Spire
Green Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Aleksandr Kolesnikov</span> - <span class="hlFld-Affiliation affiliation">†Departments
of Discovery Chemistry, ‡Drug Metabolism and Pharmacokinetics, §Translational Oncology, and ∥Biochemical
Pharmacology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Argenta Discovery, 8-9 Spire
Green Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Leslie Lee</span> - <span class="hlFld-Affiliation affiliation">†Departments
of Discovery Chemistry, ‡Drug Metabolism and Pharmacokinetics, §Translational Oncology, and ∥Biochemical
Pharmacology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Argenta Discovery, 8-9 Spire
Green Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Cristina Lewis</span> - <span class="hlFld-Affiliation affiliation">†Departments
of Discovery Chemistry, ‡Drug Metabolism and Pharmacokinetics, §Translational Oncology, and ∥Biochemical
Pharmacology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Argenta Discovery, 8-9 Spire
Green Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michelle Nannini</span> - <span class="hlFld-Affiliation affiliation">†Departments
of Discovery Chemistry, ‡Drug Metabolism and Pharmacokinetics, §Translational Oncology, and ∥Biochemical
Pharmacology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Argenta Discovery, 8-9 Spire
Green Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jim Nonomiya</span> - <span class="hlFld-Affiliation affiliation">†Departments
of Discovery Chemistry, ‡Drug Metabolism and Pharmacokinetics, §Translational Oncology, and ∥Biochemical
Pharmacology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Argenta Discovery, 8-9 Spire
Green Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jodie Pang</span> - <span class="hlFld-Affiliation affiliation">†Departments
of Discovery Chemistry, ‡Drug Metabolism and Pharmacokinetics, §Translational Oncology, and ∥Biochemical
Pharmacology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Argenta Discovery, 8-9 Spire
Green Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Steve Price</span> - <span class="hlFld-Affiliation affiliation">Argenta Discovery, 8-9 Spire
Green Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wei Wei Prior</span> - <span class="hlFld-Affiliation affiliation">†Departments
of Discovery Chemistry, ‡Drug Metabolism and Pharmacokinetics, §Translational Oncology, and ∥Biochemical
Pharmacology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Argenta Discovery, 8-9 Spire
Green Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Laurent Salphati</span> - <span class="hlFld-Affiliation affiliation">†Departments
of Discovery Chemistry, ‡Drug Metabolism and Pharmacokinetics, §Translational Oncology, and ∥Biochemical
Pharmacology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Argenta Discovery, 8-9 Spire
Green Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Steve Sideris</span> - <span class="hlFld-Affiliation affiliation">†Departments
of Discovery Chemistry, ‡Drug Metabolism and Pharmacokinetics, §Translational Oncology, and ∥Biochemical
Pharmacology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Argenta Discovery, 8-9 Spire
Green Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jeffery J. Wallin</span> - <span class="hlFld-Affiliation affiliation">†Departments
of Discovery Chemistry, ‡Drug Metabolism and Pharmacokinetics, §Translational Oncology, and ∥Biochemical
Pharmacology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Argenta Discovery, 8-9 Spire
Green Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lan Wang</span> - <span class="hlFld-Affiliation affiliation">†Departments
of Discovery Chemistry, ‡Drug Metabolism and Pharmacokinetics, §Translational Oncology, and ∥Biochemical
Pharmacology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Argenta Discovery, 8-9 Spire
Green Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">BinQing Wei</span> - <span class="hlFld-Affiliation affiliation">†Departments
of Discovery Chemistry, ‡Drug Metabolism and Pharmacokinetics, §Translational Oncology, and ∥Biochemical
Pharmacology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Argenta Discovery, 8-9 Spire
Green Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Deepak Sampath</span> - <span class="hlFld-Affiliation affiliation">†Departments
of Discovery Chemistry, ‡Drug Metabolism and Pharmacokinetics, §Translational Oncology, and ∥Biochemical
Pharmacology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Argenta Discovery, 8-9 Spire
Green Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alan G. Olivero</span> - <span class="hlFld-Affiliation affiliation">†Departments
of Discovery Chemistry, ‡Drug Metabolism and Pharmacokinetics, §Translational Oncology, and ∥Biochemical
Pharmacology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Argenta Discovery, 8-9 Spire
Green Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United Kingdom</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d92e3108-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i54">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08213" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08213" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We are grateful to Joe Lyssikatos, James Crawford, Travis Remarchuk, and Jae Chang (Genentech) for helpful discussions and critical reading of the manuscript. We thank Chris Hamman, Mengling Wong, Baiwei Lin, Yanzhou Liu, and Deven Wang for purification and analytical support. Technical support from Hoa Le and Sashi Gopaul are also acknowledged.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i55" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i55"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i56" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i56"> Abbreviations Used</h2><tr><td class="NLM_term">PI3K</td><td class="NLM_def"><p class="first last">phosphoinositide 3-kinase</p></td></tr><tr><td class="NLM_term">PTEN</td><td class="NLM_def"><p class="first last">phosphatase and tensin homologue</p></td></tr><tr><td class="NLM_term">PIP2</td><td class="NLM_def"><p class="first last">4,5-phospatidylinositolbisphosphate</p></td></tr><tr><td class="NLM_term">PIP3</td><td class="NLM_def"><p class="first last">3,4,5-phosphatidylinositoltrisphosphate</p></td></tr><tr><td class="NLM_term">mTOR</td><td class="NLM_def"><p class="first last">mammalian target of rapamycin</p></td></tr><tr><td class="NLM_term">RTK</td><td class="NLM_def"><p class="first last">receptor tyrosine kinase</p></td></tr><tr><td class="NLM_term">LogD</td><td class="NLM_def"><p class="first last">logarithm of the distribution coefficient</p></td></tr><tr><td class="NLM_term">TGI</td><td class="NLM_def"><p class="first last">tumor growth inhibition</p></td></tr><tr><td class="NLM_term">HLM</td><td class="NLM_def"><p class="first last">human liver microsome</p></td></tr><tr><td class="NLM_term">MLM</td><td class="NLM_def"><p class="first last">mouse liver microsome</p></td></tr><tr><td class="NLM_term">HH</td><td class="NLM_def"><p class="first last">human hepatocyte</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i57">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08376" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08376" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 27 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Vivanco, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span> </span><span class="NLM_article-title">The phosphatidylinositol 3-kinase AKT pathway in human cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">489</span><span class="NLM_x">–</span> <span class="NLM_lpage">501</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm4003632&amp;key=10.1038%2Fnrc839" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm4003632&amp;key=12094235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm4003632&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvFKltLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2002&pages=489-501&author=I.+Vivancoauthor=C.+L.+Sawyers&title=The+phosphatidylinositol+3-kinase+AKT+pathway+in+human+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The phosphatidylinositol 3-Kinase-AKT pathway in human cancer</span></div><div class="casAuthors">Vivanco, Igor; Sawyers, Charles L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">489-501</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  One signal that is overactivated in a wide range of tumor types is the prodn. of a phospholipid, phosphatidylinositol (3,4,5) trisphosphate, by phosphatidylinositol 3-kinase (PI3K).  This lipid and the protein kinase that is activated by it, AKT, trigger a cascade of responses, from cell growth and proliferation to survival and motility, that drive tumor progression.  Small-mol. therapeutics that block PI3K signaling might deal a severe blow to cancer cells by blocking many aspects of the tumor-cell phenotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzAQ-0qeD7pLVg90H21EOLACvtfcHk0lgA5BGKfjJCFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvFKltLs%253D&md5=c6762d32f9f1281632f4ccdbcd29268c</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrc839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc839%26sid%3Dliteratum%253Aachs%26aulast%3DVivanco%26aufirst%3DI.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26atitle%3DThe%2520phosphatidylinositol%25203-kinase%2520AKT%2520pathway%2520in%2520human%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2002%26volume%3D2%26spage%3D489%26epage%3D501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Cantley, L. C.</span><span> </span><span class="NLM_article-title">The phosphoinositide 3-kinase pathway</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">296</span><span class="NLM_x">, </span> <span class="NLM_fpage">1655</span><span class="NLM_x">–</span> <span class="NLM_lpage">1657</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm4003632&amp;key=10.1126%2Fscience.296.5573.1655" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm4003632&amp;key=12040186" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm4003632&amp;key=1%3ACAS%3A528%3ADC%252BD38XktlChu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=296&publication_year=2002&pages=1655-1657&author=L.+C.+Cantley&title=The+phosphoinositide+3-kinase+pathway"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The phosphoinositide 3-kinase pathway</span></div><div class="casAuthors">Cantley, Lewis C.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">296</span>
        (<span class="NLM_cas:issue">5573</span>),
    <span class="NLM_cas:pages">1655-1657</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review with 8 refs.  Phosphorylated lipids are produced at cellular membranes during signaling events and contribute to the recruitment and activation of various signaling components.  The role of phosphoinositide 3-kinase (PI3K), which catalyzes the prodn. of phosphatidylinositol 3,4,5-trisphosphate, in cell survival pathways; the regulation of gene expression and cell metab.; and cytoskeletal rearrangements are highlighted.  The PI3K pathway is implicated in human diseases including diabetes and cancer, and understanding the intricacies of this pathway may provide new avenues for therapeutic intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9pxSplxmS1rVg90H21EOLACvtfcHk0lgA5BGKfjJCFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XktlChu7s%253D&md5=110c8a351448aed6ab938b9ccf90a655</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1126%2Fscience.296.5573.1655&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.296.5573.1655%26sid%3Dliteratum%253Aachs%26aulast%3DCantley%26aufirst%3DL.%2BC.%26atitle%3DThe%2520phosphoinositide%25203-kinase%2520pathway%26jtitle%3DScience%26date%3D2002%26volume%3D296%26spage%3D1655%26epage%3D1657" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Campbell, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choong, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montgomery, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciavarella, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hooi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cristiano, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillips, W.</span><span> </span><span class="NLM_article-title">Mutation of the PIK3CA gene in ovarian and breast cancer</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">7678</span><span class="NLM_x">–</span> <span class="NLM_lpage">7681</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=7678-7681&author=I.+Campbellauthor=S.+Russellauthor=D.+Choongauthor=K.+Montgomeryauthor=M.+Ciavarellaauthor=C.+Hooiauthor=B.+Cristianoauthor=R.+Pearsonauthor=W.+Phillips&title=Mutation+of+the+PIK3CA+gene+in+ovarian+and+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCampbell%26aufirst%3DI.%26aulast%3DRussell%26aufirst%3DS.%26aulast%3DChoong%26aufirst%3DD.%26aulast%3DMontgomery%26aufirst%3DK.%26aulast%3DCiavarella%26aufirst%3DM.%26aulast%3DHooi%26aufirst%3DC.%26aulast%3DCristiano%26aufirst%3DB.%26aulast%3DPearson%26aufirst%3DR.%26aulast%3DPhillips%26aufirst%3DW.%26atitle%3DMutation%2520of%2520the%2520PIK3CA%2520gene%2520in%2520ovarian%2520and%2520breast%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D7678%26epage%3D7681" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Samuels, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bardelli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silliman, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ptak, J.</span><span> </span><span class="NLM_article-title">High frequency of mutations of the PIK3CA gene in human cancers</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">304</span><span class="NLM_x">, </span> <span class="NLM_fpage">554</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm4003632&amp;key=10.1126%2Fscience.1096502" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm4003632&amp;key=15016963" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm4003632&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjsVGmsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=304&publication_year=2004&pages=554&author=Y.+Samuelsauthor=Z.+Wangauthor=A.+Bardelliauthor=N.+Sillimanauthor=J.+Ptak&title=High+frequency+of+mutations+of+the+PIK3CA+gene+in+human+cancers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Brevia: High frequency of mutations of the PIK3Ca gene in human cancers</span></div><div class="casAuthors">Samuels, Yardena; Wang, Zhenghe; Bardelli, Alberto; Silliman, Natalie; Ptak, Janine; Szabo, Steve; Yan, Hai; Gazdar, Adi; Powell, Steven M.; Riggins, Gregory J.; Willson, James K. V.; Markowitz, Sanford; Kinzler, Kenneth W.; Vogelstein, Bert; Velculescu, Victor E.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">304</span>
        (<span class="NLM_cas:issue">5670</span>),
    <span class="NLM_cas:pages">554</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr74Tv7Oo80NbVg90H21EOLACvtfcHk0lhoJWF1SfQIiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjsVGmsbk%253D&md5=be8d63bf0c909971c3b7a5f475ce8fab</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1126%2Fscience.1096502&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1096502%26sid%3Dliteratum%253Aachs%26aulast%3DSamuels%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DBardelli%26aufirst%3DA.%26aulast%3DSilliman%26aufirst%3DN.%26aulast%3DPtak%26aufirst%3DJ.%26atitle%3DHigh%2520frequency%2520of%2520mutations%2520of%2520the%2520PIK3CA%2520gene%2520in%2520human%2520cancers%26jtitle%3DScience%26date%3D2004%26volume%3D304%26spage%3D554" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Bertelsen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steine, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandvei, R.</span><span> </span><span class="NLM_article-title">Molecular analysis of the PI3K-AKT pathway in uterine cervical neoplasia: Frequent PIK3CA amplification and AKT phosphorylation</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">118</span><span class="NLM_x">, </span> <span class="NLM_fpage">1877</span><span class="NLM_x">–</span> <span class="NLM_lpage">1883</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm4003632&amp;key=10.1002%2Fijc.21461" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm4003632&amp;key=16287065" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm4003632&amp;key=1%3ACAS%3A528%3ADC%252BD28Xjt1GqtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2006&pages=1877-1883&author=B.+Bertelsenauthor=S.+Steineauthor=R.+Sandvei&title=Molecular+analysis+of+the+PI3K-AKT+pathway+in+uterine+cervical+neoplasia%3A+Frequent+PIK3CA+amplification+and+AKT+phosphorylation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular analysis of the PI3K-Akt pathway in uterine cervical neoplasia: frequent PIK3CA amplification and AKT phosphorylation</span></div><div class="casAuthors">Bertelsen, Bjoern I.; Steine, Solrun J.; Sandvei, Roar; Molven, Anders; Laerum, Ole Didrik</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1877-1883</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Uterine cervical carcinogenesis is probably dependent on cellular genetic damage in addn. to the integration of high-risk HPV DNA in the epithelial cell genome.  Gain of chromosome 3q24-29 is commonly obsd. in cervical neoplasia.  The putative oncogene PIK3CA located in this region encodes a phosphatidylinositol 3-kinase (PI3K).  In a process reversed by PTEN, PI3K generates inositol phospholipids that trigger AKT phosphorylation, which in turn effects tumor driving signals.  We studied 46 specimens of formalin-fixed, paraffin-embedded cervical neoplastic tissue.  The activation state of the PI3K-AKT pathway was assessed immunohistochem. using an antibody with specificity towards serine 473-phosphorylated AKT.  AKT phosphorylation was found in 39 out of 46 examd. specimens.  To examine the possible mol. basis for this activation, we searched for PIK3CA amplification using quant. real-time polymerase chain reaction.  PIK3CA gene copy no. was estd. to be 3 or more in 28 out of 40 successfully examd. cases.  Further, a PTEN mutation anal. of all 9 PTEN exons was carried out, but except for 1 metastasis with an exon 9 V369I heterozygosity, all cases showed normal PTEN sequence.  Immunohistochem. staining for PTEN was strong in all lesions.  In conclusion, an increased activation state of AKT kinase appears to be present in cervical carcinogenesis, and may be accounted for by PIK3CA amplification, whereas PTEN mutation seems to be of little importance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBmRc-5_sOKrVg90H21EOLACvtfcHk0liYaAFzzCY-yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xjt1GqtLc%253D&md5=46f86af8802689b286d855263900dd75</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1002%2Fijc.21461&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.21461%26sid%3Dliteratum%253Aachs%26aulast%3DBertelsen%26aufirst%3DB.%26aulast%3DSteine%26aufirst%3DS.%26aulast%3DSandvei%26aufirst%3DR.%26atitle%3DMolecular%2520analysis%2520of%2520the%2520PI3K-AKT%2520pathway%2520in%2520uterine%2520cervical%2520neoplasia%253A%2520Frequent%2520PIK3CA%2520amplification%2520and%2520AKT%2520phosphorylation%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2006%26volume%3D118%26spage%3D1877%26epage%3D1883" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Byun, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chae, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chi, S.</span><span> </span><span class="NLM_article-title">Frequent monoallelic deletion of PTEN and its reciprocal associatioin with PIK3CA amplification in gastric carcinoma</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">318</span><span class="NLM_x">–</span> <span class="NLM_lpage">327</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm4003632&amp;key=10.1002%2Fijc.10962" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm4003632&amp;key=12569555" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm4003632&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhvFyks7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2003&pages=318-327&author=D.+Byunauthor=K.+Choauthor=B.+Ryuauthor=M.+Leeauthor=J.+Parkauthor=K.+Chaeauthor=H.+Kimauthor=S.+Chi&title=Frequent+monoallelic+deletion+of+PTEN+and+its+reciprocal+associatioin+with+PIK3CA+amplification+in+gastric+carcinoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Frequent monoallelic deletion of PTEN and its reciprocal association with PIK3CA amplification in gastric carcinoma</span></div><div class="casAuthors">Byun, Do-Sun; Cho, Kyucheol; Ryu, Byung-Kyu; Lee, Min-Goo; Park, Jae-Il; Chae, Kwon-Seok; Kim, Hyo-Jong; Chi, Sung-Gil</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">318-327</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Mutational alterations of PTEN and PIK3CA, which neg. and pos. regulate PI3-kinase activity, resp., have been obsd. in many types of human cancer.  To explore the implication of PTEN and PIK3CA mutations in gastric tumorigenesis, the authors characterized the expression and mutation status of the genes in 126 gastric tissues and 15 cell lines.  Expression of PTEN transcript was abnormally low in 5 of 15 (33%) cell lines and 20 of 55 (36%) primary carcinomas, whereas 0 of 71 noncancerous tissues including 16 benign tumors showed altered expression.  Allelotyping anal. using an intragenic polymorphism (IVS4+109) revealed that 14 of 30 (47%) informative cases carried LOH of the gene, which is closely linked to low expression.  The LOH rate was significantly higher in advanced tumors [12 of 19 (63%)] compared to early-stage tumors [2 of 11 (18%)] and more frequent in poorly differentiated tumors [9 of 13 (69%)] than well- or moderately differentiated tumors [5 of 17 (29%)].  Interestingly, however, none of the LOH tumors carried mutational disruption of the remaining allele, suggesting haploinsufficiency of PTEN in gastric tumorigenesis.  Methylation studies revealed that PTEN pseudogene, but not PTEN, is methylated in cell lines and primary tumors, indicating that PTEN is not a target of epigenetic silencing in gastric cancers and that the pseudogene should be considered more carefully in methylation anal. of the PTEN promoter.  Genomic amplification of PIK3CA was found in 9 of 15 (60%) cell lines and 20 of 55 (36.4%) primary tumors but in no noncancerous tissues.  Furthermore, PIK3CA amplification was predominantly detected in tumors with no PTEN alterations, suggesting that mutations of PTEN and PIK3CA are mutually exclusive events in gastric tumorigenesis.  Amplification of PIK3CA was strongly assocd. with increased expression of PIK3CA transcript and elevated levels of phospho-AKT.  Collectively, the authors' data reveal that 13 of 15 (87%) gastric cell lines and 31 of 55 (56%) primary carcinomas harbored either amplification of PIK3CA or abnormal redn. of PTEN.  Mutually exclusive alterations of PTEN and PIK3CA also suggest that mutations of either gene could activate the PI3-kinase/AKT signaling pathway, which is directly linked to the malignant progression of gastric tumor cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyKb4wS-yOdLVg90H21EOLACvtfcHk0liYaAFzzCY-yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhvFyks7o%253D&md5=be43e261f0a80601696350b5728b047a</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1002%2Fijc.10962&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.10962%26sid%3Dliteratum%253Aachs%26aulast%3DByun%26aufirst%3DD.%26aulast%3DCho%26aufirst%3DK.%26aulast%3DRyu%26aufirst%3DB.%26aulast%3DLee%26aufirst%3DM.%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DChae%26aufirst%3DK.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DChi%26aufirst%3DS.%26atitle%3DFrequent%2520monoallelic%2520deletion%2520of%2520PTEN%2520and%2520its%2520reciprocal%2520associatioin%2520with%2520PIK3CA%2520amplification%2520in%2520gastric%2520carcinoma%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2003%26volume%3D104%26spage%3D318%26epage%3D327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Shuttleworth, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silva, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cecil, A. R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomassi, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Workman, P.</span><span> </span><span class="NLM_article-title">Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">2686</span><span class="NLM_x">–</span> <span class="NLM_lpage">2714</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm4003632&amp;key=10.2174%2F092986711796011229" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm4003632&amp;key=21649578" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm4003632&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1Cit73M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=2686-2714&author=S.+J.+Shuttleworthauthor=F.+A.+Silvaauthor=A.+R.+L.+Cecilauthor=C.+D.+Tomassiauthor=T.+J.+Hillauthor=F.+I.+Raynaudauthor=P.+A.+Clarkeauthor=P.+Workman&title=Progress+in+the+preclinical+discovery+and+clinical+development+of+class+I+and+dual+class+I%2FIV+phosphoinositide+3-kinase+%28PI3K%29+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors</span></div><div class="casAuthors">Shuttleworth, S. J.; Silva, F. A.; Cecil, A. R. L.; Tomassi, C. D.; Hill, T. J.; Raynaud, F. I.; Clarke, P. A.; Workman, P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2686-2714</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The phosphoinositide 3-kinases (PI3Ks) constitute an important family of lipid kinase enzymes that control a range of cellular processes through their regulation of a network of signal transduction pathways, and have emerged as important therapeutic targets in the context of cancer, inflammation and cardiovascular diseases.  Since the mid-late 1990s, considerable progress was made in the discovery and development of small mol. ATP-competitive PI3K inhibitors, a no. of which have entered early phase human trials over recent years from which key clin. results are now being disclosed.  This review summarizes progress made to date, primarily on the discovery and characterization of class I and dual class I/IV subtype inhibitors, together with advances that were made in translational and clin. research, notably in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpibTyG_ua2WLVg90H21EOLACvtfcHk0liyQDQ21NjIfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1Cit73M&md5=baf93d773ce18eb70ebc5549c14f422c</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.2174%2F092986711796011229&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986711796011229%26sid%3Dliteratum%253Aachs%26aulast%3DShuttleworth%26aufirst%3DS.%2BJ.%26aulast%3DSilva%26aufirst%3DF.%2BA.%26aulast%3DCecil%26aufirst%3DA.%2BR.%2BL.%26aulast%3DTomassi%26aufirst%3DC.%2BD.%26aulast%3DHill%26aufirst%3DT.%2BJ.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DClarke%26aufirst%3DP.%2BA.%26aulast%3DWorkman%26aufirst%3DP.%26atitle%3DProgress%2520in%2520the%2520preclinical%2520discovery%2520and%2520clinical%2520development%2520of%2520class%2520I%2520and%2520dual%2520class%2520I%252FIV%2520phosphoinositide%25203-kinase%2520%2528PI3K%2529%2520inhibitors%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2011%26volume%3D18%26spage%3D2686%26epage%3D2714" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Jarvis, L. M.</span><span> </span><span class="NLM_article-title">PI3K at the clinical crossroads</span> <span class="citation_source-journal">Chem. Eng. News</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">89</span><span class="NLM_x">, </span> <span class="NLM_fpage">15</span><span class="NLM_x">–</span> <span class="NLM_lpage">19</span></span><div class="citationLinks">[<a href="/doi/10.1021/cen-v089n015.p015" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2011&pages=15-19&author=L.+M.+Jarvis&title=PI3K+at+the+clinical+crossroads"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Fcen-v089n015.p015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcen-v089n015.p015%26sid%3Dliteratum%253Aachs%26aulast%3DJarvis%26aufirst%3DL.%2BM.%26atitle%3DPI3K%2520at%2520the%2520clinical%2520crossroads%26jtitle%3DChem.%2520Eng.%2520News%26date%3D2011%26volume%3D89%26spage%3D15%26epage%3D19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Staben, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldsmith, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivero, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Do, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burdick, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heffron, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dotson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutherlin, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, B.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsui, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesnick, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nonomiya, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prior, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salphati, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rouge, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sampath, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sideris, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiesmann, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, P.</span><span> </span><span class="NLM_article-title">Structure-based design of thienobenzoxepin inhibitors of PI3-kinase</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">4054</span><span class="NLM_x">–</span> <span class="NLM_lpage">4058</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm4003632&amp;key=10.1016%2Fj.bmcl.2011.04.124" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm4003632&amp;key=21636270" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm4003632&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnsVCisLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=4054-4058&author=S.+T.+Stabenauthor=M.+Siuauthor=R.+Goldsmithauthor=A.+G.+Oliveroauthor=S.+Doauthor=D.+J.+Burdickauthor=T.+P.+Heffronauthor=J.+Dotsonauthor=D.+P.+Sutherlinauthor=B.-Y.+Zhuauthor=V.+Tsuiauthor=H.+Leauthor=L.+Leeauthor=J.+Lesnickauthor=C.+Lewisauthor=J.+M.+Murrayauthor=J.+Nonomiyaauthor=J.+Pangauthor=W.+W.+Priorauthor=L.+Salphatiauthor=L.+Rougeauthor=D.+Sampathauthor=S.+Siderisauthor=C.+Wiesmannauthor=P.+Wu&title=Structure-based+design+of+thienobenzoxepin+inhibitors+of+PI3-kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based design of thienobenzoxepin inhibitors of PI3-kinase</span></div><div class="casAuthors">Staben, Steven T.; Siu, Michael; Goldsmith, Richard; Olivero, Alan G.; Do, Steven; Burdick, Daniel J.; Heffron, Timothy P.; Dotson, Jenna; Sutherlin, Daniel P.; Zhu, Bing-Yan; Tsui, Vickie; Le, Hoa; Lee, Leslie; Lesnick, John; Lewis, Cristina; Murray, Jeremy M.; Nonomiya, Jim; Pang, Jodie; Prior, Wei Wei; Salphati, Laurent; Rouge, Lionel; Sampath, Deepak; Sideris, Steve; Wiesmann, Christian; Wu, Ping</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4054-4058</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Starting from thienobenzopyran HTS hit 1 (I), co-crystn., mol. modeling and metabolic anal. were used to design potent and metabolically stable inhibitors of PI3-kinase.  Compd. 15 demonstrated PI3K pathway suppression in a mouse MCF7 xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrK5PrbzVKCkbVg90H21EOLACvtfcHk0liyQDQ21NjIfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnsVCisLs%253D&md5=9b807be1ac4093a6f139c0304757037a</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.04.124&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.04.124%26sid%3Dliteratum%253Aachs%26aulast%3DStaben%26aufirst%3DS.%2BT.%26aulast%3DSiu%26aufirst%3DM.%26aulast%3DGoldsmith%26aufirst%3DR.%26aulast%3DOlivero%26aufirst%3DA.%2BG.%26aulast%3DDo%26aufirst%3DS.%26aulast%3DBurdick%26aufirst%3DD.%2BJ.%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26aulast%3DDotson%26aufirst%3DJ.%26aulast%3DSutherlin%26aufirst%3DD.%2BP.%26aulast%3DZhu%26aufirst%3DB.-Y.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DLe%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DL.%26aulast%3DLesnick%26aufirst%3DJ.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DMurray%26aufirst%3DJ.%2BM.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DPrior%26aufirst%3DW.%2BW.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DRouge%26aufirst%3DL.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DP.%26atitle%3DStructure-based%2520design%2520of%2520thienobenzoxepin%2520inhibitors%2520of%2520PI3-kinase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D4054%26epage%3D4058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Heffron, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivero, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staben, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsui, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Do, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dotson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Folkes, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldsmith, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldsmith, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunzner, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesnick, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathieu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nonomiya, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shuttleworth, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutherlin, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiesmann, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, B.-Y.</span><span> </span><span class="NLM_article-title">Rational design of phosphoinositide 3-kinase α inhibitors that exhibit selectivity over the phosphoinositide 3-kinase β isoform</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">7815</span><span class="NLM_x">–</span> <span class="NLM_lpage">7833</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm2007084" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm4003632&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlGktrvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7815-7833&author=T.+P.+Heffronauthor=B.+Weiauthor=A.+Oliveroauthor=S.+T.+Stabenauthor=V.+Tsuiauthor=S.+Doauthor=J.+Dotsonauthor=A.+J.+Folkesauthor=P.+Goldsmithauthor=R.+Goldsmithauthor=J.+Gunznerauthor=J.+Lesnickauthor=C.+Lewisauthor=S.+Mathieuauthor=J.+Nonomiyaauthor=S.+Shuttleworthauthor=D.+P.+Sutherlinauthor=N.+C.+Wanauthor=S.+Wangauthor=C.+Wiesmannauthor=B.-Y.+Zhu&title=Rational+design+of+phosphoinositide+3-kinase+%CE%B1+inhibitors+that+exhibit+selectivity+over+the+phosphoinositide+3-kinase+%CE%B2+isoform"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Design of Phosphoinositide 3-Kinase α Inhibitors That Exhibit Selectivity over the Phosphoinositide 3-Kinase β Isoform</span></div><div class="casAuthors">Heffron, Timothy P.; Wei, Bin Qing; Olivero, Alan; Staben, Steven T.; Tsui, Vickie; Do, Steven; Dotson, Jennafer; Folkes, Adrian J.; Goldsmith, Paul; Goldsmith, Richard; Gunzner, Janet; Lesnick, John; Lewis, Cristina; Mathieu, Simon; Nonomiya, Jim; Shuttleworth, Stephen; Sutherlin, Daniel P.; Wan, Nan Chi; Wang, Shumei; Wiesmann, Christian; Zhu, Bing-Yan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">7815-7833</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Of the four class I phosphoinositide 3-kinase (PI3K) isoforms, PI3Kα has justly received the most attention for its potential in cancer therapy.  Herein we report our successful approaches to achieve PI3Kα vs PI3Kβ selectivity for two chem. series.  In the thienopyrimidine series of inhibitors, we propose that select ligands achieve selectivity derived from a hydrogen bonding interaction with Arg770 of PI3Kα that is not attained with the corresponding Lys777 of PI3Kβ.  In the benzoxepin series of inhibitors, the selectivity obsd. can be rationalized by the difference in electrostatic potential between the two isoforms in a given region rather than any specific interaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquHPawgTpp87Vg90H21EOLACvtfcHk0lgSTg3EVaU-LQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlGktrvE&md5=4ebed9c985c52238eddc45c6183cf3de</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Fjm2007084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2007084%26sid%3Dliteratum%253Aachs%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DOlivero%26aufirst%3DA.%26aulast%3DStaben%26aufirst%3DS.%2BT.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DDo%26aufirst%3DS.%26aulast%3DDotson%26aufirst%3DJ.%26aulast%3DFolkes%26aufirst%3DA.%2BJ.%26aulast%3DGoldsmith%26aufirst%3DP.%26aulast%3DGoldsmith%26aufirst%3DR.%26aulast%3DGunzner%26aufirst%3DJ.%26aulast%3DLesnick%26aufirst%3DJ.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DMathieu%26aufirst%3DS.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DShuttleworth%26aufirst%3DS.%26aulast%3DSutherlin%26aufirst%3DD.%2BP.%26aulast%3DWan%26aufirst%3DN.%2BC.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DZhu%26aufirst%3DB.-Y.%26atitle%3DRational%2520design%2520of%2520phosphoinositide%25203-kinase%2520%25CE%25B1%2520inhibitors%2520that%2520exhibit%2520selectivity%2520over%2520the%2520phosphoinositide%25203-kinase%2520%25CE%25B2%2520isoform%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7815%26epage%3D7833" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Staben, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blaquiere, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradley, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolesnikov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Do, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heffron, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesnick, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nonomiya, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivero, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salphati, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, P.</span><span> </span><span class="NLM_article-title">Cis-amide isosteric replacement in thienobenzoxepin inhibitors of PI3-kinase</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">897</span><span class="NLM_x">–</span> <span class="NLM_lpage">901</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=897-901&author=S.+T.+Stabenauthor=N.+Blaquiereauthor=E.+Bradleyauthor=A.+Kolesnikovauthor=S.+Doauthor=T.+P.+Heffronauthor=J.+Lesnickauthor=J.+Murrayauthor=J.+Nonomiyaauthor=A.+G.+Oliveroauthor=J.+Pangauthor=L.+Salphatiauthor=B.+Weiauthor=P.+Wu&title=Cis-amide+isosteric+replacement+in+thienobenzoxepin+inhibitors+of+PI3-kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStaben%26aufirst%3DS.%2BT.%26aulast%3DBlaquiere%26aufirst%3DN.%26aulast%3DBradley%26aufirst%3DE.%26aulast%3DKolesnikov%26aufirst%3DA.%26aulast%3DDo%26aufirst%3DS.%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26aulast%3DLesnick%26aufirst%3DJ.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DOlivero%26aufirst%3DA.%2BG.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DWu%26aufirst%3DP.%26atitle%3DCis-amide%2520isosteric%2520replacement%2520in%2520thienobenzoxepin%2520inhibitors%2520of%2520PI3-kinase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D897%26epage%3D901" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Staben, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ndubaku, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blaquiere, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belvin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bull, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dudley, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edgar, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heald, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heffron, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolesnikov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesnick, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLean, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nonomiya, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivero, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ord, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prior, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rouge, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salphati, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sampath, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiesmann, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, P.</span><span> </span><span class="NLM_article-title">Discovery of thiazolobenzoxepin PI3-kinase inhibitors that spare the PI3-kinase β isoform</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">2606</span><span class="NLM_x">–</span> <span class="NLM_lpage">2613</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm4003632&amp;key=10.1016%2Fj.bmcl.2013.02.102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm4003632&amp;key=23540645" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm4003632&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltVenu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=2606-2613&author=S.+T.+Stabenauthor=C.+Ndubakuauthor=N.+Blaquiereauthor=M.+Belvinauthor=R.+J.+Bullauthor=D.+Dudleyauthor=K.+Edgarauthor=D.+Grayauthor=R.+Healdauthor=T.+P.+Heffronauthor=G.+E.+Jonesauthor=M.+Jonesauthor=A.+Kolesnikovauthor=L.+Leeauthor=J.+Lesnickauthor=C.+Lewisauthor=J.+Murrayauthor=N.+J.+McLeanauthor=J.+Nonomiyaauthor=A.+G.+Oliveroauthor=R.+Ordauthor=J.+Pangauthor=S.+Priceauthor=W.+W.+Priorauthor=L.+Rougeauthor=L.+Salphatiauthor=D.+Sampathauthor=J.+Wallinauthor=L.+Wangauthor=B.+Weiauthor=C.+Wiesmannauthor=P.+Wu&title=Discovery+of+thiazolobenzoxepin+PI3-kinase+inhibitors+that+spare+the+PI3-kinase+%CE%B2+isoform"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of thiazolobenzoxepin PI3-kinase inhibitors that spare the PI3-kinase β isoform</span></div><div class="casAuthors">Staben, Steven T.; Ndubaku, Chudi; Blaquiere, Nicole; Belvin, Marcia; Bull, Richard J.; Dudley, Danette; Edgar, Kyle; Gray, Daniel; Heald, Robert; Heffron, Timothy P.; Jones, Graham E.; Jones, Mark; Kolesnikov, Aleks; Lee, Leslie; Lesnick, John; Lewis, Cristina; Murray, Jeremy; McLean, Neville J.; Nonomiya, Jim; Olivero, Alan G.; Ord, Rachel; Pang, Jodie; Price, Stephen; Prior, Wei Wei; Rouge, Lionel; Salphati, Laurent; Sampath, Deepak; Wallin, Jeff; Wang, Lan; Wei, BinQing; Weismann, Christian; Wu, Ping</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2606-2613</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of suitable five-membered heterocyclic alternatives to thiophenes within a thienobenzoxepin class of PI3-kinase (PI3K) inhibitors was discovered.  Specific thiazolobenzoxepin 8-substitution was identified that increased selectivity over PI3Kβ.  PI3Kβ-sparing compd. (I) (PI3Kβ Ki,app/PI3Kα Ki,app = 57) demonstrated dose-dependent knockdown of pAKT, pPRAS40 and pS6RP in vivo as well as differential effects in an in vitro proliferation cell line screen compared to pan PI3K inhibitor GDC-0941.  A new structure-based hypothesis for reducing inhibition of the PI3K β isoform while maintaining activity against α, δ and γ isoforms is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtWjysPIycnbVg90H21EOLACvtfcHk0lgSTg3EVaU-LQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltVenu7c%253D&md5=348731ff5afa1e679a901eb228cfe71f</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.02.102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.02.102%26sid%3Dliteratum%253Aachs%26aulast%3DStaben%26aufirst%3DS.%2BT.%26aulast%3DNdubaku%26aufirst%3DC.%26aulast%3DBlaquiere%26aufirst%3DN.%26aulast%3DBelvin%26aufirst%3DM.%26aulast%3DBull%26aufirst%3DR.%2BJ.%26aulast%3DDudley%26aufirst%3DD.%26aulast%3DEdgar%26aufirst%3DK.%26aulast%3DGray%26aufirst%3DD.%26aulast%3DHeald%26aufirst%3DR.%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26aulast%3DJones%26aufirst%3DG.%2BE.%26aulast%3DJones%26aufirst%3DM.%26aulast%3DKolesnikov%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DL.%26aulast%3DLesnick%26aufirst%3DJ.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DMcLean%26aufirst%3DN.%2BJ.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DOlivero%26aufirst%3DA.%2BG.%26aulast%3DOrd%26aufirst%3DR.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DPrice%26aufirst%3DS.%26aulast%3DPrior%26aufirst%3DW.%2BW.%26aulast%3DRouge%26aufirst%3DL.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DWallin%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DP.%26atitle%3DDiscovery%2520of%2520thiazolobenzoxepin%2520PI3-kinase%2520inhibitors%2520that%2520spare%2520the%2520PI3-kinase%2520%25CE%25B2%2520isoform%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D2606%26epage%3D2613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Folkes, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmadi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alderton, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alix, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Box, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chuckowree, I. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Depledge, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eccles, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hancox, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kugendradas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lensun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivero, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pergl-Wilson, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saghir, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salphati, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sohal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ultsch, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valenti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallweber, H. J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiesmann, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Workman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhyvoloup, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zvelebil, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shuttleworth, S. J.</span><span> </span><span class="NLM_article-title">The Identification of 2-(1<i>H</i>-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-<i>d</i>]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">5522</span><span class="NLM_x">–</span> <span class="NLM_lpage">5532</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm800295d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm4003632&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVCmsr7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5522-5532&author=A.+J.+Folkesauthor=K.+Ahmadiauthor=W.+K.+Aldertonauthor=S.+Alixauthor=S.+J.+Bakerauthor=G.+Boxauthor=I.+S.+Chuckowreeauthor=P.+A.+Clarkeauthor=P.+Depledgeauthor=S.+A.+Ecclesauthor=L.+S.+Friedmanauthor=A.+Hayesauthor=T.+C.+Hancoxauthor=A.+Kugendradasauthor=L.+Lensunauthor=P.+Mooreauthor=A.+G.+Oliveroauthor=J.+Pangauthor=S.+Patelauthor=G.+H.+Pergl-Wilsonauthor=F.+I.+Raynaudauthor=A.+Robsonauthor=N.+Saghirauthor=L.+Salphatiauthor=S.+Sohalauthor=M.+H.+Ultschauthor=M.+Valentiauthor=H.+J.+A.+Wallweberauthor=N.+C.+Wanauthor=C.+Wiesmannauthor=P.+Workmanauthor=A.+Zhyvoloupauthor=M.+J.+Zvelebilauthor=S.+J.+Shuttleworth&title=The+Identification+of+2-%281H-Indazol-4-yl%29-6-%284-methanesulfonyl-piperazin-1-ylmethyl%29-4-morpholin-4-yl-thieno%5B3%2C2-d%5Dpyrimidine+%28GDC-0941%29+as+a+potent%2C+selective%2C+orally+bioavailable+inhibitor+of+class+I+PI3+kinase+for+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer</span></div><div class="casAuthors">Folkes, Adrian J.; Ahmadi, Khatereh; Alderton, Wendy K.; Alix, Sonia; Baker, Stewart J.; Box, Gary; Chuckowree, Irina S.; Clarke, Paul A.; Depledge, Paul; Eccles, Suzanne A.; Friedman, Lori S.; Hayes, Angela; Hancox, Timothy C.; Kugendradas, Arumugam; Lensun, Letitia; Moore, Pauline; Olivero, Alan G.; Pang, Jodie; Patel, Sonal; Pergl-Wilson, Giles H.; Raynaud, Florence I.; Robson, Anthony; Saghir, Nahid; Salphati, Laurent; Sohal, Sukhjit; Ultsch, Mark H.; Valenti, Melanie; Wallweber, Heidi J. A.; Wan, Nan Chi; Wiesmann, Christian; Workman, Paul; Zhyvoloup, Alexander; Zvelebil, Marketa J.; Shuttleworth, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5522-5532</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Phosphatidylinositol-3-kinase (PI3K) is an important target in cancer due to the deregulation of the PI3K/Akt signaling pathway in a wide variety of tumors.  A series of thieno[3,2-d]pyrimidine derivs. were prepd. and evaluated as inhibitors of PI3 kinase p110α.  The synthesis, biol. activity, and further profiling of these compds. are described.  This work resulted in the discovery of GDC-0941 (I) which is a potent, selective, orally bioavailable inhibitor of PI3K and is currently being evaluated in human clin. trials for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojkFv29FXqO7Vg90H21EOLACvtfcHk0ljzEbGG0P-zew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVCmsr7E&md5=742084954685353ceaf18660ab3a0703</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fjm800295d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800295d%26sid%3Dliteratum%253Aachs%26aulast%3DFolkes%26aufirst%3DA.%2BJ.%26aulast%3DAhmadi%26aufirst%3DK.%26aulast%3DAlderton%26aufirst%3DW.%2BK.%26aulast%3DAlix%26aufirst%3DS.%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26aulast%3DBox%26aufirst%3DG.%26aulast%3DChuckowree%26aufirst%3DI.%2BS.%26aulast%3DClarke%26aufirst%3DP.%2BA.%26aulast%3DDepledge%26aufirst%3DP.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DHancox%26aufirst%3DT.%2BC.%26aulast%3DKugendradas%26aufirst%3DA.%26aulast%3DLensun%26aufirst%3DL.%26aulast%3DMoore%26aufirst%3DP.%26aulast%3DOlivero%26aufirst%3DA.%2BG.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DPergl-Wilson%26aufirst%3DG.%2BH.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DRobson%26aufirst%3DA.%26aulast%3DSaghir%26aufirst%3DN.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DSohal%26aufirst%3DS.%26aulast%3DUltsch%26aufirst%3DM.%2BH.%26aulast%3DValenti%26aufirst%3DM.%26aulast%3DWallweber%26aufirst%3DH.%2BJ.%2BA.%26aulast%3DWan%26aufirst%3DN.%2BC.%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DZhyvoloup%26aufirst%3DA.%26aulast%3DZvelebil%26aufirst%3DM.%2BJ.%26aulast%3DShuttleworth%26aufirst%3DS.%2BJ.%26atitle%3DThe%2520Identification%2520of%25202-%25281H-Indazol-4-yl%2529-6-%25284-methanesulfonyl-piperazin-1-ylmethyl%2529-4-morpholin-4-yl-thieno%255B3%252C2-d%255Dpyrimidine%2520%2528GDC-0941%2529%2520as%2520a%2520potent%252C%2520selective%252C%2520orally%2520bioavailable%2520inhibitor%2520of%2520class%2520I%2520PI3%2520kinase%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D5522%26epage%3D5532" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Smith, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerns, E. H.</span><span> </span><span class="NLM_article-title">The effect of plasma protein binding on in vivo efficacy: Misconceptions in drug discovery</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">929</span><span class="NLM_x">–</span> <span class="NLM_lpage">939</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm4003632&amp;key=10.1038%2Fnrd3287" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm4003632&amp;key=21119731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm4003632&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsV2jurfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=929-939&author=D.+A.+Smithauthor=L.+Diauthor=E.+H.+Kerns&title=The+effect+of+plasma+protein+binding+on+in+vivo+efficacy%3A+Misconceptions+in+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery</span></div><div class="casAuthors">Smith, Dennis A.; Di, Li; Kerns, Edward H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">929-939</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Data from in vitro plasma protein binding expts. that det. the fraction of protein-bound drug are frequently used in drug discovery to guide structure design and to prioritize compds. for in vivo studies.  However, we consider that these practices are usually misleading, because in vivo efficacy is detd. by the free (unbound) drug concn. surrounding the therapeutic target, not by the free drug fraction.  These practices yield no enhancement of the in vivo free drug concn.  So, decisions based on free drug fraction could result in the wrong compds. being advanced through drug discovery programs.  This Perspective provides guidance on the application of plasma protein binding information in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOa3ippodhGbVg90H21EOLACvtfcHk0ljzEbGG0P-zew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsV2jurfI&md5=a45d00f68ab44580fa38a6acef49493a</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fnrd3287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3287%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DDi%26aufirst%3DL.%26aulast%3DKerns%26aufirst%3DE.%2BH.%26atitle%3DThe%2520effect%2520of%2520plasma%2520protein%2520binding%2520on%2520in%2520vivo%2520efficacy%253A%2520Misconceptions%2520in%2520drug%2520discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2010%26volume%3D9%26spage%3D929%26epage%3D939" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Sutherlin, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berry, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castanedo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chuckowree, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dotson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Folks, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldsmith, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunzner, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heffron, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesnick, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathieu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nonomiya, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pegg, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prior, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rouge, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salphati, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sampath, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsui, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiesmann, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, B.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivero, A.</span><span> </span><span class="NLM_article-title">Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">7579</span><span class="NLM_x">–</span> <span class="NLM_lpage">7587</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm2009327" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm4003632&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1Ort7%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7579-7587&author=D.+P.+Sutherlinauthor=L.+Baoauthor=M.+Berryauthor=G.+Castanedoauthor=I.+Chuckowreeauthor=J.+Dotsonauthor=A.+Folksauthor=L.+Friedmanauthor=R.+Goldsmithauthor=J.+Gunznerauthor=T.+Heffronauthor=J.+Lesnickauthor=C.+Lewisauthor=S.+Mathieuauthor=J.+Murrayauthor=J.+Nonomiyaauthor=J.+Pangauthor=N.+Peggauthor=W.+W.+Priorauthor=L.+Rougeauthor=L.+Salphatiauthor=D.+Sampathauthor=Q.+Tianauthor=V.+Tsuiauthor=N.+C.+Wanauthor=S.+Wangauthor=B.+Weiauthor=C.+Wiesmannauthor=P.+Wuauthor=B.-Y.+Zhuauthor=A.+Olivero&title=Discovery+of+a+potent%2C+selective%2C+and+orally+available+class+I+phosphatidylinositol+3-kinase+%28PI3K%29%2Fmammalian+target+of+rapamycin+%28mTOR%29+kinase+inhibitor+%28GDC-0980%29+for+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent, Selective, and Orally Available Class I Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor (GDC-0980) for the Treatment of Cancer</span></div><div class="casAuthors">Sutherlin, Daniel P.; Bao, Linda; Berry, Megan; Castanedo, Georgette; Chuckowree, Irina; Dotson, Jenna; Folks, Adrian; Friedman, Lori; Goldsmith, Richard; Gunzner, Janet; Heffron, Timothy; Lesnick, John; Lewis, Cristina; Mathieu, Simon; Murray, Jeremy; Nonomiya, Jim; Pang, Jodie; Pegg, Niel; Prior, Wei Wei; Rouge, Lionel; Salphati, Laurent; Sampath, Deepak; Tian, Qingping; Tsui, Vickie; Wan, Nan Chi; Wang, Shumei; Wei, Bin Qing; Wiesmann, Christian; Wu, Ping; Zhu, Bing-Yan; Olivero, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">7579-7587</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of 2 (GDC-0980, I), a class I PI3K and mTOR kinase inhibitor for oncol. indications, is described. mTOR inhibition was added to the class I PI3K inhibitor 1 (GDC-0941) scaffold primarily through the substitution of the indazole in 1 for a 2-aminopyrimidine.  This substitution also increased the microsomal stability and the free fraction of compds. as evidenced through a pairwise comparison of mols. that were otherwise identical.  Highlighted in detail are analogs of an advanced compd. 4 that were designed to improve soly., resulting in 2.  This compd., is potent across PI3K class I isoforms with IC50s of 5, 27, 7, and 14 nM for PI3Kα, β, δ, and γ, resp., inhibits mTOR with a Ki of 17 nM yet is highly selective vs. a large panel of kinases including others in the PIKK family.  On the basis of the cell potency, low clearance in mouse, and high free fraction, 2 demonstrated significant efficacy in mouse xenografts when dosed as low as 1 mg/kg orally and is currently in phase I clin. trials for cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-3-5KDI509bVg90H21EOLACvtfcHk0lj8us-0NKFPmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1Ort7%252FJ&md5=ba7ede710885b51fffa63977fc64d3f5</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm2009327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2009327%26sid%3Dliteratum%253Aachs%26aulast%3DSutherlin%26aufirst%3DD.%2BP.%26aulast%3DBao%26aufirst%3DL.%26aulast%3DBerry%26aufirst%3DM.%26aulast%3DCastanedo%26aufirst%3DG.%26aulast%3DChuckowree%26aufirst%3DI.%26aulast%3DDotson%26aufirst%3DJ.%26aulast%3DFolks%26aufirst%3DA.%26aulast%3DFriedman%26aufirst%3DL.%26aulast%3DGoldsmith%26aufirst%3DR.%26aulast%3DGunzner%26aufirst%3DJ.%26aulast%3DHeffron%26aufirst%3DT.%26aulast%3DLesnick%26aufirst%3DJ.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DMathieu%26aufirst%3DS.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DPegg%26aufirst%3DN.%26aulast%3DPrior%26aufirst%3DW.%2BW.%26aulast%3DRouge%26aufirst%3DL.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DTian%26aufirst%3DQ.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DWan%26aufirst%3DN.%2BC.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DP.%26aulast%3DZhu%26aufirst%3DB.-Y.%26aulast%3DOlivero%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520a%2520potent%252C%2520selective%252C%2520and%2520orally%2520available%2520class%2520I%2520phosphatidylinositol%25203-kinase%2520%2528PI3K%2529%252Fmammalian%2520target%2520of%2520rapamycin%2520%2528mTOR%2529%2520kinase%2520inhibitor%2520%2528GDC-0980%2529%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7579%26epage%3D7587" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Sutherland, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raymond, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, D. E.</span><span> </span><span class="NLM_article-title">Relating molecular properties and in vitro assay results to in vivo drug disposition and toxicity outcomes</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">6455</span><span class="NLM_x">–</span> <span class="NLM_lpage">6466</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm300684u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm4003632&amp;key=1%3ACAS%3A528%3ADC%252BC38XovFartbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6455-6466&author=J.+J.+Sutherlandauthor=J.+W.+Raymondauthor=J.+L.+Stevensauthor=T.+K.+Bakerauthor=D.+E.+Watson&title=Relating+molecular+properties+and+in+vitro+assay+results+to+in+vivo+drug+disposition+and+toxicity+outcomes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Relating Molecular Properties and in Vitro Assay Results to in Vivo Drug Disposition and Toxicity Outcomes</span></div><div class="casAuthors">Sutherland, Jeffrey J.; Raymond, John W.; Stevens, James L.; Baker, Thomas K.; Watson, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6455-6466</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A primary goal of lead optimization is to identify compds. with improved absorption, distribution, metab., excretion, and toxicity (ADMET) properties.  A no. of reports have linked computed mol. properties to desirable in vivo ADMET outcomes, but a significant limitation of these analyses is the failure to control statistically for possible covariates.  We examine the relationship between mol. properties and in vitro surrogate assays vs in vivo properties within 173 chem. series from a database of 3773 compds. with rodent pharmacokinetic and toxicol. data.  This approach identifies the following pairs of surrogates as most predictive among those examd.: rat primary hepatocyte (RPH) cytolethality/vol. of distribution (Vd) for in vivo toxicol. outcomes, scaled microsome metab./calcd. logP for in vivo unbound clearance, and calcd. logD/kinetic aq. soly. for thermodn. soly.  The impact of common functional group substitutions is examd. and provides insights for compd. design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrg26RzgGVyjbVg90H21EOLACvtfcHk0lj8us-0NKFPmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XovFartbk%253D&md5=e4465539015fef12c20b59d529b5b5cb</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm300684u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300684u%26sid%3Dliteratum%253Aachs%26aulast%3DSutherland%26aufirst%3DJ.%2BJ.%26aulast%3DRaymond%26aufirst%3DJ.%2BW.%26aulast%3DStevens%26aufirst%3DJ.%2BL.%26aulast%3DBaker%26aufirst%3DT.%2BK.%26aulast%3DWatson%26aufirst%3DD.%2BE.%26atitle%3DRelating%2520molecular%2520properties%2520and%2520in%2520vitro%2520assay%2520results%2520to%2520in%2520vivo%2520drug%2520disposition%2520and%2520toxicity%2520outcomes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6455%26epage%3D6466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="note"><p class="first last">The cLogD<sub>7.4</sub> values were calculated using MoKa software (version 1.1.0, Molecular Discovery).</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Blaquiere, N.; Do, S.; Dudley, D.; Folkes, A. J.; Heald, R.; Heffron, T.; Jones, M.; Kolesnikov, A.; Ndubaku, C.; Olivero, A. G.; Price, S.; Staben, S.; Wang, L.</span><span> </span><span class="NLM_article-title">Benzoxazepin PI3K Inhibitor Compounds and Methods of Use</span>. PCT Int. Appl.<span class="NLM_x"> </span><span class="NLM_year">2011</span><span class="NLM_x">, </span>WO/2011036280/A1.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=N.+Blaquiere&author=S.+Do&author=D.+Dudley&author=A.+J.+Folkes&author=R.+Heald&author=T.+Heffron&author=M.+Jones&author=A.+Kolesnikov&author=C.+Ndubaku&author=A.+G.+Olivero&author=S.+Price&author=S.+Staben&author=L.+Wang&title=Benzoxazepin+PI3K+Inhibitor+Compounds+and+Methods+of+Use"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBlaquiere%26aufirst%3DN.%26atitle%3DBenzoxazepin%2520PI3K%2520Inhibitor%2520Compounds%2520and%2520Methods%2520of%2520Use%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Iddon, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, B. L.</span><span> </span><span class="NLM_article-title">Reactions of 1,2-dimethylimidazole, particularly its metallation</span> <span class="citation_source-journal">J. Chem. Soc., Perkin Trans. 1</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1983</span><span class="NLM_x">, </span> <span class="NLM_fpage">271</span><span class="NLM_x">–</span> <span class="NLM_lpage">277</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1983&pages=271-277&author=B.+Iddonauthor=B.+L.+Lim&title=Reactions+of+1%2C2-dimethylimidazole%2C+particularly+its+metallation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DIddon%26aufirst%3DB.%26aulast%3DLim%26aufirst%3DB.%2BL.%26atitle%3DReactions%2520of%25201%252C2-dimethylimidazole%252C%2520particularly%2520its%2520metallation%26jtitle%3DJ.%2520Chem.%2520Soc.%252C%2520Perkin%2520Trans.%25201%26date%3D1983%26spage%3D271%26epage%3D277" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Bellina, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cauteruccio, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossi, R.</span><span> </span><span class="NLM_article-title">Efficient and practical synthesis of 4(5)-aryl-1<i>H</i>-imidazoles and 2,4(5)-diaryl-1<i>H</i>-imidazoles via highly selective palladium-catalyzed arylation reactions</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">8543</span><span class="NLM_x">–</span> <span class="NLM_lpage">8546</span></span><div class="citationLinks">[<a href="/doi/10.1021/jo701496p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2007&pages=8543-8546&author=F.+Bellinaauthor=S.+Cauteruccioauthor=R.+Rossi&title=Efficient+and+practical+synthesis+of+4%285%29-aryl-1H-imidazoles+and+2%2C4%285%29-diaryl-1H-imidazoles+via+highly+selective+palladium-catalyzed+arylation+reactions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjo701496p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo701496p%26sid%3Dliteratum%253Aachs%26aulast%3DBellina%26aufirst%3DF.%26aulast%3DCauteruccio%26aufirst%3DS.%26aulast%3DRossi%26aufirst%3DR.%26atitle%3DEfficient%2520and%2520practical%2520synthesis%2520of%25204%25285%2529-aryl-1H-imidazoles%2520and%25202%252C4%25285%2529-diaryl-1H-imidazoles%2520via%2520highly%2520selective%2520palladium-catalyzed%2520arylation%2520reactions%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2007%26volume%3D72%26spage%3D8543%26epage%3D8546" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Martinelli, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freckmann, D. M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchwald, S. L.</span><span> </span><span class="NLM_article-title">Convenient method for the preparation of weinreb amides via Pd-catalyzed aminocarbonylation of aryl bromides at atmospheric pressure</span> <span class="citation_source-journal">Org. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">4843</span><span class="NLM_x">–</span> <span class="NLM_lpage">4846</span></span><div class="citationLinks">[<a href="/doi/10.1021/ol061902t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2006&pages=4843-4846&author=J.+R.+Martinelliauthor=D.+M.+M.+Freckmannauthor=S.+L.+Buchwald&title=Convenient+method+for+the+preparation+of+weinreb+amides+via+Pd-catalyzed+aminocarbonylation+of+aryl+bromides+at+atmospheric+pressure"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fol061902t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol061902t%26sid%3Dliteratum%253Aachs%26aulast%3DMartinelli%26aufirst%3DJ.%2BR.%26aulast%3DFreckmann%26aufirst%3DD.%2BM.%2BM.%26aulast%3DBuchwald%26aufirst%3DS.%2BL.%26atitle%3DConvenient%2520method%2520for%2520the%2520preparation%2520of%2520weinreb%2520amides%2520via%2520Pd-catalyzed%2520aminocarbonylation%2520of%2520aryl%2520bromides%2520at%2520atmospheric%2520pressure%26jtitle%3DOrg.%2520Lett.%26date%3D2006%26volume%3D8%26spage%3D4843%26epage%3D4846" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Hammerich, O.</span><span> </span><span class="NLM_article-title">Anodic oxidation of hydrocarbons</span>.  <span class="citation_source-book">Organic Electrochemistry</span>, <span class="NLM_edition">4</span>th ed.; <span class="NLM_contrib-group">Lund, H.; Hammerich, O.</span>, Eds.; <span class="NLM_publisher-name">Marcel Dekker</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2001</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">471</span><span class="NLM_x">–</span> <span class="NLM_lpage">498</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2001&pages=471-498&author=O.+Hammerichauthor=H.+Lund&author=O.+Hammerich&title=Organic+Electrochemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DHammerich%26aufirst%3DO.%26atitle%3DAnodic%2520oxidation%2520of%2520hydrocarbons%26btitle%3DOrganic%2520Electrochemistry%26aulast%3DLund%26aufirst%3DH.%26pub%3DMarcel%2520Dekker%26date%3D2001%26spage%3D471%26epage%3D498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Cruciani, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carosati, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Boeck, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ethirajulu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mackie, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howe, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vianello, R.</span><span> </span><span class="NLM_article-title">MetaSite: Understanding metabolism in human cytochromes from the perspective of the chemist</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">6970</span><span class="NLM_x">–</span> <span class="NLM_lpage">6979</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm050529c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6970-6979&author=G.+Crucianiauthor=E.+Carosatiauthor=B.+De+Boeckauthor=K.+Ethirajuluauthor=C.+Mackieauthor=T.+Howeauthor=R.+Vianello&title=MetaSite%3A+Understanding+metabolism+in+human+cytochromes+from+the+perspective+of+the+chemist"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm050529c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050529c%26sid%3Dliteratum%253Aachs%26aulast%3DCruciani%26aufirst%3DG.%26aulast%3DCarosati%26aufirst%3DE.%26aulast%3DDe%2BBoeck%26aufirst%3DB.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DMackie%26aufirst%3DC.%26aulast%3DHowe%26aufirst%3DT.%26aulast%3DVianello%26aufirst%3DR.%26atitle%3DMetaSite%253A%2520Understanding%2520metabolism%2520in%2520human%2520cytochromes%2520from%2520the%2520perspective%2520of%2520the%2520chemist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D6970%26epage%3D6979" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="note"><p class="first last">Detailed information provided in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="note"><p class="first last">Data from additional pharmacokinetic experiments, human dose predictions, and preclinical safety assessments conducted with <b>11l</b> will be the subject of future reports.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Wallin, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prior, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berry, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belmont, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koeppen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belvin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sampath, D.</span><span> </span><span class="NLM_article-title">GDC-0941, a novel class I selective PI3K inhibitor, enhances the efficacy of docetaxel in human breast cancer models by increasing cell death in vitro and in vivo</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">3901</span><span class="NLM_x">–</span> <span class="NLM_lpage">3911</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Fjm4003632&amp;key=10.1158%2F1078-0432.CCR-11-2088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Fjm4003632&amp;key=22586300" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm4003632&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVelurzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=3901-3911&author=J.+J.+Wallinauthor=J.+Guanauthor=W.+W.+Priorauthor=L.+B.+Leeauthor=L.+Berryauthor=L.+D.+Belmontauthor=H.+Koeppenauthor=M.+Belvinauthor=L.+S.+Friedmanauthor=D.+Sampath&title=GDC-0941%2C+a+novel+class+I+selective+PI3K+inhibitor%2C+enhances+the+efficacy+of+docetaxel+in+human+breast+cancer+models+by+increasing+cell+death+in+vitro+and+in+vivo"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">GDC-0941, a Novel Class I Selective PI3K Inhibitor, Enhances the Efficacy of Docetaxel in Human Breast Cancer Models by Increasing Cell Death In Vitro and In Vivo</span></div><div class="casAuthors">Wallin, Jeffrey J.; Guan, Jane; Prior, Wei Wei; Lee, Leslie B.; Berry, Leanne; Belmont, Lisa D.; Koeppen, Hartmut; Belvin, Marcia; Friedman, Lori S.; Sampath, Deepak</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3901-3911</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Docetaxel is a front-line std.-of-care chemotherapeutic drug for the treatment of breast cancer.  Phosphoinositide 3-kinases (PI3K) are lipid kinases that regulate breast tumor cell growth, migration, and survival.  The current study was intended to det. whether GDC-0941, an orally bioavailable class I selective PI3K inhibitor, enhances the antitumor activity of docetaxel in human breast cancer models in vitro and in vivo.  Exptl. Design: A panel of 25 breast tumor cell lines representing HER2+, luminal, and basal subtypes were treated with GDC-0941, docetaxel, or the combination of both drugs and assayed for cellular viability, modulation of PI3K pathway markers, and apoptosis induction.  Drug combination effects on cellular viability were also assessed in nontransformed MCF10A human mammary epithelial cells.  Human xenografts of breast cancer cell lines and patient-derived tumors were used to assess efficacy of GDC-0941 and docetaxel in vivo.  Results: Combination of GDC-0941 and docetaxel decreased the cellular viability of breast tumor cell lines in vitro but to variable degrees of drug synergy.  Compared with nontransformed MCF10A cells, the addn. of both drugs resulted in stronger synergistic effects in a subset of tumor cell lines that were not predicted by breast cancer subtype.  In xenograft models, GDC-0941 enhanced the antitumor activity of docetaxel with max. combination efficacy obsd. within 1 h of administering both drugs.  GDC-0941 increased the rate of apoptosis in cells arrested in mitosis upon cotreatment with docetaxel.  Conclusion: GDC-0941 augments the efficacy of docetaxel by increasing drug-induced apoptosis in breast cancer models.  Clin Cancer Res; 18(14); 3901-11. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6QHWx5T7bgrVg90H21EOLACvtfcHk0lgMpBBm8rv6uQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVelurzF&md5=88b5534aade0580d6908710ffed87599</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-2088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-2088%26sid%3Dliteratum%253Aachs%26aulast%3DWallin%26aufirst%3DJ.%2BJ.%26aulast%3DGuan%26aufirst%3DJ.%26aulast%3DPrior%26aufirst%3DW.%2BW.%26aulast%3DLee%26aufirst%3DL.%2BB.%26aulast%3DBerry%26aufirst%3DL.%26aulast%3DBelmont%26aufirst%3DL.%2BD.%26aulast%3DKoeppen%26aufirst%3DH.%26aulast%3DBelvin%26aufirst%3DM.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DSampath%26aufirst%3DD.%26atitle%3DGDC-0941%252C%2520a%2520novel%2520class%2520I%2520selective%2520PI3K%2520inhibitor%252C%2520enhances%2520the%2520efficacy%2520of%2520docetaxel%2520in%2520human%2520breast%2520cancer%2520models%2520by%2520increasing%2520cell%2520death%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D3901%26epage%3D3911" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Wallin, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edgar, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berry, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prior, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesnick, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nonomiya, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salphati, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivero, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutherlin, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spoerke, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lensun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kassees, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lackner, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sampath, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belvin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, L. S.</span><span> </span><span class="NLM_article-title">GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">2426</span><span class="NLM_x">–</span> <span class="NLM_lpage">2436</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm4003632&amp;key=10.1158%2F1535-7163.MCT-11-0446" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Fjm4003632&amp;key=21998291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm4003632&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFylurfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=2426-2436&author=J.+J.+Wallinauthor=K.+A.+Edgarauthor=J.+Guanauthor=M.+Berryauthor=W.+W.+Priorauthor=L.+Leeauthor=J.+D.+Lesnickauthor=C.+Lewisauthor=J.+Nonomiyaauthor=J.+Pangauthor=L.+Salphatiauthor=A.+G.+Oliveroauthor=D.+P.+Sutherlinauthor=C.+O%E2%80%99Brienauthor=J.+M.+Spoerkeauthor=S.+Patelauthor=L.+Lensunauthor=R.+Kasseesauthor=L.+Rossauthor=M.+R.+Lacknerauthor=D.+Sampathauthor=M.+Belvinauthor=L.+S.+Friedman&title=GDC-0980+is+a+novel+class+I+PI3K%2FmTOR+kinase+inhibitor+with+robust+activity+in+cancer+models+driven+by+the+PI3K+pathway"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway</span></div><div class="casAuthors">Wallin, Jeffrey J.; Edgar, Kyle A.; Guan, Jane; Berry, Megan; Prior, Wei Wei; Lee, Leslie; Lesnick, John D.; Lewis, Cristina; Nonomiya, Jim; Pang, Jodie; Salphati, Laurent; Olivero, Alan G.; Sutherlin, Daniel P.; O'Brien, Carol; Spoerke, Jill M.; Patel, Sonal; Lensun, Letitia; Kassees, Robert; Ross, Leanne; Lackner, Mark R.; Sampath, Deepak; Belvin, Marcia; Friedman, Lori S.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2426-2436</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Alterations of the phosphoinositide-3 kinase (PI3K)/Akt signaling pathway occur broadly in cancer via multiple mechanisms including mutation of the PIK3CA gene, loss or mutation of phosphatase and tensin homolog (PTEN), and deregulation of mammalian target of rapamycin (mTOR) complexes.  The dysregulation of this pathway has been implicated in tumor initiation, cell growth and survival, invasion and angiogenesis, thus, PI3K and mTOR are promising therapeutic targets for cancer.  We discovered GDC-0980, a selective, potent, orally bioavailable inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2) with excellent pharmacokinetic and pharmaceutical properties.  GDC-0980 potently inhibits signal transduction downstream of both PI3K and mTOR, as measured by pharmacodynamic (PD) biomarkers, thereby acting upon two key pathway nodes to produce the strongest attainable inhibition of signaling in the pathway.  Correspondingly, GDC-0980 was potent across a broad panel of cancer cell lines, with the greatest potency in breast, prostate, and lung cancers and less activity in melanoma and pancreatic cancers, consistent with KRAS and BRAF acting as resistance markers.  Treatment of cancer cell lines with GDC-0980 resulted in G1 cell-cycle arrest, and in contrast to mTOR inhibitors, GDC-0980 induced apoptosis in certain cancer cell lines, including those with direct pathway activation via PI3K and PTEN.  Low doses of GDC-0980 potently inhibited tumor growth in xenograft models including those with activated PI3K, loss of LKB1 or PTEN, and elicited an exposure-related decrease in PD biomarkers.  These preclin. data show that GDC-0980 is a potent and effective dual PI3K/mTOR inhibitor with promise for the clinic.  Mol Cancer Ther; 10(12); 2426-36.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4yjwxW7TM3bVg90H21EOLACvtfcHk0lgMpBBm8rv6uQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFylurfJ&md5=756410aaf86377284a63d8ee70ad36ec</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0446&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0446%26sid%3Dliteratum%253Aachs%26aulast%3DWallin%26aufirst%3DJ.%2BJ.%26aulast%3DEdgar%26aufirst%3DK.%2BA.%26aulast%3DGuan%26aufirst%3DJ.%26aulast%3DBerry%26aufirst%3DM.%26aulast%3DPrior%26aufirst%3DW.%2BW.%26aulast%3DLee%26aufirst%3DL.%26aulast%3DLesnick%26aufirst%3DJ.%2BD.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DOlivero%26aufirst%3DA.%2BG.%26aulast%3DSutherlin%26aufirst%3DD.%2BP.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DC.%26aulast%3DSpoerke%26aufirst%3DJ.%2BM.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DLensun%26aufirst%3DL.%26aulast%3DKassees%26aufirst%3DR.%26aulast%3DRoss%26aufirst%3DL.%26aulast%3DLackner%26aufirst%3DM.%2BR.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DBelvin%26aufirst%3DM.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26atitle%3DGDC-0980%2520is%2520a%2520novel%2520class%2520I%2520PI3K%252FmTOR%2520kinase%2520inhibitor%2520with%2520robust%2520activity%2520in%2520cancer%2520models%2520driven%2520by%2520the%2520PI3K%2520pathway%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2011%26volume%3D10%26spage%3D2426%26epage%3D2436" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':[],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':[],'ref25':[],'ref26':['cit26'],'ref27':['cit27']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 117 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Joey L. Methot, Hua Zhou, Meredeth A. McGowan, Neville John Anthony, Matthew Christopher, Yudith Garcia, Abdelghani Achab, Kathryn Lipford, Benjamin Wesley Trotter, Michael D. Altman, Xavier Fradera, Charles A. Lesburg, Chaomin Li, Stephen Alves, Craig P. Chappell, Renu Jain, Ruban Mangado, Elaine Pinheiro, Sybill M. G. Williams, Peter Goldenblatt, Armetta Hill, Lynsey Shaffer, Dapeng Chen, Vincent Tong, Robbie L. McLeod, Hyun-Hee Lee, Hongshi Yu, Sanjiv Shah, <span class="NLM_string-name hlFld-ContribAuthor">Jason D. Katz</span>. </span><span class="cited-content_cbyCitation_article-title">Projected Dose Optimization of Amino- and Hydroxypyrrolidine Purine PI3Kδ Immunomodulators. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (8)
                                     , 5137-5156. <a href="https://doi.org/10.1021/acs.jmedchem.1c00237" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00237</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00237%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DProjected%252BDose%252BOptimization%252Bof%252BAmino-%252Band%252BHydroxypyrrolidine%252BPurine%252BPI3K%2525CE%2525B4%252BImmunomodulators%26aulast%3DMethot%26aufirst%3DJoey%2BL.%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D06022021%26date%3D02042021%26volume%3D64%26issue%3D8%26spage%3D5137%26epage%3D5156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Hengmiao Cheng, Suvi T. M. Orr, Simon Bailey, Alexei Brooun, Ping Chen, Judith G. Deal, Yali L. Deng, Martin P. Edwards, Gary M. Gallego, Neil Grodsky, Buwen Huang, Mehran Jalaie, Stephen Kaiser, Robert S. Kania, Susan E. Kephart, Jennifer Lafontaine, Martha A. Ornelas, Mason Pairish, Simon Planken, Hong Shen, Scott Sutton, Luke Zehnder, Chau D. Almaden, Shubha Bagrodia, Matthew D. Falk, Hovhannes J. Gukasyan, Caroline Ho, Xiaolin Kang, Rachel E. Kosa, Ling Liu, Mary E. Spilker, Sergei Timofeevski, Ravi Visswanathan, Zhenxiong Wang, Fanxiu Meng, Shijian Ren, Li Shao, Feng Xu, <span class="NLM_string-name hlFld-ContribAuthor">John C. Kath</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (1)
                                     , 644-661. <a href="https://doi.org/10.1021/acs.jmedchem.0c01652" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01652</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01652&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01652%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure-Based%252BDrug%252BDesign%252Band%252BSynthesis%252Bof%252BPI3K%2525CE%2525B1-Selective%252BInhibitor%252B%252528PF-06843195%252529%26aulast%3DCheng%26aufirst%3DHengmiao%26date%3D2021%26date%3D2020%26date%3D2020%26date%3D21092020%26date%3D24122020%26volume%3D64%26issue%3D1%26spage%3D644%26epage%3D661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Emily J. Hanan, Jun Liang, Xiaojing Wang, Robert A. Blake, Nicole Blaquiere, <span class="NLM_string-name hlFld-ContribAuthor">Steven T. Staben</span>. </span><span class="cited-content_cbyCitation_article-title">Monomeric Targeted Protein Degraders. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (20)
                                     , 11330-11361. <a href="https://doi.org/10.1021/acs.jmedchem.0c00093" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00093</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00093%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMonomeric%252BTargeted%252BProtein%252BDegraders%26aulast%3DHanan%26aufirst%3DEmily%2BJ.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D17012020%26date%3D15062020%26date%3D30042020%26volume%3D63%26issue%3D20%26spage%3D11330%26epage%3D11361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Lindsey G. DeRatt, Edward C. Lawson, Kiran Kumar, Soyon S. Hwang, Renee L. DesJarlais, <span class="NLM_string-name hlFld-ContribAuthor">Scott D. Kuduk</span>. </span><span class="cited-content_cbyCitation_article-title">Tandem Suzuki Coupling/Intramolecular Oxetane Ring Opening to Form Polycyclic Ring Systems. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2020,</strong> <em>22 </em>
                                    (15)
                                     , 5828-5832. <a href="https://doi.org/10.1021/acs.orglett.0c01899" title="DOI URL">https://doi.org/10.1021/acs.orglett.0c01899</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.0c01899&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.0c01899%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DTandem%252BSuzuki%252BCoupling%25252FIntramolecular%252BOxetane%252BRing%252BOpening%252Bto%252BForm%252BPolycyclic%252BRing%252BSystems%26aulast%3DDeRatt%26aufirst%3DLindsey%2BG.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D05062020%26date%3D23072020%26volume%3D22%26issue%3D15%26spage%3D5828%26epage%3D5832" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Aimie
E. Garces, <span class="NLM_string-name hlFld-ContribAuthor">Michael J. Stocks</span>. </span><span class="cited-content_cbyCitation_article-title">Class 1 PI3K Clinical Candidates and Recent Inhibitor Design Strategies: A Medicinal Chemistry Perspective. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (10)
                                     , 4815-4850. <a href="https://doi.org/10.1021/acs.jmedchem.8b01492" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01492</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01492&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01492%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DClass%252B1%252BPI3K%252BClinical%252BCandidates%252Band%252BRecent%252BInhibitor%252BDesign%252BStrategies%25253A%252BA%252BMedicinal%252BChemistry%252BPerspective%26aulast%3DGarces%26aufirst%3DAimie%2BE.%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D25092018%26date%3D24122018%26volume%3D62%26issue%3D10%26spage%3D4815%26epage%3D4850" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Travis Remarchuk, Rémy Angelaud, David Askin, Archana Kumar, Andrew S. Thompson, Hua Cheng, John F. Reichwein, Yanping Chen, <span class="NLM_string-name hlFld-ContribAuthor">Frédéric St-Jean</span>. </span><span class="cited-content_cbyCitation_article-title">Manufacture of the PI3K β-Sparing Inhibitor Taselisib. Part 1: Early-Stage Development Routes to the Bromobenzoxazepine Core. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2019,</strong> <em>23 </em>
                                    (5)
                                     , 775-782. <a href="https://doi.org/10.1021/acs.oprd.9b00049" title="DOI URL">https://doi.org/10.1021/acs.oprd.9b00049</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.9b00049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.9b00049%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DManufacture%252Bof%252Bthe%252BPI3K%252B%2525CE%2525B2-Sparing%252BInhibitor%252BTaselisib.%252BPart%252B1%25253A%252BEarly-Stage%252BDevelopment%252BRoutes%252Bto%252Bthe%252BBromobenzoxazepine%252BCore%26aulast%3DRemarchuk%26aufirst%3DTravis%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D28012019%26date%3D20032019%26date%3D06032019%26volume%3D23%26issue%3D5%26spage%3D775%26epage%3D782" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Frédéric St-Jean, Travis Remarchuk, Rémy Angelaud, Diane E. Carrera, Danial Beaudry, Sushant Malhotra, Andrew McClory, Archana Kumar, Gerd Ohlenbusch, Andreas
M. Schuster, <span class="NLM_string-name hlFld-ContribAuthor">Francis Gosselin</span>. </span><span class="cited-content_cbyCitation_article-title">Manufacture of the PI3K β-Sparing Inhibitor Taselisib. Part 2: Development of a Highly Efficient and Regioselective Late-Stage Process. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2019,</strong> <em>23 </em>
                                    (5)
                                     , 783-793. <a href="https://doi.org/10.1021/acs.oprd.9b00050" title="DOI URL">https://doi.org/10.1021/acs.oprd.9b00050</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.9b00050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.9b00050%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DManufacture%252Bof%252Bthe%252BPI3K%252B%2525CE%2525B2-Sparing%252BInhibitor%252BTaselisib.%252BPart%252B2%25253A%252BDevelopment%252Bof%252Ba%252BHighly%252BEfficient%252Band%252BRegioselective%252BLate-Stage%252BProcess%26aulast%3DSt-Jean%26aufirst%3DFr%25C3%25A9d%25C3%25A9ric%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D28012019%26date%3D20032019%26date%3D06032019%26volume%3D23%26issue%3D5%26spage%3D783%26epage%3D793" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Joey L. Methot, Hua Zhou, Sam D. Kattar, Meredeth A. McGowan, Kevin Wilson, Yudith Garcia, Yongi Deng, Michael Altman, Xavier Fradera, Charles Lesburg, Thierry Fischmann, Chaomin Li, Steve Alves, Sanjiv Shah, Rafael Fernandez, Peter Goldenblatt, Armetta Hill, Lynsey Shaffer, Dapeng Chen, Vince Tong, Robbie L. McLeod, Hongshi Yu, Alan Bass, Ray Kemper, Nicholas T. Gatto, Lisa LaFranco-Scheuch, Benjamin Wesley Trotter, Timothy Guzi, <span class="NLM_string-name hlFld-ContribAuthor">Jason D. Katz</span>. </span><span class="cited-content_cbyCitation_article-title">Structure Overhaul Affords a Potent Purine PI3Kδ Inhibitor with Improved Tolerability. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (9)
                                     , 4370-4382. <a href="https://doi.org/10.1021/acs.jmedchem.8b01818" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01818</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01818&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01818%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure%252BOverhaul%252BAffords%252Ba%252BPotent%252BPurine%252BPI3K%2525CE%2525B4%252BInhibitor%252Bwith%252BImproved%252BTolerability%26aulast%3DMethot%26aufirst%3DJoey%2BL.%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D20112018%26date%3D22042019%26date%3D15042019%26volume%3D62%26issue%3D9%26spage%3D4370%26epage%3D4382" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Vunnam Srinivasulu, Ihsan Shehadeh, Monther A. Khanfar, Omar G. Malik, Hamadeh Tarazi, Imad A. Abu-Yousef, Anusha Sebastian, Nabil Baniowda, Matthew John O’Connor, <span class="NLM_string-name hlFld-ContribAuthor">Taleb H. Al-Tel</span>. </span><span class="cited-content_cbyCitation_article-title">One-Pot Synthesis of Diverse Collections of Benzoxazepine and Indolopyrazine Fused to Heterocyclic Systems. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2019,</strong> <em>84 </em>
                                    (2)
                                     , 934-948. <a href="https://doi.org/10.1021/acs.joc.8b02878" title="DOI URL">https://doi.org/10.1021/acs.joc.8b02878</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.8b02878&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.8b02878%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DOne-Pot%252BSynthesis%252Bof%252BDiverse%252BCollections%252Bof%252BBenzoxazepine%252Band%252BIndolopyrazine%252BFused%252Bto%252BHeterocyclic%252BSystems%26aulast%3DSrinivasulu%26aufirst%3DVunnam%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D10112018%26date%3D04012019%26date%3D24122018%26volume%3D84%26issue%3D2%26spage%3D934%26epage%3D948" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor "> Rémy    Angelaud    </span><span class="hlFld-ContribAuthor "> Steve    Staben </span><span class="hlFld-ContribAuthor "> Timothy    Heffron </span><span class="hlFld-ContribAuthor "> Andreas    Schuster </span><span class="hlFld-ContribAuthor "> Frédéric    St-Jean </span>. </span><span class="cited-content_cbyCitation_article-title">From Discovery to Market Readiness: The Research and Development of the β-Sparing Phosphatidylinositol 3-Kinase Inhibitor Taselisib. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 61-83. <a href="https://doi.org/10.1021/bk-2019-1332.ch003" title="DOI URL">https://doi.org/10.1021/bk-2019-1332.ch003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/bk-2019-1332.ch003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fbk-2019-1332.ch003%26sid%3Dliteratum%253Aachs%26atitle%3DFrom%252BDiscovery%252Bto%252BMarket%252BReadiness%25253A%252BThe%252BResearch%252Band%252BDevelopment%252Bof%252Bthe%252B%2525CE%2525B2-Sparing%252BPhosphatidylinositol%252B3-Kinase%252BInhibitor%252BTaselisib%26aulast%3DAngelaud%26aufirst%3DR%25C3%25A9my%26date%3D2019%26date%3D2019%26spage%3D61%26epage%3D83%26atitle%3DComplete%252BAccounts%252Bof%252BIntegrated%252BDrug%252BDiscovery%252Band%252BDevelopment%25253A%252BRecent%252BExamples%252Bfrom%252Bthe%252BPharmaceutical%252BIndustry%252BVolume%252B2%26aulast%3DPesti%26aufirst%3DJaan%2BA.%26date%3D2019%26date%3D2019%26volume%3D1332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Michael E. Dalziel, Julie A. Deichert, Diane E. Carrera, Danial Beaudry, Chong Han, Haiming Zhang, <span class="NLM_string-name hlFld-ContribAuthor">Remy Angelaud</span>. </span><span class="cited-content_cbyCitation_article-title">Magnesium Ethoxide Promoted Conversion of Nitriles to Amidines and Its Application in 5,6-Dihydroimidazobenzoxazepine Synthesis. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2018,</strong> <em>20 </em>
                                    (9)
                                     , 2624-2627. <a href="https://doi.org/10.1021/acs.orglett.8b00824" title="DOI URL">https://doi.org/10.1021/acs.orglett.8b00824</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.8b00824&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.8b00824%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DMagnesium%252BEthoxide%252BPromoted%252BConversion%252Bof%252BNitriles%252Bto%252BAmidines%252Band%252BIts%252BApplication%252Bin%252B5%25252C6-Dihydroimidazobenzoxazepine%252BSynthesis%26aulast%3DDalziel%26aufirst%3DMichael%2BE.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D13032018%26date%3D24042018%26volume%3D20%26issue%3D9%26spage%3D2624%26epage%3D2627" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="NLM_string-name hlFld-ContribAuthor">Tanaji T. Talele</span>. </span><span class="cited-content_cbyCitation_article-title">Natural-Products-Inspired Use of the gem-Dimethyl Group in Medicinal Chemistry. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (6)
                                     , 2166-2210. <a href="https://doi.org/10.1021/acs.jmedchem.7b00315" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00315</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00315&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b00315%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNatural-Products-Inspired%252BUse%252Bof%252Bthe%252Bgem-Dimethyl%252BGroup%252Bin%252BMedicinal%252BChemistry%26aulast%3DTalele%26aufirst%3DTanaji%2BT.%26date%3D2018%26date%3D2017%26date%3D2017%26date%3D27022017%26date%3D08092017%26date%3D29082017%26volume%3D61%26issue%3D6%26spage%3D2166%26epage%3D2210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brian S.  Safina</span>, <span class="hlFld-ContribAuthor ">Richard L.  Elliott</span>, <span class="hlFld-ContribAuthor ">Andrew K.  Forrest</span>, <span class="hlFld-ContribAuthor ">Robert A.  Heald</span>, <span class="hlFld-ContribAuthor ">Jeremy M.  Murray</span>, <span class="hlFld-ContribAuthor ">Jim  Nonomiya</span>, <span class="hlFld-ContribAuthor ">Jodie  Pang</span>, <span class="hlFld-ContribAuthor ">Laurent  Salphati</span>, <span class="hlFld-ContribAuthor ">Eileen M.  Seward</span>, <span class="hlFld-ContribAuthor ">Steven T.  Staben</span>, <span class="hlFld-ContribAuthor ">Mark  Ultsch</span>, <span class="hlFld-ContribAuthor ">Binqing  Wei</span>, <span class="hlFld-ContribAuthor ">Wenqian  Yang</span>, and <span class="hlFld-ContribAuthor ">Daniel P.  Sutherlin</span>  . </span><span class="cited-content_cbyCitation_article-title">Design of Selective Benzoxazepin PI3Kδ Inhibitors Through Control of Dihedral Angles. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2017,</strong> <em>8 </em>
                                    (9)
                                     , 936-940. <a href="https://doi.org/10.1021/acsmedchemlett.7b00170" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.7b00170</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.7b00170&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.7b00170%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%252Bof%252BSelective%252BBenzoxazepin%252BPI3K%2525CE%2525B4%252BInhibitors%252BThrough%252BControl%252Bof%252BDihedral%252BAngles%26aulast%3DSafina%26aufirst%3DBrian%2BS.%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D18042017%26date%3D25082017%26date%3D29082017%26date%3D14092017%26date%3D25082017%26volume%3D8%26issue%3D9%26spage%3D936%26epage%3D940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Georgette M.  Castanedo</span>, <span class="hlFld-ContribAuthor ">Nicole  Blaquiere</span>, <span class="hlFld-ContribAuthor ">Maureen  Beresini</span>, <span class="hlFld-ContribAuthor ">Brandon  Bravo</span>, <span class="hlFld-ContribAuthor ">Hans  Brightbill</span>, <span class="hlFld-ContribAuthor ">Jacob  Chen</span>, <span class="hlFld-ContribAuthor ">Hai-Feng  Cui</span>, <span class="hlFld-ContribAuthor ">Charles  Eigenbrot</span>, <span class="hlFld-ContribAuthor ">Christine  Everett</span>, <span class="hlFld-ContribAuthor ">Jianwen  Feng</span>, <span class="hlFld-ContribAuthor ">Robert  Godemann</span>, <span class="hlFld-ContribAuthor ">Emily  Gogol</span>, <span class="hlFld-ContribAuthor ">Sarah  Hymowitz</span>, <span class="hlFld-ContribAuthor ">Adam  Johnson</span>, <span class="hlFld-ContribAuthor ">Nobuhiko  Kayagaki</span>, <span class="hlFld-ContribAuthor ">Pawan Bir  Kohli</span>, <span class="hlFld-ContribAuthor ">Kathleen  Knüppel</span>, <span class="hlFld-ContribAuthor ">Joachim  Kraemer</span>, <span class="hlFld-ContribAuthor ">Susan  Krüger</span>, <span class="hlFld-ContribAuthor ">Pui  Loke</span>, <span class="hlFld-ContribAuthor ">Paul  McEwan</span>, <span class="hlFld-ContribAuthor ">Christian  Montalbetti</span>, <span class="hlFld-ContribAuthor ">David A.  Roberts</span>, <span class="hlFld-ContribAuthor ">Myron  Smith</span>, <span class="hlFld-ContribAuthor ">Stefan  Steinbacher</span>, <span class="hlFld-ContribAuthor ">Swathi  Sujatha-Bhaskar</span>, <span class="hlFld-ContribAuthor ">Ryan  Takahashi</span>, <span class="hlFld-ContribAuthor ">Xiaolu  Wang</span>, <span class="hlFld-ContribAuthor ">Lawren C.  Wu</span>, <span class="hlFld-ContribAuthor ">Yamin  Zhang</span>, and <span class="hlFld-ContribAuthor ">Steven T.  Staben</span>  . </span><span class="cited-content_cbyCitation_article-title">Structure-Based Design of Tricyclic NF-κB Inducing Kinase (NIK) Inhibitors That Have High Selectivity over Phosphoinositide-3-kinase (PI3K). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (2)
                                     , 627-640. <a href="https://doi.org/10.1021/acs.jmedchem.6b01363" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01363</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01363&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b01363%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure-Based%252BDesign%252Bof%252BTricyclic%252BNF-%2525CE%2525BAB%252BInducing%252BKinase%252B%252528NIK%252529%252BInhibitors%252BThat%252BHave%252BHigh%252BSelectivity%252Bover%252BPhosphoinositide-3-kinase%252B%252528PI3K%252529%26aulast%3DCastanedo%26aufirst%3DGeorgette%2BM.%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D23092016%26date%3D12012017%26date%3D26012017%26date%3D22122016%26volume%3D60%26issue%3D2%26spage%3D627%26epage%3D640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Timothy P.  Heffron</span>, <span class="hlFld-ContribAuthor ">Robert A.  Heald</span>, <span class="hlFld-ContribAuthor ">Chudi  Ndubaku</span>, <span class="hlFld-ContribAuthor ">BinQing  Wei</span>, <span class="hlFld-ContribAuthor ">Martin  Augistin</span>, <span class="hlFld-ContribAuthor ">Steven  Do</span>, <span class="hlFld-ContribAuthor ">Kyle  Edgar</span>, <span class="hlFld-ContribAuthor ">Charles  Eigenbrot</span>, <span class="hlFld-ContribAuthor ">Lori  Friedman</span>, <span class="hlFld-ContribAuthor ">Emanuela  Gancia</span>, <span class="hlFld-ContribAuthor ">Philip S.  Jackson</span>, <span class="hlFld-ContribAuthor ">Graham  Jones</span>, <span class="hlFld-ContribAuthor ">Aleksander  Kolesnikov</span>, <span class="hlFld-ContribAuthor ">Leslie B.  Lee</span>, <span class="hlFld-ContribAuthor ">John D.  Lesnick</span>, <span class="hlFld-ContribAuthor ">Cristina  Lewis</span>, <span class="hlFld-ContribAuthor ">Neville  McLean</span>, <span class="hlFld-ContribAuthor ">Mario  Mörtl</span>, <span class="hlFld-ContribAuthor ">Jim  Nonomiya</span>, <span class="hlFld-ContribAuthor ">Jodie  Pang</span>, <span class="hlFld-ContribAuthor ">Steve  Price</span>, <span class="hlFld-ContribAuthor ">Wei Wei  Prior</span>, <span class="hlFld-ContribAuthor ">Laurent  Salphati</span>, <span class="hlFld-ContribAuthor ">Steve  Sideris</span>, <span class="hlFld-ContribAuthor ">Steven T.  Staben</span>, <span class="hlFld-ContribAuthor ">Stefan  Steinbacher</span>, <span class="hlFld-ContribAuthor ">Vickie  Tsui</span>, <span class="hlFld-ContribAuthor ">Jeffrey  Wallin</span>, <span class="hlFld-ContribAuthor ">Deepak  Sampath</span>, and <span class="hlFld-ContribAuthor ">Alan G.  Olivero</span>  . </span><span class="cited-content_cbyCitation_article-title">The Rational Design of Selective Benzoxazepin Inhibitors of the α-Isoform of Phosphoinositide 3-Kinase Culminating in the Identification of (S)-2-((2-(1-Isopropyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)oxy)propanamide (GDC-0326). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (3)
                                     , 985-1002. <a href="https://doi.org/10.1021/acs.jmedchem.5b01483" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01483</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01483&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b01483%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DThe%252BRational%252BDesign%252Bof%252BSelective%252BBenzoxazepin%252BInhibitors%252Bof%252Bthe%252B%2525CE%2525B1-Isoform%252Bof%252BPhosphoinositide%252B3-Kinase%252BCulminating%252Bin%252Bthe%252BIdentification%252Bof%252B%252528S%252529-2-%252528%2525282-%2525281-Isopropyl-1H-1%25252C2%25252C4-triazol-5-yl%252529-5%25252C6-dihydrobenzo%25255Bf%25255Dimidazo%25255B1%25252C2-d%25255D%25255B1%25252C4%25255Doxazepin-9-yl%252529oxy%252529propanamide%252B%252528GDC-0326%252529%26aulast%3DHeffron%26aufirst%3DTimothy%2BP.%26date%3D2016%26date%3D2016%26date%3D2015%26date%3D23092015%26date%3D20012016%26date%3D11022016%26date%3D07012016%26volume%3D59%26issue%3D3%26spage%3D985%26epage%3D1002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Robert  Heald</span>, <span class="hlFld-ContribAuthor ">Krista K.  Bowman</span>, <span class="hlFld-ContribAuthor ">Marian C.  Bryan</span>, <span class="hlFld-ContribAuthor ">Daniel  Burdick</span>, <span class="hlFld-ContribAuthor ">Bryan  Chan</span>, <span class="hlFld-ContribAuthor ">Emily  Chan</span>, <span class="hlFld-ContribAuthor ">Yuan  Chen</span>, <span class="hlFld-ContribAuthor ">Saundra  Clausen</span>, <span class="hlFld-ContribAuthor ">Belen  Dominguez-Fernandez</span>, <span class="hlFld-ContribAuthor ">Charles  Eigenbrot</span>, <span class="hlFld-ContribAuthor ">Richard  Elliott</span>, <span class="hlFld-ContribAuthor ">Emily J.  Hanan</span>, <span class="hlFld-ContribAuthor ">Philip  Jackson</span>, <span class="hlFld-ContribAuthor ">Jamie  Knight</span>, <span class="hlFld-ContribAuthor ">Hank  La</span>, <span class="hlFld-ContribAuthor ">Michael  Lainchbury</span>, <span class="hlFld-ContribAuthor ">Shiva  Malek</span>, <span class="hlFld-ContribAuthor ">Sam  Mann</span>, <span class="hlFld-ContribAuthor ">Mark  Merchant</span>, <span class="hlFld-ContribAuthor ">Kyle  Mortara</span>, <span class="hlFld-ContribAuthor ">Hans  Purkey</span>, <span class="hlFld-ContribAuthor ">Gabriele  Schaefer</span>, <span class="hlFld-ContribAuthor ">Stephen  Schmidt</span>, <span class="hlFld-ContribAuthor ">Eileen  Seward</span>, <span class="hlFld-ContribAuthor ">Steve  Sideris</span>, <span class="hlFld-ContribAuthor ">Lily  Shao</span>, <span class="hlFld-ContribAuthor ">Shumei  Wang</span>, <span class="hlFld-ContribAuthor ">Kuen  Yeap</span>, <span class="hlFld-ContribAuthor ">Ivana  Yen</span>, <span class="hlFld-ContribAuthor ">Christine  Yu</span>, and <span class="hlFld-ContribAuthor ">Timothy P.  Heffron</span>  . </span><span class="cited-content_cbyCitation_article-title">Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (22)
                                     , 8877-8895. <a href="https://doi.org/10.1021/acs.jmedchem.5b01412" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01412</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01412&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b01412%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNoncovalent%252BMutant%252BSelective%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252BInhibitors%25253A%252BA%252BLead%252BOptimization%252BCase%252BStudy%26aulast%3DHeald%26aufirst%3DRobert%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D30062015%26date%3D12112015%26date%3D25112015%26date%3D10102015%26volume%3D58%26issue%3D22%26spage%3D8877%26epage%3D8895" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Iksen</span>, <span class="hlFld-ContribAuthor ">Sutthaorn  Pothongsrisit</span>, <span class="hlFld-ContribAuthor ">Varisa  Pongrakhananon</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting the PI3K/AKT/mTOR Signaling Pathway in Lung Cancer: An Update Regarding Potential Drugs and Natural Products. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2021,</strong> <em>26 </em>
                                    (13)
                                     , 4100. <a href="https://doi.org/10.3390/molecules26134100" title="DOI URL">https://doi.org/10.3390/molecules26134100</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules26134100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules26134100%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DTargeting%252Bthe%252BPI3K%25252FAKT%25252FmTOR%252BSignaling%252BPathway%252Bin%252BLung%252BCancer%25253A%252BAn%252BUpdate%252BRegarding%252BPotential%252BDrugs%252Band%252BNatural%252BProducts%26aulast%3DIksen%26date%3D2021%26date%3D2021%26volume%3D26%26issue%3D13%26spage%3D4100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Huayi  Li</span>, <span class="hlFld-ContribAuthor ">Lorenzo  Prever</span>, <span class="hlFld-ContribAuthor ">Emilio  Hirsch</span>, <span class="hlFld-ContribAuthor ">Federico  Gulluni</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting PI3K/AKT/mTOR Signaling Pathway in Breast Cancer. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2021,</strong> <em>13 </em>
                                    (14)
                                     , 3517. <a href="https://doi.org/10.3390/cancers13143517" title="DOI URL">https://doi.org/10.3390/cancers13143517</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers13143517&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers13143517%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DTargeting%252BPI3K%25252FAKT%25252FmTOR%252BSignaling%252BPathway%252Bin%252BBreast%252BCancer%26aulast%3DLi%26aufirst%3DHuayi%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D14%26spage%3D3517" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bart  Vanhaesebroeck</span>, <span class="hlFld-ContribAuthor ">Matthew W. D.  Perry</span>, <span class="hlFld-ContribAuthor ">Jennifer R.  Brown</span>, <span class="hlFld-ContribAuthor ">Fabrice  André</span>, <span class="hlFld-ContribAuthor ">Klaus  Okkenhaug</span>. </span><span class="cited-content_cbyCitation_article-title">PI3K inhibitors are finally coming of age. </span><span class="cited-content_cbyCitation_journal-name">Nature Reviews Drug Discovery</span><span> <strong>2021,</strong> <em>170 </em><a href="https://doi.org/10.1038/s41573-021-00209-1" title="DOI URL">https://doi.org/10.1038/s41573-021-00209-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41573-021-00209-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41573-021-00209-1%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Reviews%2520Drug%2520Discovery%26atitle%3DPI3K%252Binhibitors%252Bare%252Bfinally%252Bcoming%252Bof%252Bage%26aulast%3DVanhaesebroeck%26aufirst%3DBart%26date%3D2021%26date%3D2021%26volume%3D170" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pau  Castel</span>, <span class="hlFld-ContribAuthor ">Eneda  Toska</span>, <span class="hlFld-ContribAuthor ">Jeffrey A.  Engelman</span>, <span class="hlFld-ContribAuthor ">Maurizio  Scaltriti</span>. </span><span class="cited-content_cbyCitation_article-title">The present and future of PI3K inhibitors for cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">Nature Cancer</span><span> <strong>2021,</strong> <em>2 </em>
                                    (6)
                                     , 587-597. <a href="https://doi.org/10.1038/s43018-021-00218-4" title="DOI URL">https://doi.org/10.1038/s43018-021-00218-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s43018-021-00218-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs43018-021-00218-4%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Cancer%26atitle%3DThe%252Bpresent%252Band%252Bfuture%252Bof%252BPI3K%252Binhibitors%252Bfor%252Bcancer%252Btherapy%26aulast%3DCastel%26aufirst%3DPau%26date%3D2021%26date%3D2021%26volume%3D2%26issue%3D6%26spage%3D587%26epage%3D597" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chao  Dong</span>, <span class="hlFld-ContribAuthor ">Jiao  Wu</span>, <span class="hlFld-ContribAuthor ">Yin  Chen</span>, <span class="hlFld-ContribAuthor ">Jianyun  Nie</span>, <span class="hlFld-ContribAuthor ">Ceshi  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Pharmacology</span><span> <strong>2021,</strong> <em>12 </em><a href="https://doi.org/10.3389/fphar.2021.628690" title="DOI URL">https://doi.org/10.3389/fphar.2021.628690</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fphar.2021.628690&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffphar.2021.628690%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Pharmacology%26atitle%3DActivation%252Bof%252BPI3K%25252FAKT%25252FmTOR%252BPathway%252BCauses%252BDrug%252BResistance%252Bin%252BBreast%252BCancer%26aulast%3DDong%26aufirst%3DChao%26date%3D2021%26date%3D2021%26volume%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Carmen  Criscitiello</span>, <span class="hlFld-ContribAuthor ">Antonio  Marra</span>, <span class="hlFld-ContribAuthor ">Giuseppe  Curigliano</span>. </span><span class="cited-content_cbyCitation_article-title">PIK3CA Mutation Assessment in HR+/HER2− Metastatic Breast Cancer: Overview for Oncology Clinical Practice. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Pathology</span><span> <strong>2021,</strong> <em>2 </em>
                                    (1)
                                     , 42-54. <a href="https://doi.org/10.3390/jmp2010005" title="DOI URL">https://doi.org/10.3390/jmp2010005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/jmp2010005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fjmp2010005%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Pathology%26atitle%3DPIK3CA%252BMutation%252BAssessment%252Bin%252BHR%25252B%25252FHER2%2525E2%252588%252592%252BMetastatic%252BBreast%252BCancer%25253A%252BOverview%252Bfor%252BOncology%252BClinical%252BPractice%26aulast%3DCriscitiello%26aufirst%3DCarmen%26date%3D2021%26date%3D2021%26volume%3D2%26issue%3D1%26spage%3D42%26epage%3D54" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">S.  Dent</span>, <span class="hlFld-ContribAuthor ">J.  Cortés</span>, <span class="hlFld-ContribAuthor ">Y.-H.  Im</span>, <span class="hlFld-ContribAuthor ">V.  Diéras</span>, <span class="hlFld-ContribAuthor ">N.  Harbeck</span>, <span class="hlFld-ContribAuthor ">I.E.  Krop</span>, <span class="hlFld-ContribAuthor ">T.R.  Wilson</span>, <span class="hlFld-ContribAuthor ">N.  Cui</span>, <span class="hlFld-ContribAuthor ">F.  Schimmoller</span>, <span class="hlFld-ContribAuthor ">J.Y.  Hsu</span>, <span class="hlFld-ContribAuthor ">J.  He</span>, <span class="hlFld-ContribAuthor ">M.  De Laurentiis</span>, <span class="hlFld-ContribAuthor ">S.  Sousa</span>, <span class="hlFld-ContribAuthor ">P.  Drullinsky</span>, <span class="hlFld-ContribAuthor ">W.  Jacot</span>. </span><span class="cited-content_cbyCitation_article-title">Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial. </span><span class="cited-content_cbyCitation_journal-name">Annals of Oncology</span><span> <strong>2021,</strong> <em>32 </em>
                                    (2)
                                     , 197-207. <a href="https://doi.org/10.1016/j.annonc.2020.10.596" title="DOI URL">https://doi.org/10.1016/j.annonc.2020.10.596</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.annonc.2020.10.596&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.annonc.2020.10.596%26sid%3Dliteratum%253Aachs%26jtitle%3DAnnals%2520of%2520Oncology%26atitle%3DPhase%252BIII%252Brandomized%252Bstudy%252Bof%252Btaselisib%252Bor%252Bplacebo%252Bwith%252Bfulvestrant%252Bin%252Bestrogen%252Breceptor-positive%25252C%252BPIK3CA-mutant%25252C%252BHER2-negative%25252C%252Badvanced%252Bbreast%252Bcancer%25253A%252Bthe%252BSANDPIPER%252Btrial%26aulast%3DDent%26aufirst%3DS.%26date%3D2021%26volume%3D32%26issue%3D2%26spage%3D197%26epage%3D207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Komal  Jhaveri</span>, <span class="hlFld-ContribAuthor ">Matthew T.  Chang</span>, <span class="hlFld-ContribAuthor ">Dejan  Juric</span>, <span class="hlFld-ContribAuthor ">Cristina  Saura</span>, <span class="hlFld-ContribAuthor ">Valentina  Gambardella</span>, <span class="hlFld-ContribAuthor ">Anton  Melnyk</span>, <span class="hlFld-ContribAuthor ">Manish R.  Patel</span>, <span class="hlFld-ContribAuthor ">Vincent  Ribrag</span>, <span class="hlFld-ContribAuthor ">Cynthia X.  Ma</span>, <span class="hlFld-ContribAuthor ">Raid  Aljumaily</span>, <span class="hlFld-ContribAuthor ">Philippe L.  Bedard</span>, <span class="hlFld-ContribAuthor ">Jasgit C.  Sachdev</span>, <span class="hlFld-ContribAuthor ">Lara  Dunn</span>, <span class="hlFld-ContribAuthor ">Helen  Won</span>, <span class="hlFld-ContribAuthor ">John  Bond</span>, <span class="hlFld-ContribAuthor ">Surai  Jones</span>, <span class="hlFld-ContribAuthor ">Heidi M.  Savage</span>, <span class="hlFld-ContribAuthor ">Maurizio  Scaltriti</span>, <span class="hlFld-ContribAuthor ">Timothy R.  Wilson</span>, <span class="hlFld-ContribAuthor ">Michael C.  Wei</span>, <span class="hlFld-ContribAuthor ">David M.  Hyman</span>. </span><span class="cited-content_cbyCitation_article-title">Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with
              PIK3CA
              -Mutant Cancers. </span><span class="cited-content_cbyCitation_journal-name">Clinical Cancer Research</span><span> <strong>2021,</strong> <em>27 </em>
                                    (2)
                                     , 447-459. <a href="https://doi.org/10.1158/1078-0432.CCR-20-2657" title="DOI URL">https://doi.org/10.1158/1078-0432.CCR-20-2657</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1078-0432.CCR-20-2657&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1078-0432.CCR-20-2657%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Cancer%2520Research%26atitle%3DPhase%252BI%252BBasket%252BStudy%252Bof%252BTaselisib%25252C%252Ban%252BIsoform-Selective%252BPI3K%252BInhibitor%25252C%252Bin%252BPatients%252Bwith%252BPIK3CA%252B-Mutant%252BCancers%26aulast%3DJhaveri%26aufirst%3DKomal%26date%3D2021%26date%3D2020%26volume%3D27%26issue%3D2%26spage%3D447%26epage%3D459" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dongyan  Gu</span>, <span class="hlFld-ContribAuthor ">Gang  Cheng</span>, <span class="hlFld-ContribAuthor ">Mengmeng  Zhang</span>, <span class="hlFld-ContribAuthor ">Yu-Bo  Zhou</span>, <span class="hlFld-ContribAuthor ">Jia  Li</span>, <span class="hlFld-ContribAuthor ">Rong  Sheng</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 2-(5-(quinolin-6-yl)-1,3,4-oxadiazol-2-yl)acetamide derivatives as novel PI3Kα inhibitors via docking-based virtual screening. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2021,</strong> <em>29 </em>, 115863. <a href="https://doi.org/10.1016/j.bmc.2020.115863" title="DOI URL">https://doi.org/10.1016/j.bmc.2020.115863</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2020.115863&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2020.115863%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B2-%2525285-%252528quinolin-6-yl%252529-1%25252C3%25252C4-oxadiazol-2-yl%252529acetamide%252Bderivatives%252Bas%252Bnovel%252BPI3K%2525CE%2525B1%252Binhibitors%252Bvia%252Bdocking-based%252Bvirtual%252Bscreening%26aulast%3DGu%26aufirst%3DDongyan%26date%3D2021%26volume%3D29%26spage%3D115863" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stefan G.  Koenig</span>, <span class="hlFld-ContribAuthor ">Keena L.  Green</span>, <span class="hlFld-ContribAuthor ">Barbara  Müller</span>, <span class="hlFld-ContribAuthor ">C. Gregory  Sowell</span>, <span class="hlFld-ContribAuthor ">David  Askin</span>, <span class="hlFld-ContribAuthor ">Francis  Gosselin</span>. </span><span class="cited-content_cbyCitation_article-title">Development of a practical synthesis to PI3K α-selective inhibitor GDC-0326. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2021,</strong> <em>79 </em>, 131840. <a href="https://doi.org/10.1016/j.tet.2020.131840" title="DOI URL">https://doi.org/10.1016/j.tet.2020.131840</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2020.131840&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2020.131840%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DDevelopment%252Bof%252Ba%252Bpractical%252Bsynthesis%252Bto%252BPI3K%252B%2525CE%2525B1-selective%252Binhibitor%252BGDC-0326%26aulast%3DKoenig%26aufirst%3DStefan%2BG.%26date%3D2021%26volume%3D79%26spage%3D131840" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alexander  Sapegin</span>, <span class="hlFld-ContribAuthor ">Elena  Reutskaya</span>, <span class="hlFld-ContribAuthor ">Mikhail  Krasavin</span>. </span><span class="cited-content_cbyCitation_article-title">1,4-Oxazepines and 1,4-Thiazepines. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,<a href="https://doi.org/10.1016/B978-0-12-818655-8.00077-9" title="DOI URL">https://doi.org/10.1016/B978-0-12-818655-8.00077-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-818655-8.00077-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-818655-8.00077-9%26sid%3Dliteratum%253Aachs%26atitle%3D1%25252C4-Oxazepines%252Band%252B1%25252C4-Thiazepines%26aulast%3DSapegin%26aufirst%3DAlexander%26date%3D2021%26pub%3DElsevier%26atitle%3DReference%252BModule%252Bin%252BChemistry%25252C%252BMolecular%252BSciences%252Band%252BChemical%252BEngineering%26date%3D2021%26volume%3D74" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Carly Bess  Williams</span>, <span class="hlFld-ContribAuthor ">Caroline A.  Nebhan</span>, <span class="hlFld-ContribAuthor ">Jinming  Yang</span>, <span class="hlFld-ContribAuthor ">Lauren S.  Starnes</span>, <span class="hlFld-ContribAuthor ">Chi  Yan</span>, <span class="hlFld-ContribAuthor ">Anna E.  Vilgelm</span>, <span class="hlFld-ContribAuthor ">Sheau-Chiann  Chen</span>, <span class="hlFld-ContribAuthor ">Gregory  Dan Ayers</span>, <span class="hlFld-ContribAuthor ">Vandana  Abramson</span>, <span class="hlFld-ContribAuthor ">Ingrid A.  Mayer</span>, <span class="hlFld-ContribAuthor ">Ann  Richmond</span>. </span><span class="cited-content_cbyCitation_article-title">Correlative studies investigating effects of PI3K inhibition on peripheral leukocytes in metastatic breast cancer: potential implications for immunotherapy. </span><span class="cited-content_cbyCitation_journal-name">Breast Cancer Research and Treatment</span><span> <strong>2020,</strong> <em>184 </em>
                                    (2)
                                     , 357-364. <a href="https://doi.org/10.1007/s10549-020-05846-5" title="DOI URL">https://doi.org/10.1007/s10549-020-05846-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10549-020-05846-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10549-020-05846-5%26sid%3Dliteratum%253Aachs%26jtitle%3DBreast%2520Cancer%2520Research%2520and%2520Treatment%26atitle%3DCorrelative%252Bstudies%252Binvestigating%252Beffects%252Bof%252BPI3K%252Binhibition%252Bon%252Bperipheral%252Bleukocytes%252Bin%252Bmetastatic%252Bbreast%252Bcancer%25253A%252Bpotential%252Bimplications%252Bfor%252Bimmunotherapy%26aulast%3DWilliams%26aufirst%3DCarly%2BBess%26date%3D2020%26date%3D2020%26volume%3D184%26issue%3D2%26spage%3D357%26epage%3D364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sara E.  Nunnery</span>, <span class="hlFld-ContribAuthor ">Ingrid A.  Mayer</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting the PI3K/AKT/mTOR Pathway in Hormone-Positive Breast Cancer. </span><span class="cited-content_cbyCitation_journal-name">Drugs</span><span> <strong>2020,</strong> <em>80 </em>
                                    (16)
                                     , 1685-1697. <a href="https://doi.org/10.1007/s40265-020-01394-w" title="DOI URL">https://doi.org/10.1007/s40265-020-01394-w</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s40265-020-01394-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs40265-020-01394-w%26sid%3Dliteratum%253Aachs%26jtitle%3DDrugs%26atitle%3DTargeting%252Bthe%252BPI3K%25252FAKT%25252FmTOR%252BPathway%252Bin%252BHormone-Positive%252BBreast%252BCancer%26aulast%3DNunnery%26aufirst%3DSara%2BE.%26date%3D2020%26date%3D2020%26volume%3D80%26issue%3D16%26spage%3D1685%26epage%3D1697" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Susana  Ros</span>, <span class="hlFld-ContribAuthor ">Alan J.  Wright</span>, <span class="hlFld-ContribAuthor ">Paula  D'Santos</span>, <span class="hlFld-ContribAuthor ">De-en  Hu</span>, <span class="hlFld-ContribAuthor ">Richard L.  Hesketh</span>, <span class="hlFld-ContribAuthor ">Yaniv  Lubling</span>, <span class="hlFld-ContribAuthor ">Dimitra  Georgopoulou</span>, <span class="hlFld-ContribAuthor ">Giulia  Lerda</span>, <span class="hlFld-ContribAuthor ">Dominique-Laurent  Couturier</span>, <span class="hlFld-ContribAuthor ">Pedram  Razavi</span>, <span class="hlFld-ContribAuthor ">Rapahel  Pelossof</span>, <span class="hlFld-ContribAuthor ">Ankita S.  Batra</span>, <span class="hlFld-ContribAuthor ">Elizabeth  Mannion</span>, <span class="hlFld-ContribAuthor ">David Y.  Lewis</span>, <span class="hlFld-ContribAuthor ">Alistair  Martin</span>, <span class="hlFld-ContribAuthor ">Richard D.  Baird</span>, <span class="hlFld-ContribAuthor ">Mafalda  Oliveira</span>, <span class="hlFld-ContribAuthor ">Leonora W.  de Boo</span>, <span class="hlFld-ContribAuthor ">Sabine C.  Linn</span>, <span class="hlFld-ContribAuthor ">Maurizio  Scaltriti</span>, <span class="hlFld-ContribAuthor ">Oscar M.  Rueda</span>, <span class="hlFld-ContribAuthor ">Alejandra  Bruna</span>, <span class="hlFld-ContribAuthor ">Carlos  Caldas</span>, <span class="hlFld-ContribAuthor ">Kevin M.  Brindle</span>. </span><span class="cited-content_cbyCitation_article-title">Metabolic Imaging Detects Resistance to PI3Kα Inhibition Mediated by Persistent FOXM1 Expression in ER+ Breast Cancer. </span><span class="cited-content_cbyCitation_journal-name">Cancer Cell</span><span> <strong>2020,</strong> <em>38 </em>
                                    (4)
                                     , 516-533.e9. <a href="https://doi.org/10.1016/j.ccell.2020.08.016" title="DOI URL">https://doi.org/10.1016/j.ccell.2020.08.016</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ccell.2020.08.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ccell.2020.08.016%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Cell%26atitle%3DMetabolic%252BImaging%252BDetects%252BResistance%252Bto%252BPI3K%2525CE%2525B1%252BInhibition%252BMediated%252Bby%252BPersistent%252BFOXM1%252BExpression%252Bin%252BER%25252B%252BBreast%252BCancer%26aulast%3DRos%26aufirst%3DSusana%26date%3D2020%26volume%3D38%26issue%3D4%26spage%3D516%26epage%3D533.e9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mona  Foth</span>, <span class="hlFld-ContribAuthor ">Gennie  Parkman</span>, <span class="hlFld-ContribAuthor ">Benjamin  Battistone</span>, <span class="hlFld-ContribAuthor ">Martin  McMahon</span>. </span><span class="cited-content_cbyCitation_article-title">RAC1
              mutation is not a predictive biomarker for PI3’‐kinase‐β‐selective pathway‐targeted therapy. </span><span class="cited-content_cbyCitation_journal-name">Pigment Cell & Melanoma Research</span><span> <strong>2020,</strong> <em>33 </em>
                                    (5)
                                     , 719-730. <a href="https://doi.org/10.1111/pcmr.12889" title="DOI URL">https://doi.org/10.1111/pcmr.12889</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/pcmr.12889&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fpcmr.12889%26sid%3Dliteratum%253Aachs%26jtitle%3DPigment%2520Cell%2520%2526%2520Melanoma%2520Research%26atitle%3DRAC1%252Bmutation%252Bis%252Bnot%252Ba%252Bpredictive%252Bbiomarker%252Bfor%252BPI3%2525E2%252580%252599%2525E2%252580%252590kinase%2525E2%252580%252590%2525CE%2525B2%2525E2%252580%252590selective%252Bpathway%2525E2%252580%252590targeted%252Btherapy%26aulast%3DFoth%26aufirst%3DMona%26date%3D2020%26date%3D2020%26volume%3D33%26issue%3D5%26spage%3D719%26epage%3D730" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lee S.  Schwartzberg</span>, <span class="hlFld-ContribAuthor ">Gregory A.  Vidal</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting PIK3CA Alterations in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2–Negative Advanced Breast Cancer: New Therapeutic Approaches and Practical Considerations. </span><span class="cited-content_cbyCitation_journal-name">Clinical Breast Cancer</span><span> <strong>2020,</strong> <em>20 </em>
                                    (4)
                                     , e439-e449. <a href="https://doi.org/10.1016/j.clbc.2020.02.002" title="DOI URL">https://doi.org/10.1016/j.clbc.2020.02.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.clbc.2020.02.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.clbc.2020.02.002%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Breast%2520Cancer%26atitle%3DTargeting%252BPIK3CA%252BAlterations%252Bin%252BHormone%252BReceptor-Positive%25252C%252BHuman%252BEpidermal%252BGrowth%252BFactor%252BReceptor-2%2525E2%252580%252593Negative%252BAdvanced%252BBreast%252BCancer%25253A%252BNew%252BTherapeutic%252BApproaches%252Band%252BPractical%252BConsiderations%26aulast%3DSchwartzberg%26aufirst%3DLee%2BS.%26date%3D2020%26volume%3D20%26issue%3D4%26spage%3De439%26epage%3De449" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stefania  Cocco</span>, <span class="hlFld-ContribAuthor ">Michela  Piezzo</span>, <span class="hlFld-ContribAuthor ">Alessandra  Calabrese</span>, <span class="hlFld-ContribAuthor ">Daniela  Cianniello</span>, <span class="hlFld-ContribAuthor ">Roberta  Caputo</span>, <span class="hlFld-ContribAuthor ">Vincenzo  Di Lauro</span>, <span class="hlFld-ContribAuthor ">Giuseppina  Fusco</span>, <span class="hlFld-ContribAuthor ">Germira  di Gioia</span>, <span class="hlFld-ContribAuthor ">Marina  Licenziato</span>, <span class="hlFld-ContribAuthor ">Michelino  de Laurentiis</span>. </span><span class="cited-content_cbyCitation_article-title">Biomarkers in Triple-Negative Breast Cancer: State-of-the-Art and Future Perspectives. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2020,</strong> <em>21 </em>
                                    (13)
                                     , 4579. <a href="https://doi.org/10.3390/ijms21134579" title="DOI URL">https://doi.org/10.3390/ijms21134579</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms21134579&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms21134579%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DBiomarkers%252Bin%252BTriple-Negative%252BBreast%252BCancer%25253A%252BState-of-the-Art%252Band%252BFuture%252BPerspectives%26aulast%3DCocco%26aufirst%3DStefania%26date%3D2020%26date%3D2020%26volume%3D21%26issue%3D13%26spage%3D4579" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mingzhen  Zhang</span>, <span class="hlFld-ContribAuthor ">Hyunbum  Jang</span>, <span class="hlFld-ContribAuthor ">Ruth  Nussinov</span>. </span><span class="cited-content_cbyCitation_article-title">PI3K inhibitors: review and new strategies. </span><span class="cited-content_cbyCitation_journal-name">Chemical Science</span><span> <strong>2020,</strong> <em>11 </em>
                                    (23)
                                     , 5855-5865. <a href="https://doi.org/10.1039/D0SC01676D" title="DOI URL">https://doi.org/10.1039/D0SC01676D</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0SC01676D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0SC01676D%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Science%26atitle%3DPI3K%252Binhibitors%25253A%252Breview%252Band%252Bnew%252Bstrategies%26aulast%3DZhang%26aufirst%3DMingzhen%26date%3D2020%26date%3D2020%26volume%3D11%26issue%3D23%26spage%3D5855%26epage%3D5865" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rammohan R.Y.  Bheemanaboina</span>. </span><span class="cited-content_cbyCitation_article-title">Isoform-Selective PI3K Inhibitors for Various Diseases. </span><span class="cited-content_cbyCitation_journal-name">Current Topics in Medicinal Chemistry</span><span> <strong>2020,</strong> <em>20 </em>
                                    (12)
                                     , 1074-1092. <a href="https://doi.org/10.2174/1568026620666200106141717" title="DOI URL">https://doi.org/10.2174/1568026620666200106141717</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1568026620666200106141717&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1568026620666200106141717%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Topics%2520in%2520Medicinal%2520Chemistry%26atitle%3DIsoform-Selective%252BPI3K%252BInhibitors%252Bfor%252BVarious%252BDiseases%26aulast%3DBheemanaboina%26aufirst%3DRammohan%2BR.Y.%26date%3D2020%26volume%3D20%26issue%3D12%26spage%3D1074%26epage%3D1092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pamela R.  Drullinsky</span>, <span class="hlFld-ContribAuthor ">Sara A.  Hurvitz</span>. </span><span class="cited-content_cbyCitation_article-title">Mechanistic basis for PI3K inhibitor antitumor activity and adverse reactions in advanced breast cancer. </span><span class="cited-content_cbyCitation_journal-name">Breast Cancer Research and Treatment</span><span> <strong>2020,</strong> <em>181 </em>
                                    (2)
                                     , 233-248. <a href="https://doi.org/10.1007/s10549-020-05618-1" title="DOI URL">https://doi.org/10.1007/s10549-020-05618-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10549-020-05618-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10549-020-05618-1%26sid%3Dliteratum%253Aachs%26jtitle%3DBreast%2520Cancer%2520Research%2520and%2520Treatment%26atitle%3DMechanistic%252Bbasis%252Bfor%252BPI3K%252Binhibitor%252Bantitumor%252Bactivity%252Band%252Badverse%252Breactions%252Bin%252Badvanced%252Bbreast%252Bcancer%26aulast%3DDrullinsky%26aufirst%3DPamela%2BR.%26date%3D2020%26date%3D2020%26volume%3D181%26issue%3D2%26spage%3D233%26epage%3D248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kuanglei  Wang</span>, <span class="hlFld-ContribAuthor ">Hongxi  Zhu</span>, <span class="hlFld-ContribAuthor ">Hongqian  Zhao</span>, <span class="hlFld-ContribAuthor ">Kun  Zhang</span>, <span class="hlFld-ContribAuthor ">Yongshou  Tian</span>. </span><span class="cited-content_cbyCitation_article-title">Application of carbamyl in structural optimization. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>98 </em>, 103757. <a href="https://doi.org/10.1016/j.bioorg.2020.103757" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.103757</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.103757&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.103757%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DApplication%252Bof%252Bcarbamyl%252Bin%252Bstructural%252Boptimization%26aulast%3DWang%26aufirst%3DKuanglei%26date%3D2020%26volume%3D98%26spage%3D103757" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xingrong  Liu</span>, <span class="hlFld-ContribAuthor ">Xiaorong  Liang</span>, <span class="hlFld-ContribAuthor ">Jenninfer  LeCouter</span>, <span class="hlFld-ContribAuthor ">Savita  Ubhayakar</span>, <span class="hlFld-ContribAuthor ">Jacob  Chen</span>, <span class="hlFld-ContribAuthor ">Jay  Cheng</span>, <span class="hlFld-ContribAuthor ">Tom  Lee</span>, <span class="hlFld-ContribAuthor ">Joe  Lubach</span>, <span class="hlFld-ContribAuthor ">Jim  Nonomiya</span>, <span class="hlFld-ContribAuthor ">Sheerin  Shahidi-Latham</span>, <span class="hlFld-ContribAuthor ">Cristine  Quiason</span>, <span class="hlFld-ContribAuthor ">Eric  Solon</span>, <span class="hlFld-ContribAuthor ">Matthew  Wright</span>, <span class="hlFld-ContribAuthor ">Cornelis E.C.A.  Hop</span>, <span class="hlFld-ContribAuthor ">Timothy P.  Heffron</span>. </span><span class="cited-content_cbyCitation_article-title">Characterization of Antineovascularization Activity and Ocular Pharmacokinetics of Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor GNE-947. </span><span class="cited-content_cbyCitation_journal-name">Drug Metabolism and Disposition</span><span> <strong>2020,</strong> <em>48 </em>
                                    (5)
                                     , 408-419. <a href="https://doi.org/10.1124/dmd.119.089763" title="DOI URL">https://doi.org/10.1124/dmd.119.089763</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/dmd.119.089763&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fdmd.119.089763%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Metabolism%2520and%2520Disposition%26atitle%3DCharacterization%252Bof%252BAntineovascularization%252BActivity%252Band%252BOcular%252BPharmacokinetics%252Bof%252BPhosphoinositide%252B3-Kinase%25252FMammalian%252BTarget%252Bof%252BRapamycin%252BInhibitor%252BGNE-947%26aulast%3DLiu%26aufirst%3DXingrong%26date%3D2020%26date%3D2020%26volume%3D48%26issue%3D5%26spage%3D408%26epage%3D419" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Franziska E.  Marquard</span>, <span class="hlFld-ContribAuthor ">Manfred  Jücker</span>. </span><span class="cited-content_cbyCitation_article-title">PI3K/AKT/mTOR signaling as a molecular target in head and neck cancer. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Pharmacology</span><span> <strong>2020,</strong> <em>172 </em>, 113729. <a href="https://doi.org/10.1016/j.bcp.2019.113729" title="DOI URL">https://doi.org/10.1016/j.bcp.2019.113729</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bcp.2019.113729&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bcp.2019.113729%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Pharmacology%26atitle%3DPI3K%25252FAKT%25252FmTOR%252Bsignaling%252Bas%252Ba%252Bmolecular%252Btarget%252Bin%252Bhead%252Band%252Bneck%252Bcancer%26aulast%3DMarquard%26aufirst%3DFranziska%2BE.%26date%3D2020%26volume%3D172%26spage%3D113729" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Heather M.  Moore</span>, <span class="hlFld-ContribAuthor ">Heidi M.  Savage</span>, <span class="hlFld-ContribAuthor ">Carol  O'Brien</span>, <span class="hlFld-ContribAuthor ">Wei  Zhou</span>, <span class="hlFld-ContribAuthor ">Ethan S.  Sokol</span>, <span class="hlFld-ContribAuthor ">Michael E.  Goldberg</span>, <span class="hlFld-ContribAuthor ">Ciara  Metcalfe</span>, <span class="hlFld-ContribAuthor ">Lori S.  Friedman</span>, <span class="hlFld-ContribAuthor ">Mark R.  Lackner</span>, <span class="hlFld-ContribAuthor ">Timothy R.  Wilson</span>. </span><span class="cited-content_cbyCitation_article-title">Predictive and Pharmacodynamic Biomarkers of Response to the Phosphatidylinositol 3-Kinase Inhibitor Taselisib in Breast Cancer Preclinical Models. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Therapeutics</span><span> <strong>2020,</strong> <em>19 </em>
                                    (1)
                                     , 292-303. <a href="https://doi.org/10.1158/1535-7163.MCT-19-0284" title="DOI URL">https://doi.org/10.1158/1535-7163.MCT-19-0284</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1535-7163.MCT-19-0284&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1535-7163.MCT-19-0284%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Therapeutics%26atitle%3DPredictive%252Band%252BPharmacodynamic%252BBiomarkers%252Bof%252BResponse%252Bto%252Bthe%252BPhosphatidylinositol%252B3-Kinase%252BInhibitor%252BTaselisib%252Bin%252BBreast%252BCancer%252BPreclinical%252BModels%26aulast%3DMoore%26aufirst%3DHeather%2BM.%26date%3D2020%26date%3D2019%26volume%3D19%26issue%3D1%26spage%3D292%26epage%3D303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Monica M.  Kangussu-Marcolino</span>, <span class="hlFld-ContribAuthor ">Gretchen M.  Ehrenkaufer</span>, <span class="hlFld-ContribAuthor ">Emily  Chen</span>, <span class="hlFld-ContribAuthor ">Anjan  Debnath</span>, <span class="hlFld-ContribAuthor ">Upinder  Singh</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of plicamycin, TG02, panobinostat, lestaurtinib, and GDC-0084 as promising compounds for the treatment of central nervous system infections caused by the free-living amebae Naegleria, Acanthamoeba and Balamuthia. </span><span class="cited-content_cbyCitation_journal-name">International Journal for Parasitology: Drugs and Drug Resistance</span><span> <strong>2019,</strong> <em>11 </em>, 80-94. <a href="https://doi.org/10.1016/j.ijpddr.2019.10.003" title="DOI URL">https://doi.org/10.1016/j.ijpddr.2019.10.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ijpddr.2019.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ijpddr.2019.10.003%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520for%2520Parasitology%253A%2520Drugs%2520and%2520Drug%2520Resistance%26atitle%3DIdentification%252Bof%252Bplicamycin%25252C%252BTG02%25252C%252Bpanobinostat%25252C%252Blestaurtinib%25252C%252Band%252BGDC-0084%252Bas%252Bpromising%252Bcompounds%252Bfor%252Bthe%252Btreatment%252Bof%252Bcentral%252Bnervous%252Bsystem%252Binfections%252Bcaused%252Bby%252Bthe%252Bfree-living%252Bamebae%252BNaegleria%25252C%252BAcanthamoeba%252Band%252BBalamuthia%26aulast%3DKangussu-Marcolino%26aufirst%3DMonica%2BM.%26date%3D2019%26volume%3D11%26spage%3D80%26epage%3D94" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rand  Arafeh</span>, <span class="hlFld-ContribAuthor ">Yardena  Samuels</span>. </span><span class="cited-content_cbyCitation_article-title">PIK3CA in cancer: The past 30 years. </span><span class="cited-content_cbyCitation_journal-name">Seminars in Cancer Biology</span><span> <strong>2019,</strong> <em>59 </em>, 36-49. <a href="https://doi.org/10.1016/j.semcancer.2019.02.002" title="DOI URL">https://doi.org/10.1016/j.semcancer.2019.02.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.semcancer.2019.02.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.semcancer.2019.02.002%26sid%3Dliteratum%253Aachs%26jtitle%3DSeminars%2520in%2520Cancer%2520Biology%26atitle%3DPIK3CA%252Bin%252Bcancer%25253A%252BThe%252Bpast%252B30%252Byears%26aulast%3DArafeh%26aufirst%3DRand%26date%3D2019%26volume%3D59%26spage%3D36%26epage%3D49" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">B.  Verret</span>, <span class="hlFld-ContribAuthor ">J.  Cortes</span>, <span class="hlFld-ContribAuthor ">T.  Bachelot</span>, <span class="hlFld-ContribAuthor ">F.  Andre</span>, <span class="hlFld-ContribAuthor ">M.  Arnedos</span>. </span><span class="cited-content_cbyCitation_article-title">Efficacy of PI3K inhibitors in advanced breast cancer. </span><span class="cited-content_cbyCitation_journal-name">Annals of Oncology</span><span> <strong>2019,</strong> <em>30 </em>, x12-x20. <a href="https://doi.org/10.1093/annonc/mdz381" title="DOI URL">https://doi.org/10.1093/annonc/mdz381</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/annonc/mdz381&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Fannonc%2Fmdz381%26sid%3Dliteratum%253Aachs%26jtitle%3DAnnals%2520of%2520Oncology%26atitle%3DEfficacy%252Bof%252BPI3K%252Binhibitors%252Bin%252Badvanced%252Bbreast%252Bcancer%26aulast%3DVerret%26aufirst%3DB.%26date%3D2019%26volume%3D30%26spage%3Dx12%26epage%3Dx20" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Richard D.  Baird</span>, <span class="hlFld-ContribAuthor ">Annelot G.J.  van Rossum</span>, <span class="hlFld-ContribAuthor ">Mafalda  Oliveira</span>, <span class="hlFld-ContribAuthor ">Karin  Beelen</span>, <span class="hlFld-ContribAuthor ">Meiling  Gao</span>, <span class="hlFld-ContribAuthor ">Mariette  Schrier</span>, <span class="hlFld-ContribAuthor ">Ingrid A.M.  Mandjes</span>, <span class="hlFld-ContribAuthor ">Javier  Garcia-Corbacho</span>, <span class="hlFld-ContribAuthor ">Anne-Laure  Vallier</span>, <span class="hlFld-ContribAuthor ">Greig  Dougall</span>, <span class="hlFld-ContribAuthor ">Erik  van Werkhoven</span>, <span class="hlFld-ContribAuthor ">Constanza  Linossi</span>, <span class="hlFld-ContribAuthor ">Sanjeev  Kumar</span>, <span class="hlFld-ContribAuthor ">Harm  van Tinteren</span>, <span class="hlFld-ContribAuthor ">Maurizio  Callari</span>, <span class="hlFld-ContribAuthor ">Emma  Beddowes</span>, <span class="hlFld-ContribAuthor ">José-Manuel  Perez-Garcia</span>, <span class="hlFld-ContribAuthor ">Hilde  Rosing</span>, <span class="hlFld-ContribAuthor ">Else  Platte</span>, <span class="hlFld-ContribAuthor ">Petra  Nederlof</span>, <span class="hlFld-ContribAuthor ">Margaret  Schot</span>, <span class="hlFld-ContribAuthor ">Aurelia  de Vries Schultink</span>, <span class="hlFld-ContribAuthor ">René  Bernards</span>, <span class="hlFld-ContribAuthor ">Cristina  Saura</span>, <span class="hlFld-ContribAuthor ">William  Gallagher</span>, <span class="hlFld-ContribAuthor ">Javier  Cortès</span>, <span class="hlFld-ContribAuthor ">Carlos  Caldas</span>, <span class="hlFld-ContribAuthor ">Sabine C.  Linn</span>. </span><span class="cited-content_cbyCitation_article-title">POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients. </span><span class="cited-content_cbyCitation_journal-name">Clinical Cancer Research</span><span> <strong>2019,</strong> <em>25 </em>
                                    (22)
                                     , 6598-6605. <a href="https://doi.org/10.1158/1078-0432.CCR-19-0508" title="DOI URL">https://doi.org/10.1158/1078-0432.CCR-19-0508</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1078-0432.CCR-19-0508&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1078-0432.CCR-19-0508%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Cancer%2520Research%26atitle%3DPOSEIDON%252BTrial%252BPhase%252B1b%252BResults%25253A%252BSafety%25252C%252BEfficacy%252Band%252BCirculating%252BTumor%252BDNA%252BResponse%252Bof%252Bthe%252BBeta%252BIsoform-Sparing%252BPI3K%252BInhibitor%252BTaselisib%252B%252528GDC-0032%252529%252BCombined%252Bwith%252BTamoxifen%252Bin%252BHormone%252BReceptor%252BPositive%252BMetastatic%252BBreast%252BCancer%252BPatients%26aulast%3DBaird%26aufirst%3DRichard%2BD.%26date%3D2019%26date%3D2019%26volume%3D25%26issue%3D22%26spage%3D6598%26epage%3D6605" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Neil  Vasan</span>, <span class="hlFld-ContribAuthor ">Pedram  Razavi</span>, <span class="hlFld-ContribAuthor ">Jared L.  Johnson</span>, <span class="hlFld-ContribAuthor ">Hong  Shao</span>, <span class="hlFld-ContribAuthor ">Hardik  Shah</span>, <span class="hlFld-ContribAuthor ">Alesia  Antoine</span>, <span class="hlFld-ContribAuthor ">Erik  Ladewig</span>, <span class="hlFld-ContribAuthor ">Alexander  Gorelick</span>, <span class="hlFld-ContribAuthor ">Ting-Yu  Lin</span>, <span class="hlFld-ContribAuthor ">Eneda  Toska</span>, <span class="hlFld-ContribAuthor ">Guotai  Xu</span>, <span class="hlFld-ContribAuthor ">Abiha  Kazmi</span>, <span class="hlFld-ContribAuthor ">Matthew T.  Chang</span>, <span class="hlFld-ContribAuthor ">Barry S.  Taylor</span>, <span class="hlFld-ContribAuthor ">Maura N.  Dickler</span>, <span class="hlFld-ContribAuthor ">Komal  Jhaveri</span>, <span class="hlFld-ContribAuthor ">Sarat  Chandarlapaty</span>, <span class="hlFld-ContribAuthor ">Raul  Rabadan</span>, <span class="hlFld-ContribAuthor ">Ed  Reznik</span>, <span class="hlFld-ContribAuthor ">Melissa L.  Smith</span>, <span class="hlFld-ContribAuthor ">Robert  Sebra</span>, <span class="hlFld-ContribAuthor ">Frauke  Schimmoller</span>, <span class="hlFld-ContribAuthor ">Timothy R.  Wilson</span>, <span class="hlFld-ContribAuthor ">Lori S.  Friedman</span>, <span class="hlFld-ContribAuthor ">Lewis C.  Cantley</span>, <span class="hlFld-ContribAuthor ">Maurizio  Scaltriti</span>, <span class="hlFld-ContribAuthor ">José  Baselga</span>. </span><span class="cited-content_cbyCitation_article-title">Double
              PIK3CA
              mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Science</span><span> <strong>2019,</strong> <em>366 </em>
                                    (6466)
                                     , 714-723. <a href="https://doi.org/10.1126/science.aaw9032" title="DOI URL">https://doi.org/10.1126/science.aaw9032</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1126/science.aaw9032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1126%2Fscience.aaw9032%26sid%3Dliteratum%253Aachs%26jtitle%3DScience%26atitle%3DDouble%252BPIK3CA%252Bmutations%252Bin%252Bcis%252Bincrease%252Boncogenicity%252Band%252Bsensitivity%252Bto%252BPI3K%2525CE%2525B1%252Binhibitors%26aulast%3DVasan%26aufirst%3DNeil%26date%3D2019%26date%3D2019%26volume%3D366%26issue%3D6466%26spage%3D714%26epage%3D723" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vandana G.  Abramson</span>, <span class="hlFld-ContribAuthor ">Mafalda  Oliveira</span>, <span class="hlFld-ContribAuthor ">Andrés  Cervantes</span>, <span class="hlFld-ContribAuthor ">Hans  Wildiers</span>, <span class="hlFld-ContribAuthor ">Manish R.  Patel</span>, <span class="hlFld-ContribAuthor ">Todd M.  Bauer</span>, <span class="hlFld-ContribAuthor ">Philippe L.  Bedard</span>, <span class="hlFld-ContribAuthor ">Carlos  Becerra</span>, <span class="hlFld-ContribAuthor ">Stephen  Richey</span>, <span class="hlFld-ContribAuthor ">Michael C.  Wei</span>, <span class="hlFld-ContribAuthor ">Eric  Reyner</span>, <span class="hlFld-ContribAuthor ">John  Bond</span>, <span class="hlFld-ContribAuthor ">Na  Cui</span>, <span class="hlFld-ContribAuthor ">Timothy R.  Wilson</span>, <span class="hlFld-ContribAuthor ">Heather M.  Moore</span>, <span class="hlFld-ContribAuthor ">Cristina  Saura</span>, <span class="hlFld-ContribAuthor ">Ian E.  Krop</span>. </span><span class="cited-content_cbyCitation_article-title">A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer. </span><span class="cited-content_cbyCitation_journal-name">Breast Cancer Research and Treatment</span><span> <strong>2019,</strong> <em>178 </em>
                                    (1)
                                     , 121-133. <a href="https://doi.org/10.1007/s10549-019-05360-3" title="DOI URL">https://doi.org/10.1007/s10549-019-05360-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10549-019-05360-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10549-019-05360-3%26sid%3Dliteratum%253Aachs%26jtitle%3DBreast%2520Cancer%2520Research%2520and%2520Treatment%26atitle%3DA%252Bphase%252BIb%25252C%252Bopen-label%25252C%252Bdose-escalation%252Bstudy%252Bof%252Bthe%252Bsafety%252Band%252Bpharmacology%252Bof%252Btaselisib%252B%252528GDC-0032%252529%252Bin%252Bcombination%252Bwith%252Beither%252Bdocetaxel%252Bor%252Bpaclitaxel%252Bin%252Bpatients%252Bwith%252BHER2-negative%25252C%252Blocally%252Badvanced%25252C%252Bor%252Bmetastatic%252Bbreast%252Bcancer%26aulast%3DAbramson%26aufirst%3DVandana%2BG.%26date%3D2019%26date%3D2019%26volume%3D178%26issue%3D1%26spage%3D121%26epage%3D133" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mohsin  Soleja</span>, <span class="hlFld-ContribAuthor ">Ganesh V.  Raj</span>, <span class="hlFld-ContribAuthor ">Nisha  Unni</span>. </span><span class="cited-content_cbyCitation_article-title">An evaluation of fulvestrant for the treatment of metastatic breast cancer. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Pharmacotherapy</span><span> <strong>2019,</strong> <em>20 </em>
                                    (15)
                                     , 1819-1829. <a href="https://doi.org/10.1080/14656566.2019.1651293" title="DOI URL">https://doi.org/10.1080/14656566.2019.1651293</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14656566.2019.1651293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14656566.2019.1651293%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Pharmacotherapy%26atitle%3DAn%252Bevaluation%252Bof%252Bfulvestrant%252Bfor%252Bthe%252Btreatment%252Bof%252Bmetastatic%252Bbreast%252Bcancer%26aulast%3DSoleja%26aufirst%3DMohsin%26date%3D2019%26date%3D2019%26volume%3D20%26issue%3D15%26spage%3D1819%26epage%3D1829" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cristina  Saura</span>, <span class="hlFld-ContribAuthor ">Dominik  Hlauschek</span>, <span class="hlFld-ContribAuthor ">Mafalda  Oliveira</span>, <span class="hlFld-ContribAuthor ">Dimitrios  Zardavas</span>, <span class="hlFld-ContribAuthor ">Anita  Jallitsch-Halper</span>, <span class="hlFld-ContribAuthor ">Lorena  de la Peña</span>, <span class="hlFld-ContribAuthor ">Paolo  Nuciforo</span>, <span class="hlFld-ContribAuthor ">Alberto  Ballestrero</span>, <span class="hlFld-ContribAuthor ">Peter  Dubsky</span>, <span class="hlFld-ContribAuthor ">Janine M  Lombard</span>, <span class="hlFld-ContribAuthor ">Peter  Vuylsteke</span>, <span class="hlFld-ContribAuthor ">Carlos A  Castaneda</span>, <span class="hlFld-ContribAuthor ">Marco  Colleoni</span>, <span class="hlFld-ContribAuthor ">Giuliano  Santos Borges</span>, <span class="hlFld-ContribAuthor ">Eva  Ciruelos</span>, <span class="hlFld-ContribAuthor ">Monica  Fornier</span>, <span class="hlFld-ContribAuthor ">Katalin  Boer</span>, <span class="hlFld-ContribAuthor ">Aditya  Bardia</span>, <span class="hlFld-ContribAuthor ">Timothy R  Wilson</span>, <span class="hlFld-ContribAuthor ">Thomas J  Stout</span>, <span class="hlFld-ContribAuthor ">Jerry Y  Hsu</span>, <span class="hlFld-ContribAuthor ">Yi  Shi</span>, <span class="hlFld-ContribAuthor ">Martine  Piccart</span>, <span class="hlFld-ContribAuthor ">Michael  Gnant</span>, <span class="hlFld-ContribAuthor ">José  Baselga</span>, <span class="hlFld-ContribAuthor ">Evandro  de Azambuja</span>. </span><span class="cited-content_cbyCitation_article-title">Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. </span><span class="cited-content_cbyCitation_journal-name">The Lancet Oncology</span><span> <strong>2019,</strong> <em>20 </em>
                                    (9)
                                     , 1226-1238. <a href="https://doi.org/10.1016/S1470-2045(19)30334-1" title="DOI URL">https://doi.org/10.1016/S1470-2045(19)30334-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/S1470-2045(19)30334-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FS1470-2045%2819%2930334-1%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Lancet%2520Oncology%26atitle%3DNeoadjuvant%252Bletrozole%252Bplus%252Btaselisib%252Bversus%252Bletrozole%252Bplus%252Bplacebo%252Bin%252Bpostmenopausal%252Bwomen%252Bwith%252Boestrogen%252Breceptor-positive%25252C%252BHER2-negative%25252C%252Bearly-stage%252Bbreast%252Bcancer%252B%252528LORELEI%252529%25253A%252Ba%252Bmulticentre%25252C%252Brandomised%25252C%252Bdouble-blind%25252C%252Bplacebo-controlled%25252C%252Bphase%252B2%252Btrial%26aulast%3DSaura%26aufirst%3DCristina%26date%3D2019%26volume%3D20%26issue%3D9%26spage%3D1226%26epage%3D1238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chong  Han</span>, <span class="hlFld-ContribAuthor ">Sean M.  Kelly</span>, <span class="hlFld-ContribAuthor ">Theresa  Cravillion</span>, <span class="hlFld-ContribAuthor ">Scott J.  Savage</span>, <span class="hlFld-ContribAuthor ">Tina  Nguyen</span>, <span class="hlFld-ContribAuthor ">Francis  Gosselin</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of PI3K inhibitor GDC-0077 via a stereocontrolled N-arylation of α-amino acids. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2019,</strong> <em>75 </em>
                                    (32)
                                     , 4351-4357. <a href="https://doi.org/10.1016/j.tet.2019.04.057" title="DOI URL">https://doi.org/10.1016/j.tet.2019.04.057</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2019.04.057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2019.04.057%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DSynthesis%252Bof%252BPI3K%252Binhibitor%252BGDC-0077%252Bvia%252Ba%252Bstereocontrolled%252BN-arylation%252Bof%252B%2525CE%2525B1-amino%252Bacids%26aulast%3DHan%26aufirst%3DChong%26date%3D2019%26volume%3D75%26issue%3D32%26spage%3D4351%26epage%3D4357" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stefania  Crisci</span>, <span class="hlFld-ContribAuthor ">Filomena  Amitrano</span>, <span class="hlFld-ContribAuthor ">Mariangela  Saggese</span>, <span class="hlFld-ContribAuthor ">Tommaso  Muto</span>, <span class="hlFld-ContribAuthor ">Sabrina  Sarno</span>, <span class="hlFld-ContribAuthor ">Sara  Mele</span>, <span class="hlFld-ContribAuthor ">Pasquale  Vitale</span>, <span class="hlFld-ContribAuthor ">Giuseppina  Ronga</span>, <span class="hlFld-ContribAuthor ">Massimiliano  Berretta</span>, <span class="hlFld-ContribAuthor ">Raffaele  Di Francia</span>. </span><span class="cited-content_cbyCitation_article-title">Overview of Current Targeted Anti-Cancer Drugs for Therapy in Onco-Hematology. </span><span class="cited-content_cbyCitation_journal-name">Medicina</span><span> <strong>2019,</strong> <em>55 </em>
                                    (8)
                                     , 414. <a href="https://doi.org/10.3390/medicina55080414" title="DOI URL">https://doi.org/10.3390/medicina55080414</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/medicina55080414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmedicina55080414%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicina%26atitle%3DOverview%252Bof%252BCurrent%252BTargeted%252BAnti-Cancer%252BDrugs%252Bfor%252BTherapy%252Bin%252BOnco-Hematology%26aulast%3DCrisci%26aufirst%3DStefania%26date%3D2019%26date%3D2019%26volume%3D55%26issue%3D8%26spage%3D414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Valentina  Romeo</span>, <span class="hlFld-ContribAuthor ">Sarah  Gierke</span>, <span class="hlFld-ContribAuthor ">Kyle A.  Edgar</span>, <span class="hlFld-ContribAuthor ">Scot D.  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Effects of PI3K Inhibition on Afucosylated Antibody–Driven FcγRIIIa Events and Phospho-S6 Activity in NK Cells. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Immunology</span><span> <strong>2019,</strong> <em>203 </em>
                                    (1)
                                     , 137-147. <a href="https://doi.org/10.4049/jimmunol.1801418" title="DOI URL">https://doi.org/10.4049/jimmunol.1801418</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4049/jimmunol.1801418&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4049%2Fjimmunol.1801418%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Immunology%26atitle%3DEffects%252Bof%252BPI3K%252BInhibition%252Bon%252BAfucosylated%252BAntibody%2525E2%252580%252593Driven%252BFc%2525CE%2525B3RIIIa%252BEvents%252Band%252BPhospho-S6%252BActivity%252Bin%252BNK%252BCells%26aulast%3DRomeo%26aufirst%3DValentina%26date%3D2019%26date%3D2019%26volume%3D203%26issue%3D1%26spage%3D137%26epage%3D147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Raymond  Chang</span>, <span class="hlFld-ContribAuthor ">Umberto  Tosi</span>, <span class="hlFld-ContribAuthor ">Julia  Voronina</span>, <span class="hlFld-ContribAuthor ">Oluwaseyi  Adeuyan</span>, <span class="hlFld-ContribAuthor ">Linda Y  Wu</span>, <span class="hlFld-ContribAuthor ">Melanie E  Schweitzer</span>, <span class="hlFld-ContribAuthor ">David J  Pisapia</span>, <span class="hlFld-ContribAuthor ">Oren J  Becher</span>, <span class="hlFld-ContribAuthor ">Mark M  Souweidane</span>, <span class="hlFld-ContribAuthor ">Uday B  Maachani</span>. </span><span class="cited-content_cbyCitation_article-title">Combined targeting of PI3K and MEK effector pathways via CED for DIPG therapy. </span><span class="cited-content_cbyCitation_journal-name">Neuro-Oncology Advances</span><span> <strong>2019,</strong> <em>1 </em>
                                    (1)
                                     <a href="https://doi.org/10.1093/noajnl/vdz004" title="DOI URL">https://doi.org/10.1093/noajnl/vdz004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/noajnl/vdz004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Fnoajnl%2Fvdz004%26sid%3Dliteratum%253Aachs%26jtitle%3DNeuro-Oncology%2520Advances%26atitle%3DCombined%252Btargeting%252Bof%252BPI3K%252Band%252BMEK%252Beffector%252Bpathways%252Bvia%252BCED%252Bfor%252BDIPG%252Btherapy%26aulast%3DChang%26aufirst%3DRaymond%26date%3D2019%26date%3D2019%26volume%3D1%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaodong  Ma</span>, <span class="hlFld-ContribAuthor ">Li  Shen</span>, <span class="hlFld-ContribAuthor ">Jiankang  Zhang</span>, <span class="hlFld-ContribAuthor ">Guoqiang  Liu</span>, <span class="hlFld-ContribAuthor ">Shuyu  Zhan</span>, <span class="hlFld-ContribAuthor ">Baoyue  Ding</span>, <span class="hlFld-ContribAuthor ">Xiaoqing  Lv</span>. </span><span class="cited-content_cbyCitation_article-title">Novel 4-Acrylamido-Quinoline Derivatives as Potent PI3K/mTOR Dual Inhibitors: The Design, Synthesis, and in vitro and in vivo Biological Evaluation. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Chemistry</span><span> <strong>2019,</strong> <em>7 </em><a href="https://doi.org/10.3389/fchem.2019.00236" title="DOI URL">https://doi.org/10.3389/fchem.2019.00236</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fchem.2019.00236&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffchem.2019.00236%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Chemistry%26atitle%3DNovel%252B4-Acrylamido-Quinoline%252BDerivatives%252Bas%252BPotent%252BPI3K%25252FmTOR%252BDual%252BInhibitors%25253A%252BThe%252BDesign%25252C%252BSynthesis%25252C%252Band%252Bin%252Bvitro%252Band%252Bin%252Bvivo%252BBiological%252BEvaluation%26aulast%3DMa%26aufirst%3DXiaodong%26date%3D2019%26date%3D2019%26volume%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Virginia G.  Kaklamani</span>, <span class="hlFld-ContribAuthor ">Andrea L.  Richardson</span>, <span class="hlFld-ContribAuthor ">Carlos L.  Arteaga</span>. </span><span class="cited-content_cbyCitation_article-title">Exploring Biomarkers of Phosphoinositide 3‐Kinase Pathway Activation in the Treatment of Hormone Receptor Positive, Human Epidermal Growth Receptor 2 Negative Advanced Breast Cancer. </span><span class="cited-content_cbyCitation_journal-name">The Oncologist</span><span> <strong>2019,</strong> <em>24 </em>
                                    (3)
                                     , 305-312. <a href="https://doi.org/10.1634/theoncologist.2018-0314" title="DOI URL">https://doi.org/10.1634/theoncologist.2018-0314</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1634/theoncologist.2018-0314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1634%2Ftheoncologist.2018-0314%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Oncologist%26atitle%3DExploring%252BBiomarkers%252Bof%252BPhosphoinositide%252B3%2525E2%252580%252590Kinase%252BPathway%252BActivation%252Bin%252Bthe%252BTreatment%252Bof%252BHormone%252BReceptor%252BPositive%25252C%252BHuman%252BEpidermal%252BGrowth%252BReceptor%252B2%252BNegative%252BAdvanced%252BBreast%252BCancer%26aulast%3DKaklamani%26aufirst%3DVirginia%2BG.%26date%3D2019%26date%3D2019%26volume%3D24%26issue%3D3%26spage%3D305%26epage%3D312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michelle  Miller</span>, <span class="hlFld-ContribAuthor ">Philip  Thompson</span>, <span class="hlFld-ContribAuthor ">Sandra  Gabelli</span>. </span><span class="cited-content_cbyCitation_article-title">Structural Determinants of Isoform Selectivity in PI3K Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Biomolecules</span><span> <strong>2019,</strong> <em>9 </em>
                                    (3)
                                     , 82. <a href="https://doi.org/10.3390/biom9030082" title="DOI URL">https://doi.org/10.3390/biom9030082</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/biom9030082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fbiom9030082%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomolecules%26atitle%3DStructural%252BDeterminants%252Bof%252BIsoform%252BSelectivity%252Bin%252BPI3K%252BInhibitors%26aulast%3DMiller%26aufirst%3DMichelle%26date%3D2019%26date%3D2019%26volume%3D9%26issue%3D3%26spage%3D82" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shu-Kee  Eng</span>, <span class="hlFld-ContribAuthor ">Teng Hern Tan  Loh</span>, <span class="hlFld-ContribAuthor ">Bey-Hing  Goh</span>, <span class="hlFld-ContribAuthor ">Wai-Leng  Lee</span>. </span><span class="cited-content_cbyCitation_article-title">KRAS as Potential Target in Colorectal Cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 389-424. <a href="https://doi.org/10.1007/978-981-13-7154-7_12" title="DOI URL">https://doi.org/10.1007/978-981-13-7154-7_12</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-981-13-7154-7_12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-981-13-7154-7_12%26sid%3Dliteratum%253Aachs%26atitle%3DKRAS%252Bas%252BPotential%252BTarget%252Bin%252BColorectal%252BCancer%252BTherapy%26aulast%3DEng%26aufirst%3DShu-Kee%26date%3D2019%26date%3D2019%26spage%3D389%26epage%3D424%26pub%3DSpringer%2520Singapore%26atitle%3DNatural%252BBio-active%252BCompounds%26aulast%3DAkhtar%26aufirst%3DMohd%2BSayeed%26date%3D2019%26volume%3D595" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Elias E.  Stratikopoulos</span>, <span class="hlFld-ContribAuthor ">Nicole  Kiess</span>, <span class="hlFld-ContribAuthor ">Matthias  Szabolcs</span>, <span class="hlFld-ContribAuthor ">Sarah  Pegno</span>, <span class="hlFld-ContribAuthor ">Cheung  Kakit</span>, <span class="hlFld-ContribAuthor ">Xuewei  Wu</span>, <span class="hlFld-ContribAuthor ">Poulikos I.  Poulikakos</span>, <span class="hlFld-ContribAuthor ">Pamela  Cheung</span>, <span class="hlFld-ContribAuthor ">Hank  Schmidt</span>, <span class="hlFld-ContribAuthor ">Ramon  Parsons</span>. </span><span class="cited-content_cbyCitation_article-title">Mouse ER+/PIK3CAH1047R breast cancers caused by exogenous estrogen are heterogeneously dependent on estrogen and undergo BIM-dependent apoptosis with BH3 and PI3K agents. </span><span class="cited-content_cbyCitation_journal-name">Oncogene</span><span> <strong>2019,</strong> <em>38 </em>
                                    (1)
                                     , 47-59. <a href="https://doi.org/10.1038/s41388-018-0436-4" title="DOI URL">https://doi.org/10.1038/s41388-018-0436-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41388-018-0436-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41388-018-0436-4%26sid%3Dliteratum%253Aachs%26jtitle%3DOncogene%26atitle%3DMouse%252BER%25252B%25252FPIK3CAH1047R%252Bbreast%252Bcancers%252Bcaused%252Bby%252Bexogenous%252Bestrogen%252Bare%252Bheterogeneously%252Bdependent%252Bon%252Bestrogen%252Band%252Bundergo%252BBIM-dependent%252Bapoptosis%252Bwith%252BBH3%252Band%252BPI3K%252Bagents%26aulast%3DStratikopoulos%26aufirst%3DElias%2BE.%26date%3D2019%26date%3D2018%26volume%3D38%26issue%3D1%26spage%3D47%26epage%3D59" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kai  Bi</span>, <span class="hlFld-ContribAuthor ">Tao  Chen</span>, <span class="hlFld-ContribAuthor ">Zhangchao  He</span>, <span class="hlFld-ContribAuthor ">Zhixiao  Gao</span>, <span class="hlFld-ContribAuthor ">Ying  Zhao</span>, <span class="hlFld-ContribAuthor ">Yanping  Fu</span>, <span class="hlFld-ContribAuthor ">Jiasen  Cheng</span>, <span class="hlFld-ContribAuthor ">Jiatao  Xie</span>, <span class="hlFld-ContribAuthor ">Daohong  Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Proto-oncogenes in a eukaryotic unicellular organism play essential roles in plasmodial growth in host cells. </span><span class="cited-content_cbyCitation_journal-name">BMC Genomics</span><span> <strong>2018,</strong> <em>19 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s12864-018-5307-4" title="DOI URL">https://doi.org/10.1186/s12864-018-5307-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s12864-018-5307-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs12864-018-5307-4%26sid%3Dliteratum%253Aachs%26jtitle%3DBMC%2520Genomics%26atitle%3DProto-oncogenes%252Bin%252Ba%252Beukaryotic%252Bunicellular%252Borganism%252Bplay%252Bessential%252Broles%252Bin%252Bplasmodial%252Bgrowth%252Bin%252Bhost%252Bcells%26aulast%3DBi%26aufirst%3DKai%26date%3D2018%26date%3D2018%26volume%3D19%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maura N.  Dickler</span>, <span class="hlFld-ContribAuthor ">Cristina  Saura</span>, <span class="hlFld-ContribAuthor ">Donald A.  Richards</span>, <span class="hlFld-ContribAuthor ">Ian E.  Krop</span>, <span class="hlFld-ContribAuthor ">Andrés  Cervantes</span>, <span class="hlFld-ContribAuthor ">Philippe L.  Bedard</span>, <span class="hlFld-ContribAuthor ">Manish R.  Patel</span>, <span class="hlFld-ContribAuthor ">Lajos  Pusztai</span>, <span class="hlFld-ContribAuthor ">Mafalda  Oliveira</span>, <span class="hlFld-ContribAuthor ">Alison K.  Cardenas</span>, <span class="hlFld-ContribAuthor ">Na  Cui</span>, <span class="hlFld-ContribAuthor ">Timothy R.  Wilson</span>, <span class="hlFld-ContribAuthor ">Thomas J.  Stout</span>, <span class="hlFld-ContribAuthor ">Michael C.  Wei</span>, <span class="hlFld-ContribAuthor ">Jerry Y.  Hsu</span>, <span class="hlFld-ContribAuthor ">José  Baselga</span>. </span><span class="cited-content_cbyCitation_article-title">Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor–Positive Advanced Breast Cancer. </span><span class="cited-content_cbyCitation_journal-name">Clinical Cancer Research</span><span> <strong>2018,</strong> <em>24 </em>
                                    (18)
                                     , 4380-4387. <a href="https://doi.org/10.1158/1078-0432.CCR-18-0613" title="DOI URL">https://doi.org/10.1158/1078-0432.CCR-18-0613</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1078-0432.CCR-18-0613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1078-0432.CCR-18-0613%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Cancer%2520Research%26atitle%3DPhase%252BII%252BStudy%252Bof%252BTaselisib%252B%252528GDC-0032%252529%252Bin%252BCombination%252Bwith%252BFulvestrant%252Bin%252BPatients%252Bwith%252BHER2-Negative%25252C%252BHormone%252BReceptor%2525E2%252580%252593Positive%252BAdvanced%252BBreast%252BCancer%26aulast%3DDickler%26aufirst%3DMaura%2BN.%26date%3D2018%26date%3D2018%26volume%3D24%26issue%3D18%26spage%3D4380%26epage%3D4387" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">John E.  Burke</span>. </span><span class="cited-content_cbyCitation_article-title">Structural Basis for Regulation of Phosphoinositide Kinases and Their Involvement in Human Disease. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cell</span><span> <strong>2018,</strong> <em>71 </em>
                                    (5)
                                     , 653-673. <a href="https://doi.org/10.1016/j.molcel.2018.08.005" title="DOI URL">https://doi.org/10.1016/j.molcel.2018.08.005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.molcel.2018.08.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.molcel.2018.08.005%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cell%26atitle%3DStructural%252BBasis%252Bfor%252BRegulation%252Bof%252BPhosphoinositide%252BKinases%252Band%252BTheir%252BInvolvement%252Bin%252BHuman%252BDisease%26aulast%3DBurke%26aufirst%3DJohn%2BE.%26date%3D2018%26volume%3D71%26issue%3D5%26spage%3D653%26epage%3D673" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Aneta  Pogorzelska</span>, <span class="hlFld-ContribAuthor ">Jarosław  Sławiński</span>, <span class="hlFld-ContribAuthor ">Anna  Kawiak</span>, <span class="hlFld-ContribAuthor ">Beata  Żołnowska</span>, <span class="hlFld-ContribAuthor ">Jarosław  Chojnacki</span>, <span class="hlFld-ContribAuthor ">Grzegorz  Stasiłojć</span>, <span class="hlFld-ContribAuthor ">Szymon  Ulenberg</span>, <span class="hlFld-ContribAuthor ">Krzysztof  Szafrański</span>, <span class="hlFld-ContribAuthor ">Tomasz  Bączek</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, molecular structure, and metabolic stability of new series of N'-(2-alkylthio-4-chloro-5-methylbenzenesulfonyl)-1-(5-phenyl-1H-pyrazol-1-yl)amidine as potential anti-cancer agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>155 </em>, 670-680. <a href="https://doi.org/10.1016/j.ejmech.2018.06.032" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.06.032</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.06.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.06.032%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%25252C%252Bmolecular%252Bstructure%25252C%252Band%252Bmetabolic%252Bstability%252Bof%252Bnew%252Bseries%252Bof%252BN%252527-%2525282-alkylthio-4-chloro-5-methylbenzenesulfonyl%252529-1-%2525285-phenyl-1H-pyrazol-1-yl%252529amidine%252Bas%252Bpotential%252Banti-cancer%252Bagents%26aulast%3DPogorzelska%26aufirst%3DAneta%26date%3D2018%26volume%3D155%26spage%3D670%26epage%3D680" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ricardo L. B.  Costa</span>, <span class="hlFld-ContribAuthor ">Hyo Sook  Han</span>, <span class="hlFld-ContribAuthor ">William J.  Gradishar</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review. </span><span class="cited-content_cbyCitation_journal-name">Breast Cancer Research and Treatment</span><span> <strong>2018,</strong> <em>169 </em>
                                    (3)
                                     , 397-406. <a href="https://doi.org/10.1007/s10549-018-4697-y" title="DOI URL">https://doi.org/10.1007/s10549-018-4697-y</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10549-018-4697-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10549-018-4697-y%26sid%3Dliteratum%253Aachs%26jtitle%3DBreast%2520Cancer%2520Research%2520and%2520Treatment%26atitle%3DTargeting%252Bthe%252BPI3K%25252FAKT%25252FmTOR%252Bpathway%252Bin%252Btriple-negative%252Bbreast%252Bcancer%25253A%252Ba%252Breview%26aulast%3DCosta%26aufirst%3DRicardo%2BL.%2BB.%26date%3D2018%26date%3D2018%26volume%3D169%26issue%3D3%26spage%3D397%26epage%3D406" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mohamed  Rahmani</span>, <span class="hlFld-ContribAuthor ">Jewel  Nkwocha</span>, <span class="hlFld-ContribAuthor ">Elisa  Hawkins</span>, <span class="hlFld-ContribAuthor ">Xinyan  Pei</span>, <span class="hlFld-ContribAuthor ">Rebecca E.  Parker</span>, <span class="hlFld-ContribAuthor ">Maciej  Kmieciak</span>, <span class="hlFld-ContribAuthor ">Joel D.  Leverson</span>, <span class="hlFld-ContribAuthor ">Deepak  Sampath</span>, <span class="hlFld-ContribAuthor ">Andrea  Ferreira-Gonzalez</span>, <span class="hlFld-ContribAuthor ">Steven  Grant</span>. </span><span class="cited-content_cbyCitation_article-title">Cotargeting BCL-2 and PI3K Induces BAX-Dependent Mitochondrial Apoptosis in AML Cells. </span><span class="cited-content_cbyCitation_journal-name">Cancer Research</span><span> <strong>2018,</strong> <em>78 </em>
                                    (11)
                                     , 3075-3086. <a href="https://doi.org/10.1158/0008-5472.CAN-17-3024" title="DOI URL">https://doi.org/10.1158/0008-5472.CAN-17-3024</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/0008-5472.CAN-17-3024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F0008-5472.CAN-17-3024%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Research%26atitle%3DCotargeting%252BBCL-2%252Band%252BPI3K%252BInduces%252BBAX-Dependent%252BMitochondrial%252BApoptosis%252Bin%252BAML%252BCells%26aulast%3DRahmani%26aufirst%3DMohamed%26date%3D2018%26date%3D2018%26volume%3D78%26issue%3D11%26spage%3D3075%26epage%3D3086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Adam M.  Brufsky</span>, <span class="hlFld-ContribAuthor ">Maura N.  Dickler</span>. </span><span class="cited-content_cbyCitation_article-title">Estrogen Receptor‐Positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance. </span><span class="cited-content_cbyCitation_journal-name">The Oncologist</span><span> <strong>2018,</strong> <em>23 </em>
                                    (5)
                                     , 528-539. <a href="https://doi.org/10.1634/theoncologist.2017-0423" title="DOI URL">https://doi.org/10.1634/theoncologist.2017-0423</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1634/theoncologist.2017-0423&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1634%2Ftheoncologist.2017-0423%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Oncologist%26atitle%3DEstrogen%252BReceptor%2525E2%252580%252590Positive%252BBreast%252BCancer%25253A%252BExploiting%252BSignaling%252BPathways%252BImplicated%252Bin%252BEndocrine%252BResistance%26aulast%3DBrufsky%26aufirst%3DAdam%2BM.%26date%3D2018%26date%3D2018%26volume%3D23%26issue%3D5%26spage%3D528%26epage%3D539" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hai H.  Bui</span>, <span class="hlFld-ContribAuthor ">Phillip E.  Sanders</span>, <span class="hlFld-ContribAuthor ">Diane  Bodenmiller</span>, <span class="hlFld-ContribAuthor ">Ming Shang  Kuo</span>, <span class="hlFld-ContribAuthor ">Gregory P.  Donoho</span>, <span class="hlFld-ContribAuthor ">Anthony S.  Fischl</span>. </span><span class="cited-content_cbyCitation_article-title">Direct analysis of PI(3,4,5)P3 using liquid chromatography electrospray ionization tandem mass spectrometry. </span><span class="cited-content_cbyCitation_journal-name">Analytical Biochemistry</span><span> <strong>2018,</strong> <em>547 </em>, 66-76. <a href="https://doi.org/10.1016/j.ab.2018.02.014" title="DOI URL">https://doi.org/10.1016/j.ab.2018.02.014</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ab.2018.02.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ab.2018.02.014%26sid%3Dliteratum%253Aachs%26jtitle%3DAnalytical%2520Biochemistry%26atitle%3DDirect%252Banalysis%252Bof%252BPI%2525283%25252C4%25252C5%252529P3%252Busing%252Bliquid%252Bchromatography%252Belectrospray%252Bionization%252Btandem%252Bmass%252Bspectrometry%26aulast%3DBui%26aufirst%3DHai%2BH.%26date%3D2018%26volume%3D547%26spage%3D66%26epage%3D76" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">M.  Srinivas</span>, <span class="hlFld-ContribAuthor ">Anup  Singh Pathania</span>, <span class="hlFld-ContribAuthor ">Priya  Mahajan</span>, <span class="hlFld-ContribAuthor ">Praveen K.  Verma</span>, <span class="hlFld-ContribAuthor ">Santosh S.  Chobe</span>, <span class="hlFld-ContribAuthor ">Fayaz A.  Malik</span>, <span class="hlFld-ContribAuthor ">Amit  Nargotra</span>, <span class="hlFld-ContribAuthor ">Ram A.  Vishwakarma</span>, <span class="hlFld-ContribAuthor ">Sanghapal D.  Sawant</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of 1,4-substituted 1H-1,2,3-triazolo-quinazolin-4(3H)-ones by Huisgen 1,3-dipolar cycloaddition with PI3Kγ isoform selective activity. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>28 </em>
                                    (6)
                                     , 1005-1010. <a href="https://doi.org/10.1016/j.bmcl.2018.02.032" title="DOI URL">https://doi.org/10.1016/j.bmcl.2018.02.032</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2018.02.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2018.02.032%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252B1%25252C4-substituted%252B1H-1%25252C2%25252C3-triazolo-quinazolin-4%2525283H%252529-ones%252Bby%252BHuisgen%252B1%25252C3-dipolar%252Bcycloaddition%252Bwith%252BPI3K%2525CE%2525B3%252Bisoform%252Bselective%252Bactivity%26aulast%3DSrinivas%26aufirst%3DM.%26date%3D2018%26volume%3D28%26issue%3D6%26spage%3D1005%26epage%3D1010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ana Christina  Garrido-Castro</span>, <span class="hlFld-ContribAuthor ">Beth  Overmoyer</span>. </span><span class="cited-content_cbyCitation_article-title">New Treatments for Metastatic Breast Cancer. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 167-197. <a href="https://doi.org/10.1007/978-3-319-60336-0_12" title="DOI URL">https://doi.org/10.1007/978-3-319-60336-0_12</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-319-60336-0_12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-319-60336-0_12%26sid%3Dliteratum%253Aachs%26atitle%3DNew%252BTreatments%252Bfor%252BMetastatic%252BBreast%252BCancer%26aulast%3DGarrido-Castro%26aufirst%3DAna%2BChristina%26date%3D2018%26date%3D2017%26spage%3D167%26epage%3D197%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DChanging%252BParadigms%252Bin%252Bthe%252BManagement%252Bof%252BBreast%252BCancer%26aulast%3DHoward-McNatt%26aufirst%3DMarissa%26date%3D2018%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pau  Castel</span>, <span class="hlFld-ContribAuthor ">Maurizio  Scaltriti</span>. </span><span class="cited-content_cbyCitation_article-title">Mechanisms of Resistance to PI3K and AKT Inhibitors. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 117-146. <a href="https://doi.org/10.1007/978-3-319-67932-7_6" title="DOI URL">https://doi.org/10.1007/978-3-319-67932-7_6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-319-67932-7_6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-319-67932-7_6%26sid%3Dliteratum%253Aachs%26atitle%3DMechanisms%252Bof%252BResistance%252Bto%252BPI3K%252Band%252BAKT%252BInhibitors%26aulast%3DCastel%26aufirst%3DPau%26date%3D2018%26date%3D2018%26spage%3D117%26epage%3D146%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DResistance%252Bto%252BAnti-Cancer%252BTherapeutics%252BTargeting%252BReceptor%252BTyrosine%252BKinases%252Band%252BDownstream%252BPathways%26aulast%3DYarden%26aufirst%3DYosef%26date%3D2018%26volume%3D15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hua-fu  Zhao</span>, <span class="hlFld-ContribAuthor ">Jing  Wang</span>, <span class="hlFld-ContribAuthor ">Wei  Shao</span>, <span class="hlFld-ContribAuthor ">Chang-peng  Wu</span>, <span class="hlFld-ContribAuthor ">Zhong-ping  Chen</span>, <span class="hlFld-ContribAuthor ">Shing-shun Tony  To</span>, <span class="hlFld-ContribAuthor ">Wei-ping  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer</span><span> <strong>2017,</strong> <em>16 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s12943-017-0670-3" title="DOI URL">https://doi.org/10.1186/s12943-017-0670-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s12943-017-0670-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs12943-017-0670-3%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%26atitle%3DRecent%252Badvances%252Bin%252Bthe%252Buse%252Bof%252BPI3K%252Binhibitors%252Bfor%252Bglioblastoma%252Bmultiforme%25253A%252Bcurrent%252Bpreclinical%252Band%252Bclinical%252Bdevelopment%26aulast%3DZhao%26aufirst%3DHua-fu%26date%3D2017%26date%3D2017%26volume%3D16%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhi Ling  Teo</span>, <span class="hlFld-ContribAuthor ">Stephanie  Versaci</span>, <span class="hlFld-ContribAuthor ">Sathana  Dushyanthen</span>, <span class="hlFld-ContribAuthor ">Franco  Caramia</span>, <span class="hlFld-ContribAuthor ">Peter  Savas</span>, <span class="hlFld-ContribAuthor ">Chris P.  Mintoff</span>, <span class="hlFld-ContribAuthor ">Magnus  Zethoven</span>, <span class="hlFld-ContribAuthor ">Balaji  Virassamy</span>, <span class="hlFld-ContribAuthor ">Stephen J.  Luen</span>, <span class="hlFld-ContribAuthor ">Grant A.  McArthur</span>, <span class="hlFld-ContribAuthor ">Wayne A.  Phillips</span>, <span class="hlFld-ContribAuthor ">Phillip K.  Darcy</span>, <span class="hlFld-ContribAuthor ">Sherene  Loi</span>. </span><span class="cited-content_cbyCitation_article-title">Combined CDK4/6 and PI3Kα Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer. </span><span class="cited-content_cbyCitation_journal-name">Cancer Research</span><span> <strong>2017,</strong> <em>77 </em>
                                    (22)
                                     , 6340-6352. <a href="https://doi.org/10.1158/0008-5472.CAN-17-2210" title="DOI URL">https://doi.org/10.1158/0008-5472.CAN-17-2210</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/0008-5472.CAN-17-2210&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F0008-5472.CAN-17-2210%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Research%26atitle%3DCombined%252BCDK4%25252F6%252Band%252BPI3K%2525CE%2525B1%252BInhibition%252BIs%252BSynergistic%252Band%252BImmunogenic%252Bin%252BTriple-Negative%252BBreast%252BCancer%26aulast%3DTeo%26aufirst%3DZhi%2BLing%26date%3D2017%26date%3D2017%26volume%3D77%26issue%3D22%26spage%3D6340%26epage%3D6352" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gordon W.  Rewcastle</span>, <span class="hlFld-ContribAuthor ">Sharada  Kolekar</span>, <span class="hlFld-ContribAuthor ">Christina M.  Buchanan</span>, <span class="hlFld-ContribAuthor ">Swarna A.  Gamage</span>, <span class="hlFld-ContribAuthor ">Anna C.  Giddens</span>, <span class="hlFld-ContribAuthor ">Kit Y.  Tsang</span>, <span class="hlFld-ContribAuthor ">Jackie D.  Kendall</span>, <span class="hlFld-ContribAuthor ">Ripudaman  Singh</span>, <span class="hlFld-ContribAuthor ">Woo-Jeong  Lee</span>, <span class="hlFld-ContribAuthor ">Greg C.  Smith</span>, <span class="hlFld-ContribAuthor ">Weiping  Han</span>, <span class="hlFld-ContribAuthor ">David J.  Matthews</span>, <span class="hlFld-ContribAuthor ">William A.  Denny</span>, <span class="hlFld-ContribAuthor ">Peter R.  Shepherd</span>, <span class="hlFld-ContribAuthor ">Stephen M.F.  Jamieson</span>. </span><span class="cited-content_cbyCitation_article-title">Biological characterization of SN32976, a selective inhibitor of PI3K and mTOR with preferential activity to PI3Kα, in comparison to established pan PI3K inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2017,</strong> <em>8 </em>
                                    (29)
                                     , 47725-47740. <a href="https://doi.org/10.18632/oncotarget.17730" title="DOI URL">https://doi.org/10.18632/oncotarget.17730</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.17730&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.17730%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DBiological%252Bcharacterization%252Bof%252BSN32976%25252C%252Ba%252Bselective%252Binhibitor%252Bof%252BPI3K%252Band%252BmTOR%252Bwith%252Bpreferential%252Bactivity%252Bto%252BPI3K%2525CE%2525B1%25252C%252Bin%252Bcomparison%252Bto%252Bestablished%252Bpan%252BPI3K%252Binhibitors%26aulast%3DRewcastle%26aufirst%3DGordon%2BW.%26date%3D2017%26date%3D2017%26volume%3D8%26issue%3D29%26spage%3D47725%26epage%3D47740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Grace Q.  Gong</span>, <span class="hlFld-ContribAuthor ">Jackie D.  Kendall</span>, <span class="hlFld-ContribAuthor ">James M.J.  Dickson</span>, <span class="hlFld-ContribAuthor ">Gordon W.  Rewcastle</span>, <span class="hlFld-ContribAuthor ">Christina M.  Buchanan</span>, <span class="hlFld-ContribAuthor ">William A.  Denny</span>, <span class="hlFld-ContribAuthor ">Peter R.  Shepherd</span>, <span class="hlFld-ContribAuthor ">Jack U.  Flanagan</span>. </span><span class="cited-content_cbyCitation_article-title">Combining properties of different classes of PI3Kα inhibitors to understand the molecular features that confer selectivity. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Journal</span><span> <strong>2017,</strong> <em>474 </em>
                                    (13)
                                     , 2261-2276. <a href="https://doi.org/10.1042/BCJ20161098" title="DOI URL">https://doi.org/10.1042/BCJ20161098</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1042/BCJ20161098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1042%2FBCJ20161098%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Journal%26atitle%3DCombining%252Bproperties%252Bof%252Bdifferent%252Bclasses%252Bof%252BPI3K%2525CE%2525B1%252Binhibitors%252Bto%252Bunderstand%252Bthe%252Bmolecular%252Bfeatures%252Bthat%252Bconfer%252Bselectivity%26aulast%3DGong%26aufirst%3DGrace%2BQ.%26date%3D2017%26date%3D2017%26volume%3D474%26issue%3D13%26spage%3D2261%26epage%3D2276" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dejan  Juric</span>, <span class="hlFld-ContribAuthor ">Ian  Krop</span>, <span class="hlFld-ContribAuthor ">Ramesh K.  Ramanathan</span>, <span class="hlFld-ContribAuthor ">Timothy R.  Wilson</span>, <span class="hlFld-ContribAuthor ">Joseph A.  Ware</span>, <span class="hlFld-ContribAuthor ">Sandra M.  Sanabria Bohorquez</span>, <span class="hlFld-ContribAuthor ">Heidi M.  Savage</span>, <span class="hlFld-ContribAuthor ">Deepak  Sampath</span>, <span class="hlFld-ContribAuthor ">Laurent  Salphati</span>, <span class="hlFld-ContribAuthor ">Ray S.  Lin</span>, <span class="hlFld-ContribAuthor ">Huan  Jin</span>, <span class="hlFld-ContribAuthor ">Hema  Parmar</span>, <span class="hlFld-ContribAuthor ">Jerry Y.  Hsu</span>, <span class="hlFld-ContribAuthor ">Daniel D.  Von Hoff</span>, <span class="hlFld-ContribAuthor ">José  Baselga</span>. </span><span class="cited-content_cbyCitation_article-title">Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors. </span><span class="cited-content_cbyCitation_journal-name">Cancer Discovery</span><span> <strong>2017,</strong> <em>7 </em>
                                    (7)
                                     , 704-715. <a href="https://doi.org/10.1158/2159-8290.CD-16-1080" title="DOI URL">https://doi.org/10.1158/2159-8290.CD-16-1080</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/2159-8290.CD-16-1080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F2159-8290.CD-16-1080%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Discovery%26atitle%3DPhase%252BI%252BDose-Escalation%252BStudy%252Bof%252BTaselisib%25252C%252Ban%252BOral%252BPI3K%252BInhibitor%25252C%252Bin%252BPatients%252Bwith%252BAdvanced%252BSolid%252BTumors%26aulast%3DJuric%26aufirst%3DDejan%26date%3D2017%26date%3D2017%26volume%3D7%26issue%3D7%26spage%3D704%26epage%3D715" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Joanna  Janus</span>, <span class="hlFld-ContribAuthor ">Ryan  O’Shaughnessy</span>, <span class="hlFld-ContribAuthor ">Catherine  Harwood</span>, <span class="hlFld-ContribAuthor ">Tania  Maffucci</span>. </span><span class="cited-content_cbyCitation_article-title">Phosphoinositide 3-Kinase-Dependent Signalling Pathways in Cutaneous Squamous Cell Carcinomas. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2017,</strong> <em>9 </em>
                                    (7)
                                     , 86. <a href="https://doi.org/10.3390/cancers9070086" title="DOI URL">https://doi.org/10.3390/cancers9070086</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers9070086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers9070086%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DPhosphoinositide%252B3-Kinase-Dependent%252BSignalling%252BPathways%252Bin%252BCutaneous%252BSquamous%252BCell%252BCarcinomas%26aulast%3DJanus%26aufirst%3DJoanna%26date%3D2017%26date%3D2017%26volume%3D9%26issue%3D7%26spage%3D86" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sonia  Martínez González</span>, <span class="hlFld-ContribAuthor ">Sonsoles  Rodríguez-Arístegui</span>, <span class="hlFld-ContribAuthor ">Ana Isabel  Hernández</span>, <span class="hlFld-ContribAuthor ">Carmen  Varela</span>, <span class="hlFld-ContribAuthor ">Esther  González Cantalapiedra</span>, <span class="hlFld-ContribAuthor ">Rosa María  Álvarez</span>, <span class="hlFld-ContribAuthor ">Antonio  Rodríguez Hergueta</span>, <span class="hlFld-ContribAuthor ">James R.  Bischoff</span>, <span class="hlFld-ContribAuthor ">María Isabel  Albarrán</span>, <span class="hlFld-ContribAuthor ">Antonio  Cebriá</span>, <span class="hlFld-ContribAuthor ">Elena  Cendón</span>, <span class="hlFld-ContribAuthor ">David  Cebrián</span>, <span class="hlFld-ContribAuthor ">Patricia  Alfonso</span>, <span class="hlFld-ContribAuthor ">Joaquín  Pastor</span>. </span><span class="cited-content_cbyCitation_article-title">Generation of tricyclic imidazo[1,2- a ]pyrazines as novel PI3K inhibitors by application of a conformational restriction strategy. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2017,</strong> <em>27 </em>
                                    (11)
                                     , 2536-2543. <a href="https://doi.org/10.1016/j.bmcl.2017.03.090" title="DOI URL">https://doi.org/10.1016/j.bmcl.2017.03.090</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2017.03.090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2017.03.090%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DGeneration%252Bof%252Btricyclic%252Bimidazo%25255B1%25252C2-%252Ba%252B%25255Dpyrazines%252Bas%252Bnovel%252BPI3K%252Binhibitors%252Bby%252Bapplication%252Bof%252Ba%252Bconformational%252Brestriction%252Bstrategy%26aulast%3DMart%25C3%25ADnez%2BGonz%25C3%25A1lez%26aufirst%3DSonia%26date%3D2017%26volume%3D27%26issue%3D11%26spage%3D2536%26epage%3D2543" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jillian M.  Silva</span>, <span class="hlFld-ContribAuthor ">Marian M.  Deuker</span>, <span class="hlFld-ContribAuthor ">Bruce C.  Baguley</span>, <span class="hlFld-ContribAuthor ">Martin  McMahon</span>. </span><span class="cited-content_cbyCitation_article-title">PIK3CA
              -mutated melanoma cells rely on cooperative signaling through mTORC1/2 for sustained proliferation. </span><span class="cited-content_cbyCitation_journal-name">Pigment Cell & Melanoma Research</span><span> <strong>2017,</strong> <em>30 </em>
                                    (3)
                                     , 353-367. <a href="https://doi.org/10.1111/pcmr.12586" title="DOI URL">https://doi.org/10.1111/pcmr.12586</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/pcmr.12586&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fpcmr.12586%26sid%3Dliteratum%253Aachs%26jtitle%3DPigment%2520Cell%2520%2526%2520Melanoma%2520Research%26atitle%3DPIK3CA%252B-mutated%252Bmelanoma%252Bcells%252Brely%252Bon%252Bcooperative%252Bsignaling%252Bthrough%252BmTORC1%25252F2%252Bfor%252Bsustained%252Bproliferation%26aulast%3DSilva%26aufirst%3DJillian%2BM.%26date%3D2017%26date%3D2017%26volume%3D30%26issue%3D3%26spage%3D353%26epage%3D367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yu  Liu</span>, <span class="hlFld-ContribAuthor ">Wen-zhu  Wan</span>, <span class="hlFld-ContribAuthor ">Yan  Li</span>, <span class="hlFld-ContribAuthor ">Guan-lian  Zhou</span>, <span class="hlFld-ContribAuthor ">Xin-guang  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Recent development of ATP-competitive small molecule phosphatidylinostitol-3-kinase inhibitors as anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2017,</strong> <em>8 </em>
                                    (4)
                                     , 7181-7200. <a href="https://doi.org/10.18632/oncotarget.12742" title="DOI URL">https://doi.org/10.18632/oncotarget.12742</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.12742&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.12742%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DRecent%252Bdevelopment%252Bof%252BATP-competitive%252Bsmall%252Bmolecule%252Bphosphatidylinostitol-3-kinase%252Binhibitors%252Bas%252Banticancer%252Bagents%26aulast%3DLiu%26aufirst%3DYu%26date%3D2017%26date%3D2016%26volume%3D8%26issue%3D4%26spage%3D7181%26epage%3D7200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Steven T.  Staben</span>. </span><span class="cited-content_cbyCitation_article-title">Isoform Selective PI3K Inhibitors for Treating Cancer. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 333-333. <a href="https://doi.org/10.1007/7355_2016_27" title="DOI URL">https://doi.org/10.1007/7355_2016_27</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/7355_2016_27&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F7355_2016_27%26sid%3Dliteratum%253Aachs%26atitle%3DIsoform%252BSelective%252BPI3K%252BInhibitors%252Bfor%252BTreating%252BCancer%26aulast%3DStaben%26aufirst%3DSteven%2BT.%26date%3D2017%26spage%3D333%26epage%3D333%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DCancer%252BII%26aulast%3DWaring%26aufirst%3DMichael%2BJ.%26date%3D2018%26volume%3D28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stine  Daldorff</span>, <span class="hlFld-ContribAuthor ">Randi Margit Ruud  Mathiesen</span>, <span class="hlFld-ContribAuthor ">Olav Erich  Yri</span>, <span class="hlFld-ContribAuthor ">Hilde Presterud  Ødegård</span>, <span class="hlFld-ContribAuthor ">Jürgen  Geisler</span>. </span><span class="cited-content_cbyCitation_article-title">Cotargeting of CYP-19 (aromatase) and emerging, pivotal signalling pathways in metastatic breast cancer. </span><span class="cited-content_cbyCitation_journal-name">British Journal of Cancer</span><span> <strong>2017,</strong> <em>116 </em>
                                    (1)
                                     , 10-20. <a href="https://doi.org/10.1038/bjc.2016.405" title="DOI URL">https://doi.org/10.1038/bjc.2016.405</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/bjc.2016.405&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fbjc.2016.405%26sid%3Dliteratum%253Aachs%26jtitle%3DBritish%2520Journal%2520of%2520Cancer%26atitle%3DCotargeting%252Bof%252BCYP-19%252B%252528aromatase%252529%252Band%252Bemerging%25252C%252Bpivotal%252Bsignalling%252Bpathways%252Bin%252Bmetastatic%252Bbreast%252Bcancer%26aulast%3DDaldorff%26aufirst%3DStine%26date%3D2017%26date%3D2016%26volume%3D116%26issue%3D1%26spage%3D10%26epage%3D20" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dongyan  Yang</span>, <span class="hlFld-ContribAuthor ">Chuan  Wan</span>, <span class="hlFld-ContribAuthor ">MengMeng  He</span>, <span class="hlFld-ContribAuthor ">Chuanliang  Che</span>, <span class="hlFld-ContribAuthor ">Yumei  Xiao</span>, <span class="hlFld-ContribAuthor ">Bin  Fu</span>, <span class="hlFld-ContribAuthor ">Zhaohai  Qin</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, crystal structure and fungicidal activity of (E)-5-(methoxyimino)-3,5-dihydrobenzo[e][1,2]oxazepin-4(1H)-one analogues. </span><span class="cited-content_cbyCitation_journal-name">MedChemComm</span><span> <strong>2017,</strong> <em>8 </em>
                                    (5)
                                     , 1007-1014. <a href="https://doi.org/10.1039/C7MD00025A" title="DOI URL">https://doi.org/10.1039/C7MD00025A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C7MD00025A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC7MD00025A%26sid%3Dliteratum%253Aachs%26jtitle%3DMedChemComm%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Bcrystal%252Bstructure%252Band%252Bfungicidal%252Bactivity%252Bof%252B%252528E%252529-5-%252528methoxyimino%252529-3%25252C5-dihydrobenzo%25255Be%25255D%25255B1%25252C2%25255Doxazepin-4%2525281H%252529-one%252Banalogues%26aulast%3DYang%26aufirst%3DDongyan%26date%3D2017%26date%3D2017%26volume%3D8%26issue%3D5%26spage%3D1007%26epage%3D1014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Angel  Guerrero-Zotano</span>, <span class="hlFld-ContribAuthor ">Ingrid A.  Mayer</span>, <span class="hlFld-ContribAuthor ">Carlos L.  Arteaga</span>. </span><span class="cited-content_cbyCitation_article-title">PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment. </span><span class="cited-content_cbyCitation_journal-name">Cancer and Metastasis Reviews</span><span> <strong>2016,</strong> <em>35 </em>
                                    (4)
                                     , 515-524. <a href="https://doi.org/10.1007/s10555-016-9637-x" title="DOI URL">https://doi.org/10.1007/s10555-016-9637-x</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10555-016-9637-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10555-016-9637-x%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520and%2520Metastasis%2520Reviews%26atitle%3DPI3K%25252FAKT%25252FmTOR%25253A%252Brole%252Bin%252Bbreast%252Bcancer%252Bprogression%25252C%252Bdrug%252Bresistance%25252C%252Band%252Btreatment%26aulast%3DGuerrero-Zotano%26aufirst%3DAngel%26date%3D2016%26date%3D2016%26volume%3D35%26issue%3D4%26spage%3D515%26epage%3D524" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">A. C.  Garrido-Castro</span>, <span class="hlFld-ContribAuthor ">O.  Metzger-Filho</span>. </span><span class="cited-content_cbyCitation_article-title">Novel Strategies in Hormone Receptor-Positive Advanced Breast Cancer: Overcoming Endocrine Resistance. </span><span class="cited-content_cbyCitation_journal-name">Current Breast Cancer Reports</span><span> <strong>2016,</strong> <em>8 </em>
                                    (4)
                                     , 193-205. <a href="https://doi.org/10.1007/s12609-016-0228-1" title="DOI URL">https://doi.org/10.1007/s12609-016-0228-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s12609-016-0228-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs12609-016-0228-1%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Breast%2520Cancer%2520Reports%26atitle%3DNovel%252BStrategies%252Bin%252BHormone%252BReceptor-Positive%252BAdvanced%252BBreast%252BCancer%25253A%252BOvercoming%252BEndocrine%252BResistance%26aulast%3DGarrido-Castro%26aufirst%3DA.%2BC.%26date%3D2016%26date%3D2016%26volume%3D8%26issue%3D4%26spage%3D193%26epage%3D205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Haluk  Yuzugullu</span>, <span class="hlFld-ContribAuthor ">Thanh  Von</span>, <span class="hlFld-ContribAuthor ">Lauren M  Thorpe</span>, <span class="hlFld-ContribAuthor ">Sarah R  Walker</span>, <span class="hlFld-ContribAuthor ">Thomas M  Roberts</span>, <span class="hlFld-ContribAuthor ">David A  Frank</span>, <span class="hlFld-ContribAuthor ">Jean J  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">NTRK2 activation cooperates with PTEN deficiency in T-ALL through activation of both the PI3K–AKT and JAK–STAT3 pathways. </span><span class="cited-content_cbyCitation_journal-name">Cell Discovery</span><span> <strong>2016,</strong> <em>2 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/celldisc.2016.30" title="DOI URL">https://doi.org/10.1038/celldisc.2016.30</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/celldisc.2016.30&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fcelldisc.2016.30%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Discovery%26atitle%3DNTRK2%252Bactivation%252Bcooperates%252Bwith%252BPTEN%252Bdeficiency%252Bin%252BT-ALL%252Bthrough%252Bactivation%252Bof%252Bboth%252Bthe%252BPI3K%2525E2%252580%252593AKT%252Band%252BJAK%2525E2%252580%252593STAT3%252Bpathways%26aulast%3DYuzugullu%26aufirst%3DHaluk%26date%3D2016%26date%3D2016%26volume%3D2%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rossella  Martinello</span>, <span class="hlFld-ContribAuthor ">Sofia  Genta</span>, <span class="hlFld-ContribAuthor ">Danilo  Galizia</span>, <span class="hlFld-ContribAuthor ">Elena  Geuna</span>, <span class="hlFld-ContribAuthor ">Andrea  Milani</span>, <span class="hlFld-ContribAuthor ">Giorgia  Zucchini</span>, <span class="hlFld-ContribAuthor ">Giorgio  Valabrega</span>, <span class="hlFld-ContribAuthor ">Filippo  Montemurro</span>. </span><span class="cited-content_cbyCitation_article-title">New and developing chemical pharmacotherapy for treating hormone receptor-positive/HER2-negative breast cancer. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Pharmacotherapy</span><span> <strong>2016,</strong> <em>17 </em>
                                    (16)
                                     , 2179-2189. <a href="https://doi.org/10.1080/14656566.2016.1236914" title="DOI URL">https://doi.org/10.1080/14656566.2016.1236914</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14656566.2016.1236914&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14656566.2016.1236914%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Pharmacotherapy%26atitle%3DNew%252Band%252Bdeveloping%252Bchemical%252Bpharmacotherapy%252Bfor%252Btreating%252Bhormone%252Breceptor-positive%25252FHER2-negative%252Bbreast%252Bcancer%26aulast%3DMartinello%26aufirst%3DRossella%26date%3D2016%26date%3D2016%26volume%3D17%26issue%3D16%26spage%3D2179%26epage%3D2189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Patricia Mucci  LoRusso</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Clinical Oncology</span><span> <strong>2016,</strong> <em>34 </em>
                                    (31)
                                     , 3803-3815. <a href="https://doi.org/10.1200/JCO.2014.59.0018" title="DOI URL">https://doi.org/10.1200/JCO.2014.59.0018</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1200/JCO.2014.59.0018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1200%2FJCO.2014.59.0018%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Clinical%2520Oncology%26atitle%3DInhibition%252Bof%252Bthe%252BPI3K%25252FAKT%25252FmTOR%252BPathway%252Bin%252BSolid%252BTumors%26aulast%3DLoRusso%26aufirst%3DPatricia%2BMucci%26date%3D2016%26volume%3D34%26issue%3D31%26spage%3D3803%26epage%3D3815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rammohan R.  Yadav</span>, <span class="hlFld-ContribAuthor ">Santosh K.  Guru</span>, <span class="hlFld-ContribAuthor ">Prashant  Joshi</span>, <span class="hlFld-ContribAuthor ">Girish  Mahajan</span>, <span class="hlFld-ContribAuthor ">Mubashir J.  Mintoo</span>, <span class="hlFld-ContribAuthor ">Vikas  Kumar</span>, <span class="hlFld-ContribAuthor ">Sonali S.  Bharate</span>, <span class="hlFld-ContribAuthor ">Dilip M.  Mondhe</span>, <span class="hlFld-ContribAuthor ">Ram A.  Vishwakarma</span>, <span class="hlFld-ContribAuthor ">Shashi  Bhushan</span>, <span class="hlFld-ContribAuthor ">Sandip B.  Bharate</span>. </span><span class="cited-content_cbyCitation_article-title">6-Aryl substituted 4-(4-cyanomethyl) phenylamino quinazolines as a new class of isoform-selective PI3K-alpha inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>122 </em>, 731-743. <a href="https://doi.org/10.1016/j.ejmech.2016.07.006" title="DOI URL">https://doi.org/10.1016/j.ejmech.2016.07.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2016.07.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2016.07.006%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3D6-Aryl%252Bsubstituted%252B4-%2525284-cyanomethyl%252529%252Bphenylamino%252Bquinazolines%252Bas%252Ba%252Bnew%252Bclass%252Bof%252Bisoform-selective%252BPI3K-alpha%252Binhibitors%26aulast%3DYadav%26aufirst%3DRammohan%2BR.%26date%3D2016%26volume%3D122%26spage%3D731%26epage%3D743" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Conleth G  Murphy</span>, <span class="hlFld-ContribAuthor ">Maura N  Dickler</span>. </span><span class="cited-content_cbyCitation_article-title">Endocrine resistance in hormone-responsive breast cancer: mechanisms and therapeutic strategies. </span><span class="cited-content_cbyCitation_journal-name">Endocrine-Related Cancer</span><span> <strong>2016,</strong> <em>23 </em>
                                    (8)
                                     , R337-R352. <a href="https://doi.org/10.1530/ERC-16-0121" title="DOI URL">https://doi.org/10.1530/ERC-16-0121</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1530/ERC-16-0121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1530%2FERC-16-0121%26sid%3Dliteratum%253Aachs%26jtitle%3DEndocrine-Related%2520Cancer%26atitle%3DEndocrine%252Bresistance%252Bin%252Bhormone-responsive%252Bbreast%252Bcancer%25253A%252Bmechanisms%252Band%252Btherapeutic%252Bstrategies%26aulast%3DMurphy%26aufirst%3DConleth%2BG%26date%3D2016%26volume%3D23%26issue%3D8%26spage%3DR337%26epage%3DR352" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Florian  Gnad</span>, <span class="hlFld-ContribAuthor ">Jeffrey  Wallin</span>, <span class="hlFld-ContribAuthor ">Kyle  Edgar</span>, <span class="hlFld-ContribAuthor ">Sophia  Doll</span>, <span class="hlFld-ContribAuthor ">David  Arnott</span>, <span class="hlFld-ContribAuthor ">Liliane  Robillard</span>, <span class="hlFld-ContribAuthor ">Donald S.  Kirkpatrick</span>, <span class="hlFld-ContribAuthor ">Matthew P.  Stokes</span>, <span class="hlFld-ContribAuthor ">Ulka  Vijapurkar</span>, <span class="hlFld-ContribAuthor ">Georgia  Hatzivassiliou</span>, <span class="hlFld-ContribAuthor ">Lori S.  Friedman</span>, <span class="hlFld-ContribAuthor ">Marcia  Belvin</span>. </span><span class="cited-content_cbyCitation_article-title">Quantitative phosphoproteomic analysis of the PI3K-regulated signaling network. </span><span class="cited-content_cbyCitation_journal-name">PROTEOMICS</span><span> <strong>2016,</strong> <em>16 </em>
                                    (14)
                                     , 1992-1997. <a href="https://doi.org/10.1002/pmic.201600118" title="DOI URL">https://doi.org/10.1002/pmic.201600118</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/pmic.201600118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fpmic.201600118%26sid%3Dliteratum%253Aachs%26jtitle%3DPROTEOMICS%26atitle%3DQuantitative%252Bphosphoproteomic%252Banalysis%252Bof%252Bthe%252BPI3K-regulated%252Bsignaling%252Bnetwork%26aulast%3DGnad%26aufirst%3DFlorian%26date%3D2016%26date%3D2016%26volume%3D16%26issue%3D14%26spage%3D1992%26epage%3D1997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">X.  Ding</span>, <span class="hlFld-ContribAuthor ">K.  Faber</span>, <span class="hlFld-ContribAuthor ">Y.  Shi</span>, <span class="hlFld-ContribAuthor ">J.  McKnight</span>, <span class="hlFld-ContribAuthor ">D.  Dorshorst</span>, <span class="hlFld-ContribAuthor ">J.A.  Ware</span>, <span class="hlFld-ContribAuthor ">B.  Dean</span>. </span><span class="cited-content_cbyCitation_article-title">Validation and determination of taselisib, a β-sparing phosphoinositide 3-kinase (PI3K) inhibitor, in human plasma by LC–MS/MS. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pharmaceutical and Biomedical Analysis</span><span> <strong>2016,</strong> <em>126 </em>, 117-123. <a href="https://doi.org/10.1016/j.jpba.2016.04.030" title="DOI URL">https://doi.org/10.1016/j.jpba.2016.04.030</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jpba.2016.04.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jpba.2016.04.030%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pharmaceutical%2520and%2520Biomedical%2520Analysis%26atitle%3DValidation%252Band%252Bdetermination%252Bof%252Btaselisib%25252C%252Ba%252B%2525CE%2525B2-sparing%252Bphosphoinositide%252B3-kinase%252B%252528PI3K%252529%252Binhibitor%25252C%252Bin%252Bhuman%252Bplasma%252Bby%252BLC%2525E2%252580%252593MS%25252FMS%26aulast%3DDing%26aufirst%3DX.%26date%3D2016%26volume%3D126%26spage%3D117%26epage%3D123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zachary S.  Zumsteg</span>, <span class="hlFld-ContribAuthor ">Natasha  Morse</span>, <span class="hlFld-ContribAuthor ">Gabriel  Krigsfeld</span>, <span class="hlFld-ContribAuthor ">Gaorav  Gupta</span>, <span class="hlFld-ContribAuthor ">Daniel S.  Higginson</span>, <span class="hlFld-ContribAuthor ">Nancy Y.  Lee</span>, <span class="hlFld-ContribAuthor ">Luc  Morris</span>, <span class="hlFld-ContribAuthor ">Ian  Ganly</span>, <span class="hlFld-ContribAuthor ">Stephan L.  Shiao</span>, <span class="hlFld-ContribAuthor ">Simon N.  Powell</span>, <span class="hlFld-ContribAuthor ">Christine H.  Chung</span>, <span class="hlFld-ContribAuthor ">Maurizio  Scaltriti</span>, <span class="hlFld-ContribAuthor ">José  Baselga</span>. </span><span class="cited-content_cbyCitation_article-title">Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating
              PIK3CA
              Alterations. </span><span class="cited-content_cbyCitation_journal-name">Clinical Cancer Research</span><span> <strong>2016,</strong> <em>22 </em>
                                    (8)
                                     , 2009-2019. <a href="https://doi.org/10.1158/1078-0432.CCR-15-2245" title="DOI URL">https://doi.org/10.1158/1078-0432.CCR-15-2245</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1078-0432.CCR-15-2245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1078-0432.CCR-15-2245%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Cancer%2520Research%26atitle%3DTaselisib%252B%252528GDC-0032%252529%25252C%252Ba%252BPotent%252B%2525CE%2525B2-Sparing%252BSmall%252BMolecule%252BInhibitor%252Bof%252BPI3K%25252C%252BRadiosensitizes%252BHead%252Band%252BNeck%252BSquamous%252BCarcinomas%252BContaining%252BActivating%252BPIK3CA%252BAlterations%26aulast%3DZumsteg%26aufirst%3DZachary%2BS.%26date%3D2016%26date%3D2015%26volume%3D22%26issue%3D8%26spage%3D2009%26epage%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Klaus P.  Hoeflich</span>, <span class="hlFld-ContribAuthor ">Jane  Guan</span>, <span class="hlFld-ContribAuthor ">Kyle A.  Edgar</span>, <span class="hlFld-ContribAuthor ">Carol  O’Brien</span>, <span class="hlFld-ContribAuthor ">Heidi  Savage</span>, <span class="hlFld-ContribAuthor ">Timothy R.  Wilson</span>, <span class="hlFld-ContribAuthor ">Richard M.  Neve</span>, <span class="hlFld-ContribAuthor ">Lori S.  Friedman</span>, <span class="hlFld-ContribAuthor ">Jeffrey J.  Wallin</span>. </span><span class="cited-content_cbyCitation_article-title">The PI3K inhibitor taselisib overcomes letrozole resistance in a breast cancer model expressing aromatase. </span><span class="cited-content_cbyCitation_journal-name">Genes & Cancer</span><span> <strong>2016,</strong> <em>7 </em>
                                    (3-4)
                                     , 73-85. <a href="https://doi.org/10.18632/genesandcancer.100" title="DOI URL">https://doi.org/10.18632/genesandcancer.100</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/genesandcancer.100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Fgenesandcancer.100%26sid%3Dliteratum%253Aachs%26jtitle%3DGenes%2520%2526%2520Cancer%26atitle%3DThe%252BPI3K%252Binhibitor%252Btaselisib%252Bovercomes%252Bletrozole%252Bresistance%252Bin%252Ba%252Bbreast%252Bcancer%252Bmodel%252Bexpressing%252Baromatase%26aulast%3DHoeflich%26aufirst%3DKlaus%2BP.%26date%3D2016%26volume%3D7%26issue%3D3-4%26spage%3D73%26epage%3D85" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yoshito  Nakanishi</span>, <span class="hlFld-ContribAuthor ">Kimberly  Walter</span>, <span class="hlFld-ContribAuthor ">Jill M.  Spoerke</span>, <span class="hlFld-ContribAuthor ">Carol  O'Brien</span>, <span class="hlFld-ContribAuthor ">Ling Y.  Huw</span>, <span class="hlFld-ContribAuthor ">Garret M.  Hampton</span>, <span class="hlFld-ContribAuthor ">Mark R.  Lackner</span>. </span><span class="cited-content_cbyCitation_article-title">Activating Mutations in
              PIK3CB
              Confer Resistance to PI3K Inhibition and Define a Novel Oncogenic Role for p110β. </span><span class="cited-content_cbyCitation_journal-name">Cancer Research</span><span> <strong>2016,</strong> <em>76 </em>
                                    (5)
                                     , 1193-1203. <a href="https://doi.org/10.1158/0008-5472.CAN-15-2201" title="DOI URL">https://doi.org/10.1158/0008-5472.CAN-15-2201</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/0008-5472.CAN-15-2201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F0008-5472.CAN-15-2201%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Research%26atitle%3DActivating%252BMutations%252Bin%252BPIK3CB%252BConfer%252BResistance%252Bto%252BPI3K%252BInhibition%252Band%252BDefine%252Ba%252BNovel%252BOncogenic%252BRole%252Bfor%252Bp110%2525CE%2525B2%26aulast%3DNakanishi%26aufirst%3DYoshito%26date%3D2016%26date%3D2016%26volume%3D76%26issue%3D5%26spage%3D1193%26epage%3D1203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yingcai  Ding</span>, <span class="hlFld-ContribAuthor ">Ping  Xie</span>, <span class="hlFld-ContribAuthor ">Wenhui  Zhu</span>, <span class="hlFld-ContribAuthor ">Baojun  Xu</span>, <span class="hlFld-ContribAuthor ">Wannian  Zhao</span>, <span class="hlFld-ContribAuthor ">Aihua  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Cu-catalyzed sulfenylation of imidazol[1,2-a]pyridine via C–H functionalization using a combination of Na
              2
              S
              2
              O
              3
              and halides. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2016,</strong> <em>6 </em>
                                    (85)
                                     , 81932-81935. <a href="https://doi.org/10.1039/C6RA18136H" title="DOI URL">https://doi.org/10.1039/C6RA18136H</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C6RA18136H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC6RA18136H%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DCu-catalyzed%252Bsulfenylation%252Bof%252Bimidazol%25255B1%25252C2-a%25255Dpyridine%252Bvia%252BC%2525E2%252580%252593H%252Bfunctionalization%252Busing%252Ba%252Bcombination%252Bof%252BNa%252B2%252BS%252B2%252BO%252B3%252Band%252Bhalides%26aulast%3DDing%26aufirst%3DYingcai%26date%3D2016%26date%3D2016%26volume%3D6%26issue%3D85%26spage%3D81932%26epage%3D81935" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Liang  Lu</span>, <span class="hlFld-ContribAuthor ">Shao  Sha</span>, <span class="hlFld-ContribAuthor ">Kai  Wang</span>, <span class="hlFld-ContribAuthor ">Yuan-Heng  Zhang</span>, <span class="hlFld-ContribAuthor ">Yan-Dong  Liu</span>, <span class="hlFld-ContribAuthor ">Guo-Dong  Ju</span>, <span class="hlFld-ContribAuthor ">Baozhong  Wang</span>, <span class="hlFld-ContribAuthor ">Hai-Liang  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Chromeno[4,3-c]pyrazol-4(2H)-one Containing Carbonyl or Oxime Derivatives as Potential, Selective Inhibitors PI3Kα. </span><span class="cited-content_cbyCitation_journal-name">CHEMICAL & PHARMACEUTICAL BULLETIN</span><span> <strong>2016,</strong> <em>64 </em>
                                    (11)
                                     , 1576-1581. <a href="https://doi.org/10.1248/cpb.c16-00388" title="DOI URL">https://doi.org/10.1248/cpb.c16-00388</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1248/cpb.c16-00388&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1248%2Fcpb.c16-00388%26sid%3Dliteratum%253Aachs%26jtitle%3DCHEMICAL%2520%2526%2520PHARMACEUTICAL%2520BULLETIN%26atitle%3DDiscovery%252Bof%252BChromeno%25255B4%25252C3-c%25255Dpyrazol-4%2525282H%252529-one%252BContaining%252BCarbonyl%252Bor%252BOxime%252BDerivatives%252Bas%252BPotential%25252C%252BSelective%252BInhibitors%252BPI3K%2525CE%2525B1%26aulast%3DLu%26aufirst%3DLiang%26date%3D2016%26volume%3D64%26issue%3D11%26spage%3D1576%26epage%3D1581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hao  Zhang</span>, <span class="hlFld-ContribAuthor ">Min-Hang  Xin</span>, <span class="hlFld-ContribAuthor ">Xiao-Xiao  Xie</span>, <span class="hlFld-ContribAuthor ">Shuai  Mao</span>, <span class="hlFld-ContribAuthor ">Sai-Jie  Zuo</span>, <span class="hlFld-ContribAuthor ">She-Min  Lu</span>, <span class="hlFld-ContribAuthor ">San-Qi  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and antitumor activity evaluation of PI3K inhibitors containing 3-substituted quinazolin-4(3H)-one moiety. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2015,</strong> <em>23 </em>
                                    (24)
                                     , 7765-7776. <a href="https://doi.org/10.1016/j.bmc.2015.11.027" title="DOI URL">https://doi.org/10.1016/j.bmc.2015.11.027</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2015.11.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2015.11.027%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bantitumor%252Bactivity%252Bevaluation%252Bof%252BPI3K%252Binhibitors%252Bcontaining%252B3-substituted%252Bquinazolin-4%2525283H%252529-one%252Bmoiety%26aulast%3DZhang%26aufirst%3DHao%26date%3D2015%26volume%3D23%26issue%3D24%26spage%3D7765%26epage%3D7776" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bernard  Barlaam</span>, <span class="hlFld-ContribAuthor ">Sabina  Cosulich</span>, <span class="hlFld-ContribAuthor ">Bénédicte  Delouvrié</span>, <span class="hlFld-ContribAuthor ">Rebecca  Ellston</span>, <span class="hlFld-ContribAuthor ">Martina  Fitzek</span>, <span class="hlFld-ContribAuthor ">Hervé  Germain</span>, <span class="hlFld-ContribAuthor ">Stephen  Green</span>, <span class="hlFld-ContribAuthor ">Urs  Hancox</span>, <span class="hlFld-ContribAuthor ">Craig S.  Harris</span>, <span class="hlFld-ContribAuthor ">Kevin  Hudson</span>, <span class="hlFld-ContribAuthor ">Christine  Lambert-van der Brempt</span>, <span class="hlFld-ContribAuthor ">Honorine  Lebraud</span>, <span class="hlFld-ContribAuthor ">Françoise  Magnien</span>, <span class="hlFld-ContribAuthor ">Maryannick  Lamorlette</span>, <span class="hlFld-ContribAuthor ">Antoine  Le Griffon</span>, <span class="hlFld-ContribAuthor ">Rémy  Morgentin</span>, <span class="hlFld-ContribAuthor ">Gilles  Ouvry</span>, <span class="hlFld-ContribAuthor ">Ken  Page</span>, <span class="hlFld-ContribAuthor ">Georges  Pasquet</span>, <span class="hlFld-ContribAuthor ">Urszula  Polanska</span>, <span class="hlFld-ContribAuthor ">Linette  Ruston</span>, <span class="hlFld-ContribAuthor ">Twana  Saleh</span>, <span class="hlFld-ContribAuthor ">Michel  Vautier</span>, <span class="hlFld-ContribAuthor ">Lara  Ward</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 1-(4-(5-(5-amino-6-(5-tert-butyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl)-1-ethyl-1,2,4-triazol-3-yl)piperidin-1-yl)-3-hydroxypropan-1-one (AZD8835): A potent and selective inhibitor of PI3Kα and PI3Kδ for the treatment of cancers. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2015,</strong> <em>25 </em>
                                    (22)
                                     , 5155-5162. <a href="https://doi.org/10.1016/j.bmcl.2015.10.002" title="DOI URL">https://doi.org/10.1016/j.bmcl.2015.10.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2015.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2015.10.002%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252B1-%2525284-%2525285-%2525285-amino-6-%2525285-tert-butyl-1%25252C3%25252C4-oxadiazol-2-yl%252529pyrazin-2-yl%252529-1-ethyl-1%25252C2%25252C4-triazol-3-yl%252529piperidin-1-yl%252529-3-hydroxypropan-1-one%252B%252528AZD8835%252529%25253A%252BA%252Bpotent%252Band%252Bselective%252Binhibitor%252Bof%252BPI3K%2525CE%2525B1%252Band%252BPI3K%2525CE%2525B4%252Bfor%252Bthe%252Btreatment%252Bof%252Bcancers%26aulast%3DBarlaam%26aufirst%3DBernard%26date%3D2015%26volume%3D25%26issue%3D22%26spage%3D5155%26epage%3D5162" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Salvatore  Lopez</span>, <span class="hlFld-ContribAuthor ">Emiliano  Cocco</span>, <span class="hlFld-ContribAuthor ">Jonathan  Black</span>, <span class="hlFld-ContribAuthor ">Stefania  Bellone</span>, <span class="hlFld-ContribAuthor ">Elena  Bonazzoli</span>, <span class="hlFld-ContribAuthor ">Federica  Predolini</span>, <span class="hlFld-ContribAuthor ">Francesca  Ferrari</span>, <span class="hlFld-ContribAuthor ">Carlton L.  Schwab</span>, <span class="hlFld-ContribAuthor ">Diana P.  English</span>, <span class="hlFld-ContribAuthor ">Elena  Ratner</span>, <span class="hlFld-ContribAuthor ">Dan-Arin  Silasi</span>, <span class="hlFld-ContribAuthor ">Masoud  Azodi</span>, <span class="hlFld-ContribAuthor ">Peter E.  Schwartz</span>, <span class="hlFld-ContribAuthor ">Corrado  Terranova</span>, <span class="hlFld-ContribAuthor ">Roberto  Angioli</span>, <span class="hlFld-ContribAuthor ">Alessandro D.  Santin</span>. </span><span class="cited-content_cbyCitation_article-title">Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines
              In Vitro
              and
              In Vivo. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Therapeutics</span><span> <strong>2015,</strong> <em>14 </em>
                                    (11)
                                     , 2519-2526. <a href="https://doi.org/10.1158/1535-7163.MCT-15-0383" title="DOI URL">https://doi.org/10.1158/1535-7163.MCT-15-0383</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1535-7163.MCT-15-0383&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1535-7163.MCT-15-0383%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Therapeutics%26atitle%3DDual%252BHER2%25252FPIK3CA%252BTargeting%252BOvercomes%252BSingle-Agent%252BAcquired%252BResistance%252Bin%252BHER2-Amplified%252BUterine%252BSerous%252BCarcinoma%252BCell%252BLines%252BIn%252BVitro%252Band%252BIn%252BVivo%26aulast%3DLopez%26aufirst%3DSalvatore%26date%3D2015%26date%3D2015%26volume%3D14%26issue%3D11%26spage%3D2519%26epage%3D2526" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiang  Wang</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Ling-hua  Meng</span>. </span><span class="cited-content_cbyCitation_article-title">PI3K isoform-selective inhibitors: next-generation targeted cancer therapies. </span><span class="cited-content_cbyCitation_journal-name">Acta Pharmacologica Sinica</span><span> <strong>2015,</strong> <em>36 </em>
                                    (10)
                                     , 1170-1176. <a href="https://doi.org/10.1038/aps.2015.71" title="DOI URL">https://doi.org/10.1038/aps.2015.71</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/aps.2015.71&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Faps.2015.71%26sid%3Dliteratum%253Aachs%26jtitle%3DActa%2520Pharmacologica%2520Sinica%26atitle%3DPI3K%252Bisoform-selective%252Binhibitors%25253A%252Bnext-generation%252Btargeted%252Bcancer%252Btherapies%26aulast%3DWang%26aufirst%3DXiang%26date%3D2015%26date%3D2015%26volume%3D36%26issue%3D10%26spage%3D1170%26epage%3D1176" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiao-Meng  Wang</span>, <span class="hlFld-ContribAuthor ">Shuai  Mao</span>, <span class="hlFld-ContribAuthor ">Lei  Cao</span>, <span class="hlFld-ContribAuthor ">Xiao-Xiao  Xie</span>, <span class="hlFld-ContribAuthor ">Min-Hang  Xin</span>, <span class="hlFld-ContribAuthor ">Jia-Fang  Lian</span>, <span class="hlFld-ContribAuthor ">Yong-Xiao  Cao</span>, <span class="hlFld-ContribAuthor ">San-Qi  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Modification of N -(6-(2-methoxy-3-(4-fluorophenylsulfonamido)pyridin-5-yl)-[1,2,4]triazolo[1,5- a ]pyridin-2-yl)acetamide as PI3Ks inhibitor by replacement of the acetamide group with alkylurea. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2015,</strong> <em>23 </em>
                                    (17)
                                     , 5662-5671. <a href="https://doi.org/10.1016/j.bmc.2015.07.017" title="DOI URL">https://doi.org/10.1016/j.bmc.2015.07.017</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2015.07.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2015.07.017%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DModification%252Bof%252BN%252B-%2525286-%2525282-methoxy-3-%2525284-fluorophenylsulfonamido%252529pyridin-5-yl%252529-%25255B1%25252C2%25252C4%25255Dtriazolo%25255B1%25252C5-%252Ba%252B%25255Dpyridin-2-yl%252529acetamide%252Bas%252BPI3Ks%252Binhibitor%252Bby%252Breplacement%252Bof%252Bthe%252Bacetamide%252Bgroup%252Bwith%252Balkylurea%26aulast%3DWang%26aufirst%3DXiao-Meng%26date%3D2015%26volume%3D23%26issue%3D17%26spage%3D5662%26epage%3D5671" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Manman  Wei</span>, <span class="hlFld-ContribAuthor ">Xiang  Wang</span>, <span class="hlFld-ContribAuthor ">Zilan  Song</span>, <span class="hlFld-ContribAuthor ">Mingkun  Jiao</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Ling-Hua  Meng</span>, <span class="hlFld-ContribAuthor ">Ao  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting PI3Kδ: Emerging Therapy for Chronic Lymphocytic Leukemia and Beyond. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2015,</strong> <em>35 </em>
                                    (4)
                                     , 720-752. <a href="https://doi.org/10.1002/med.21341" title="DOI URL">https://doi.org/10.1002/med.21341</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21341&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21341%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DTargeting%252BPI3K%2525CE%2525B4%25253A%252BEmerging%252BTherapy%252Bfor%252BChronic%252BLymphocytic%252BLeukemia%252Band%252BBeyond%26aulast%3DWei%26aufirst%3DManman%26date%3D2015%26date%3D2015%26volume%3D35%26issue%3D4%26spage%3D720%26epage%3D752" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div><a href="#" data-source="/pb/widgets/cited-by?doi=10.1021%2Fjm4003632&amp;widgetId=9cf770f4-a9a2-46e0-bd29-3da15bcf4ae0&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Fjm4003632%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2013.56.issue-11%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text&amp;citedByCount=117&amp;pagesCount=2&amp;pageNumber=-1" title="Load all citations" class="button_primary float-right cited-by__see-more mb-5"><i aria-hidden="”true”" class="icon-angle-double-down"></i><span>Load all citations</span></a></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/medium/jm-2013-003632_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/large/jm-2013-003632_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4003632&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/medium/jm-2013-003632_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/large/jm-2013-003632_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (A) Dose curves of tumor volume response of compound <b>2</b> against MCF7-neo/HER2 xenografts in mice relative to vehicle over the course of 21 days (0.5% methycellulose/0.2% Tween-80). (B) Comparison of % tumor growth inhibition of compounds <b>1</b> and <b>2</b> in MCF7-neo/HER2 xenografts at the four doses evaluated.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/large/jm-2013-003632_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4003632&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/medium/jm-2013-003632_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/large/jm-2013-003632_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Scaffold replacements to reduce lipophilic nature of thiazolobenzoxepin <b>B</b> (cLogD values are given for analogues terminated by methyl groups).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/large/jm-2013-003632_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4003632&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/medium/jm-2013-003632_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/large/jm-2013-003632_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthetic Route to the Imidazobenzoxazepin Bromoiodide Core</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/large/jm-2013-003632_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4003632&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/medium/jm-2013-003632_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/large/jm-2013-003632_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Elaboration of Bromoiodide <b>7</b> to PI3K Inhibitors (<b>11a</b>–<b>l</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/large/jm-2013-003632_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4003632&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/medium/jm-2013-003632_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/large/jm-2013-003632_0009.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Dose–response curves of fitted tumor volumes in response to <b>1</b> and <b>11l</b> at the doses shown against MCF7-neo/HER2 xenografts in mice relative to vehicle (MCT; 0.5% methycellulose/0.2% Tween-80) after daily (QD) oral (PO) dosing for 20 days.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/large/jm-2013-003632_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4003632&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/medium/jm-2013-003632_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/large/jm-2013-003632_0010.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Quantification of pAkt<sup>Ser473</sup> levels in MCF7-neo-Her2 tumor xenografts 1 h after a single dose of MCT vehicle (0.5% methycellulose/0.2% Tween-80), compound <b>1</b> at 45 mg/kg, or compound <b>11l</b> at 1.4, 2.8, 5.8, 11.125, or 22.5 mg/kg. Phosphorylated Akt (pAkt<sup>Ser473</sup>) and total Akt (tAkt) levels were measured by Mesoscale Discovery assay, and values are expressed as the ratio of pAkt/tAkt. Error bars represent SEM for tumor xenograft samples from four different animals. Corresponding plasma free-drug concentrations (closed diamonds) for each dose of compound <b>1</b> or compound <b>11l</b> are plotted on the right <i>y</i> axis.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/large/jm-2013-003632_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4003632&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/medium/jm-2013-003632_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/large/jm-2013-003632_0011.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Pie charts of mouse liver microsomal clearance categories according to scaffolds <b>A</b>–<b>E</b>. Numbers above individual pie charts correspond to sample size. Green = stable, <27 mL/(min·kg); orange = moderate, 27–63 mL/(min·kg); and red = high, >63 mL/(min·kg).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/large/jm-2013-003632_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4003632&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/medium/jm-2013-003632_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/large/jm-2013-003632_0012.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. MetaSite predictions for site of CYP-mediated oxidation of the α-methyl group adjacent to the heterocyclic subunit at the center of each scaffold <b>A</b>–<b>E</b>. Red spheres indicate severe magnitude of such oxidation while gray spheres indicate moderate oxidation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/large/jm-2013-003632_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4003632&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch3" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/medium/jm-2013-003632_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/large/jm-2013-003632_0013.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Thiazolobenzoxepin <b>2</b> Was Extensively Converted to the Oxidized Product when Incubated with Human Hepatocytes<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/large/jm-2013-003632_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4003632&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>The corresponding product is minimal when <b>11l</b> is subjected to similar conditions.</p></p></figure><figure data-id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/medium/jm-2013-003632_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/large/jm-2013-003632_0014.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Two-dimensional plot of 10 matched-pair comparisons with unbound clearance (CL<sub>u</sub>) of imidazobenzoxazepins (<b>E</b>) on the <i>y</i> axis and thiazolobenzoxepins (<b>B</b>) on the <i>x</i> axis. The diagonal blue line represents the line of unity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/large/jm-2013-003632_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4003632&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/medium/jm-2013-003632_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/large/jm-2013-003632_0015.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Preclinical candidate profile of PI3K β-sparing inhibitor <b>11l</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm4003632/production/images/large/jm-2013-003632_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4003632&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i57">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_18248" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_18248" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 27 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Vivanco, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span> </span><span class="NLM_article-title">The phosphatidylinositol 3-kinase AKT pathway in human cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">489</span><span class="NLM_x">–</span> <span class="NLM_lpage">501</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm4003632&amp;key=10.1038%2Fnrc839" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm4003632&amp;key=12094235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm4003632&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvFKltLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2002&pages=489-501&author=I.+Vivancoauthor=C.+L.+Sawyers&title=The+phosphatidylinositol+3-kinase+AKT+pathway+in+human+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The phosphatidylinositol 3-Kinase-AKT pathway in human cancer</span></div><div class="casAuthors">Vivanco, Igor; Sawyers, Charles L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">489-501</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  One signal that is overactivated in a wide range of tumor types is the prodn. of a phospholipid, phosphatidylinositol (3,4,5) trisphosphate, by phosphatidylinositol 3-kinase (PI3K).  This lipid and the protein kinase that is activated by it, AKT, trigger a cascade of responses, from cell growth and proliferation to survival and motility, that drive tumor progression.  Small-mol. therapeutics that block PI3K signaling might deal a severe blow to cancer cells by blocking many aspects of the tumor-cell phenotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzAQ-0qeD7pLVg90H21EOLACvtfcHk0lgUpU93mj6NOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvFKltLs%253D&md5=c6762d32f9f1281632f4ccdbcd29268c</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrc839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc839%26sid%3Dliteratum%253Aachs%26aulast%3DVivanco%26aufirst%3DI.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26atitle%3DThe%2520phosphatidylinositol%25203-kinase%2520AKT%2520pathway%2520in%2520human%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2002%26volume%3D2%26spage%3D489%26epage%3D501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Cantley, L. C.</span><span> </span><span class="NLM_article-title">The phosphoinositide 3-kinase pathway</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">296</span><span class="NLM_x">, </span> <span class="NLM_fpage">1655</span><span class="NLM_x">–</span> <span class="NLM_lpage">1657</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm4003632&amp;key=10.1126%2Fscience.296.5573.1655" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm4003632&amp;key=12040186" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm4003632&amp;key=1%3ACAS%3A528%3ADC%252BD38XktlChu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=296&publication_year=2002&pages=1655-1657&author=L.+C.+Cantley&title=The+phosphoinositide+3-kinase+pathway"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The phosphoinositide 3-kinase pathway</span></div><div class="casAuthors">Cantley, Lewis C.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">296</span>
        (<span class="NLM_cas:issue">5573</span>),
    <span class="NLM_cas:pages">1655-1657</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review with 8 refs.  Phosphorylated lipids are produced at cellular membranes during signaling events and contribute to the recruitment and activation of various signaling components.  The role of phosphoinositide 3-kinase (PI3K), which catalyzes the prodn. of phosphatidylinositol 3,4,5-trisphosphate, in cell survival pathways; the regulation of gene expression and cell metab.; and cytoskeletal rearrangements are highlighted.  The PI3K pathway is implicated in human diseases including diabetes and cancer, and understanding the intricacies of this pathway may provide new avenues for therapeutic intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9pxSplxmS1rVg90H21EOLACvtfcHk0lj63Pcxhquvug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XktlChu7s%253D&md5=110c8a351448aed6ab938b9ccf90a655</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1126%2Fscience.296.5573.1655&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.296.5573.1655%26sid%3Dliteratum%253Aachs%26aulast%3DCantley%26aufirst%3DL.%2BC.%26atitle%3DThe%2520phosphoinositide%25203-kinase%2520pathway%26jtitle%3DScience%26date%3D2002%26volume%3D296%26spage%3D1655%26epage%3D1657" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Campbell, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choong, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montgomery, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciavarella, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hooi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cristiano, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillips, W.</span><span> </span><span class="NLM_article-title">Mutation of the PIK3CA gene in ovarian and breast cancer</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">7678</span><span class="NLM_x">–</span> <span class="NLM_lpage">7681</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=7678-7681&author=I.+Campbellauthor=S.+Russellauthor=D.+Choongauthor=K.+Montgomeryauthor=M.+Ciavarellaauthor=C.+Hooiauthor=B.+Cristianoauthor=R.+Pearsonauthor=W.+Phillips&title=Mutation+of+the+PIK3CA+gene+in+ovarian+and+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCampbell%26aufirst%3DI.%26aulast%3DRussell%26aufirst%3DS.%26aulast%3DChoong%26aufirst%3DD.%26aulast%3DMontgomery%26aufirst%3DK.%26aulast%3DCiavarella%26aufirst%3DM.%26aulast%3DHooi%26aufirst%3DC.%26aulast%3DCristiano%26aufirst%3DB.%26aulast%3DPearson%26aufirst%3DR.%26aulast%3DPhillips%26aufirst%3DW.%26atitle%3DMutation%2520of%2520the%2520PIK3CA%2520gene%2520in%2520ovarian%2520and%2520breast%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D7678%26epage%3D7681" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Samuels, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bardelli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silliman, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ptak, J.</span><span> </span><span class="NLM_article-title">High frequency of mutations of the PIK3CA gene in human cancers</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">304</span><span class="NLM_x">, </span> <span class="NLM_fpage">554</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm4003632&amp;key=10.1126%2Fscience.1096502" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm4003632&amp;key=15016963" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm4003632&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjsVGmsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=304&publication_year=2004&pages=554&author=Y.+Samuelsauthor=Z.+Wangauthor=A.+Bardelliauthor=N.+Sillimanauthor=J.+Ptak&title=High+frequency+of+mutations+of+the+PIK3CA+gene+in+human+cancers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Brevia: High frequency of mutations of the PIK3Ca gene in human cancers</span></div><div class="casAuthors">Samuels, Yardena; Wang, Zhenghe; Bardelli, Alberto; Silliman, Natalie; Ptak, Janine; Szabo, Steve; Yan, Hai; Gazdar, Adi; Powell, Steven M.; Riggins, Gregory J.; Willson, James K. V.; Markowitz, Sanford; Kinzler, Kenneth W.; Vogelstein, Bert; Velculescu, Victor E.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">304</span>
        (<span class="NLM_cas:issue">5670</span>),
    <span class="NLM_cas:pages">554</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr74Tv7Oo80NbVg90H21EOLACvtfcHk0lj63Pcxhquvug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjsVGmsbk%253D&md5=be8d63bf0c909971c3b7a5f475ce8fab</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1126%2Fscience.1096502&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1096502%26sid%3Dliteratum%253Aachs%26aulast%3DSamuels%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DBardelli%26aufirst%3DA.%26aulast%3DSilliman%26aufirst%3DN.%26aulast%3DPtak%26aufirst%3DJ.%26atitle%3DHigh%2520frequency%2520of%2520mutations%2520of%2520the%2520PIK3CA%2520gene%2520in%2520human%2520cancers%26jtitle%3DScience%26date%3D2004%26volume%3D304%26spage%3D554" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Bertelsen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steine, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandvei, R.</span><span> </span><span class="NLM_article-title">Molecular analysis of the PI3K-AKT pathway in uterine cervical neoplasia: Frequent PIK3CA amplification and AKT phosphorylation</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">118</span><span class="NLM_x">, </span> <span class="NLM_fpage">1877</span><span class="NLM_x">–</span> <span class="NLM_lpage">1883</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm4003632&amp;key=10.1002%2Fijc.21461" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm4003632&amp;key=16287065" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm4003632&amp;key=1%3ACAS%3A528%3ADC%252BD28Xjt1GqtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2006&pages=1877-1883&author=B.+Bertelsenauthor=S.+Steineauthor=R.+Sandvei&title=Molecular+analysis+of+the+PI3K-AKT+pathway+in+uterine+cervical+neoplasia%3A+Frequent+PIK3CA+amplification+and+AKT+phosphorylation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular analysis of the PI3K-Akt pathway in uterine cervical neoplasia: frequent PIK3CA amplification and AKT phosphorylation</span></div><div class="casAuthors">Bertelsen, Bjoern I.; Steine, Solrun J.; Sandvei, Roar; Molven, Anders; Laerum, Ole Didrik</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1877-1883</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Uterine cervical carcinogenesis is probably dependent on cellular genetic damage in addn. to the integration of high-risk HPV DNA in the epithelial cell genome.  Gain of chromosome 3q24-29 is commonly obsd. in cervical neoplasia.  The putative oncogene PIK3CA located in this region encodes a phosphatidylinositol 3-kinase (PI3K).  In a process reversed by PTEN, PI3K generates inositol phospholipids that trigger AKT phosphorylation, which in turn effects tumor driving signals.  We studied 46 specimens of formalin-fixed, paraffin-embedded cervical neoplastic tissue.  The activation state of the PI3K-AKT pathway was assessed immunohistochem. using an antibody with specificity towards serine 473-phosphorylated AKT.  AKT phosphorylation was found in 39 out of 46 examd. specimens.  To examine the possible mol. basis for this activation, we searched for PIK3CA amplification using quant. real-time polymerase chain reaction.  PIK3CA gene copy no. was estd. to be 3 or more in 28 out of 40 successfully examd. cases.  Further, a PTEN mutation anal. of all 9 PTEN exons was carried out, but except for 1 metastasis with an exon 9 V369I heterozygosity, all cases showed normal PTEN sequence.  Immunohistochem. staining for PTEN was strong in all lesions.  In conclusion, an increased activation state of AKT kinase appears to be present in cervical carcinogenesis, and may be accounted for by PIK3CA amplification, whereas PTEN mutation seems to be of little importance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBmRc-5_sOKrVg90H21EOLACvtfcHk0lj63Pcxhquvug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xjt1GqtLc%253D&md5=46f86af8802689b286d855263900dd75</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1002%2Fijc.21461&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.21461%26sid%3Dliteratum%253Aachs%26aulast%3DBertelsen%26aufirst%3DB.%26aulast%3DSteine%26aufirst%3DS.%26aulast%3DSandvei%26aufirst%3DR.%26atitle%3DMolecular%2520analysis%2520of%2520the%2520PI3K-AKT%2520pathway%2520in%2520uterine%2520cervical%2520neoplasia%253A%2520Frequent%2520PIK3CA%2520amplification%2520and%2520AKT%2520phosphorylation%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2006%26volume%3D118%26spage%3D1877%26epage%3D1883" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Byun, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chae, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chi, S.</span><span> </span><span class="NLM_article-title">Frequent monoallelic deletion of PTEN and its reciprocal associatioin with PIK3CA amplification in gastric carcinoma</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">318</span><span class="NLM_x">–</span> <span class="NLM_lpage">327</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm4003632&amp;key=10.1002%2Fijc.10962" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm4003632&amp;key=12569555" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm4003632&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhvFyks7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2003&pages=318-327&author=D.+Byunauthor=K.+Choauthor=B.+Ryuauthor=M.+Leeauthor=J.+Parkauthor=K.+Chaeauthor=H.+Kimauthor=S.+Chi&title=Frequent+monoallelic+deletion+of+PTEN+and+its+reciprocal+associatioin+with+PIK3CA+amplification+in+gastric+carcinoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Frequent monoallelic deletion of PTEN and its reciprocal association with PIK3CA amplification in gastric carcinoma</span></div><div class="casAuthors">Byun, Do-Sun; Cho, Kyucheol; Ryu, Byung-Kyu; Lee, Min-Goo; Park, Jae-Il; Chae, Kwon-Seok; Kim, Hyo-Jong; Chi, Sung-Gil</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">318-327</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Mutational alterations of PTEN and PIK3CA, which neg. and pos. regulate PI3-kinase activity, resp., have been obsd. in many types of human cancer.  To explore the implication of PTEN and PIK3CA mutations in gastric tumorigenesis, the authors characterized the expression and mutation status of the genes in 126 gastric tissues and 15 cell lines.  Expression of PTEN transcript was abnormally low in 5 of 15 (33%) cell lines and 20 of 55 (36%) primary carcinomas, whereas 0 of 71 noncancerous tissues including 16 benign tumors showed altered expression.  Allelotyping anal. using an intragenic polymorphism (IVS4+109) revealed that 14 of 30 (47%) informative cases carried LOH of the gene, which is closely linked to low expression.  The LOH rate was significantly higher in advanced tumors [12 of 19 (63%)] compared to early-stage tumors [2 of 11 (18%)] and more frequent in poorly differentiated tumors [9 of 13 (69%)] than well- or moderately differentiated tumors [5 of 17 (29%)].  Interestingly, however, none of the LOH tumors carried mutational disruption of the remaining allele, suggesting haploinsufficiency of PTEN in gastric tumorigenesis.  Methylation studies revealed that PTEN pseudogene, but not PTEN, is methylated in cell lines and primary tumors, indicating that PTEN is not a target of epigenetic silencing in gastric cancers and that the pseudogene should be considered more carefully in methylation anal. of the PTEN promoter.  Genomic amplification of PIK3CA was found in 9 of 15 (60%) cell lines and 20 of 55 (36.4%) primary tumors but in no noncancerous tissues.  Furthermore, PIK3CA amplification was predominantly detected in tumors with no PTEN alterations, suggesting that mutations of PTEN and PIK3CA are mutually exclusive events in gastric tumorigenesis.  Amplification of PIK3CA was strongly assocd. with increased expression of PIK3CA transcript and elevated levels of phospho-AKT.  Collectively, the authors' data reveal that 13 of 15 (87%) gastric cell lines and 31 of 55 (56%) primary carcinomas harbored either amplification of PIK3CA or abnormal redn. of PTEN.  Mutually exclusive alterations of PTEN and PIK3CA also suggest that mutations of either gene could activate the PI3-kinase/AKT signaling pathway, which is directly linked to the malignant progression of gastric tumor cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyKb4wS-yOdLVg90H21EOLACvtfcHk0ljPnuZ4eHgYcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhvFyks7o%253D&md5=be43e261f0a80601696350b5728b047a</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1002%2Fijc.10962&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.10962%26sid%3Dliteratum%253Aachs%26aulast%3DByun%26aufirst%3DD.%26aulast%3DCho%26aufirst%3DK.%26aulast%3DRyu%26aufirst%3DB.%26aulast%3DLee%26aufirst%3DM.%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DChae%26aufirst%3DK.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DChi%26aufirst%3DS.%26atitle%3DFrequent%2520monoallelic%2520deletion%2520of%2520PTEN%2520and%2520its%2520reciprocal%2520associatioin%2520with%2520PIK3CA%2520amplification%2520in%2520gastric%2520carcinoma%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2003%26volume%3D104%26spage%3D318%26epage%3D327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Shuttleworth, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silva, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cecil, A. R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomassi, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Workman, P.</span><span> </span><span class="NLM_article-title">Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">2686</span><span class="NLM_x">–</span> <span class="NLM_lpage">2714</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm4003632&amp;key=10.2174%2F092986711796011229" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm4003632&amp;key=21649578" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm4003632&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1Cit73M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=2686-2714&author=S.+J.+Shuttleworthauthor=F.+A.+Silvaauthor=A.+R.+L.+Cecilauthor=C.+D.+Tomassiauthor=T.+J.+Hillauthor=F.+I.+Raynaudauthor=P.+A.+Clarkeauthor=P.+Workman&title=Progress+in+the+preclinical+discovery+and+clinical+development+of+class+I+and+dual+class+I%2FIV+phosphoinositide+3-kinase+%28PI3K%29+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors</span></div><div class="casAuthors">Shuttleworth, S. J.; Silva, F. A.; Cecil, A. R. L.; Tomassi, C. D.; Hill, T. J.; Raynaud, F. I.; Clarke, P. A.; Workman, P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2686-2714</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The phosphoinositide 3-kinases (PI3Ks) constitute an important family of lipid kinase enzymes that control a range of cellular processes through their regulation of a network of signal transduction pathways, and have emerged as important therapeutic targets in the context of cancer, inflammation and cardiovascular diseases.  Since the mid-late 1990s, considerable progress was made in the discovery and development of small mol. ATP-competitive PI3K inhibitors, a no. of which have entered early phase human trials over recent years from which key clin. results are now being disclosed.  This review summarizes progress made to date, primarily on the discovery and characterization of class I and dual class I/IV subtype inhibitors, together with advances that were made in translational and clin. research, notably in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpibTyG_ua2WLVg90H21EOLACvtfcHk0ljPnuZ4eHgYcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1Cit73M&md5=baf93d773ce18eb70ebc5549c14f422c</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.2174%2F092986711796011229&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986711796011229%26sid%3Dliteratum%253Aachs%26aulast%3DShuttleworth%26aufirst%3DS.%2BJ.%26aulast%3DSilva%26aufirst%3DF.%2BA.%26aulast%3DCecil%26aufirst%3DA.%2BR.%2BL.%26aulast%3DTomassi%26aufirst%3DC.%2BD.%26aulast%3DHill%26aufirst%3DT.%2BJ.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DClarke%26aufirst%3DP.%2BA.%26aulast%3DWorkman%26aufirst%3DP.%26atitle%3DProgress%2520in%2520the%2520preclinical%2520discovery%2520and%2520clinical%2520development%2520of%2520class%2520I%2520and%2520dual%2520class%2520I%252FIV%2520phosphoinositide%25203-kinase%2520%2528PI3K%2529%2520inhibitors%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2011%26volume%3D18%26spage%3D2686%26epage%3D2714" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Jarvis, L. M.</span><span> </span><span class="NLM_article-title">PI3K at the clinical crossroads</span> <span class="citation_source-journal">Chem. Eng. News</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">89</span><span class="NLM_x">, </span> <span class="NLM_fpage">15</span><span class="NLM_x">–</span> <span class="NLM_lpage">19</span></span><div class="citationLinks">[<a href="/doi/10.1021/cen-v089n015.p015" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2011&pages=15-19&author=L.+M.+Jarvis&title=PI3K+at+the+clinical+crossroads"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Fcen-v089n015.p015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcen-v089n015.p015%26sid%3Dliteratum%253Aachs%26aulast%3DJarvis%26aufirst%3DL.%2BM.%26atitle%3DPI3K%2520at%2520the%2520clinical%2520crossroads%26jtitle%3DChem.%2520Eng.%2520News%26date%3D2011%26volume%3D89%26spage%3D15%26epage%3D19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Staben, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldsmith, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivero, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Do, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burdick, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heffron, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dotson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutherlin, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, B.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsui, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesnick, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nonomiya, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prior, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salphati, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rouge, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sampath, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sideris, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiesmann, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, P.</span><span> </span><span class="NLM_article-title">Structure-based design of thienobenzoxepin inhibitors of PI3-kinase</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">4054</span><span class="NLM_x">–</span> <span class="NLM_lpage">4058</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm4003632&amp;key=10.1016%2Fj.bmcl.2011.04.124" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm4003632&amp;key=21636270" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm4003632&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnsVCisLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=4054-4058&author=S.+T.+Stabenauthor=M.+Siuauthor=R.+Goldsmithauthor=A.+G.+Oliveroauthor=S.+Doauthor=D.+J.+Burdickauthor=T.+P.+Heffronauthor=J.+Dotsonauthor=D.+P.+Sutherlinauthor=B.-Y.+Zhuauthor=V.+Tsuiauthor=H.+Leauthor=L.+Leeauthor=J.+Lesnickauthor=C.+Lewisauthor=J.+M.+Murrayauthor=J.+Nonomiyaauthor=J.+Pangauthor=W.+W.+Priorauthor=L.+Salphatiauthor=L.+Rougeauthor=D.+Sampathauthor=S.+Siderisauthor=C.+Wiesmannauthor=P.+Wu&title=Structure-based+design+of+thienobenzoxepin+inhibitors+of+PI3-kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based design of thienobenzoxepin inhibitors of PI3-kinase</span></div><div class="casAuthors">Staben, Steven T.; Siu, Michael; Goldsmith, Richard; Olivero, Alan G.; Do, Steven; Burdick, Daniel J.; Heffron, Timothy P.; Dotson, Jenna; Sutherlin, Daniel P.; Zhu, Bing-Yan; Tsui, Vickie; Le, Hoa; Lee, Leslie; Lesnick, John; Lewis, Cristina; Murray, Jeremy M.; Nonomiya, Jim; Pang, Jodie; Prior, Wei Wei; Salphati, Laurent; Rouge, Lionel; Sampath, Deepak; Sideris, Steve; Wiesmann, Christian; Wu, Ping</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4054-4058</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Starting from thienobenzopyran HTS hit 1 (I), co-crystn., mol. modeling and metabolic anal. were used to design potent and metabolically stable inhibitors of PI3-kinase.  Compd. 15 demonstrated PI3K pathway suppression in a mouse MCF7 xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrK5PrbzVKCkbVg90H21EOLACvtfcHk0lgB0Hewi9pjzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnsVCisLs%253D&md5=9b807be1ac4093a6f139c0304757037a</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.04.124&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.04.124%26sid%3Dliteratum%253Aachs%26aulast%3DStaben%26aufirst%3DS.%2BT.%26aulast%3DSiu%26aufirst%3DM.%26aulast%3DGoldsmith%26aufirst%3DR.%26aulast%3DOlivero%26aufirst%3DA.%2BG.%26aulast%3DDo%26aufirst%3DS.%26aulast%3DBurdick%26aufirst%3DD.%2BJ.%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26aulast%3DDotson%26aufirst%3DJ.%26aulast%3DSutherlin%26aufirst%3DD.%2BP.%26aulast%3DZhu%26aufirst%3DB.-Y.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DLe%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DL.%26aulast%3DLesnick%26aufirst%3DJ.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DMurray%26aufirst%3DJ.%2BM.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DPrior%26aufirst%3DW.%2BW.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DRouge%26aufirst%3DL.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DP.%26atitle%3DStructure-based%2520design%2520of%2520thienobenzoxepin%2520inhibitors%2520of%2520PI3-kinase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D4054%26epage%3D4058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Heffron, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivero, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staben, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsui, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Do, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dotson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Folkes, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldsmith, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldsmith, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunzner, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesnick, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathieu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nonomiya, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shuttleworth, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutherlin, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiesmann, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, B.-Y.</span><span> </span><span class="NLM_article-title">Rational design of phosphoinositide 3-kinase α inhibitors that exhibit selectivity over the phosphoinositide 3-kinase β isoform</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">7815</span><span class="NLM_x">–</span> <span class="NLM_lpage">7833</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm2007084" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm4003632&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlGktrvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7815-7833&author=T.+P.+Heffronauthor=B.+Weiauthor=A.+Oliveroauthor=S.+T.+Stabenauthor=V.+Tsuiauthor=S.+Doauthor=J.+Dotsonauthor=A.+J.+Folkesauthor=P.+Goldsmithauthor=R.+Goldsmithauthor=J.+Gunznerauthor=J.+Lesnickauthor=C.+Lewisauthor=S.+Mathieuauthor=J.+Nonomiyaauthor=S.+Shuttleworthauthor=D.+P.+Sutherlinauthor=N.+C.+Wanauthor=S.+Wangauthor=C.+Wiesmannauthor=B.-Y.+Zhu&title=Rational+design+of+phosphoinositide+3-kinase+%CE%B1+inhibitors+that+exhibit+selectivity+over+the+phosphoinositide+3-kinase+%CE%B2+isoform"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Design of Phosphoinositide 3-Kinase α Inhibitors That Exhibit Selectivity over the Phosphoinositide 3-Kinase β Isoform</span></div><div class="casAuthors">Heffron, Timothy P.; Wei, Bin Qing; Olivero, Alan; Staben, Steven T.; Tsui, Vickie; Do, Steven; Dotson, Jennafer; Folkes, Adrian J.; Goldsmith, Paul; Goldsmith, Richard; Gunzner, Janet; Lesnick, John; Lewis, Cristina; Mathieu, Simon; Nonomiya, Jim; Shuttleworth, Stephen; Sutherlin, Daniel P.; Wan, Nan Chi; Wang, Shumei; Wiesmann, Christian; Zhu, Bing-Yan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">7815-7833</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Of the four class I phosphoinositide 3-kinase (PI3K) isoforms, PI3Kα has justly received the most attention for its potential in cancer therapy.  Herein we report our successful approaches to achieve PI3Kα vs PI3Kβ selectivity for two chem. series.  In the thienopyrimidine series of inhibitors, we propose that select ligands achieve selectivity derived from a hydrogen bonding interaction with Arg770 of PI3Kα that is not attained with the corresponding Lys777 of PI3Kβ.  In the benzoxepin series of inhibitors, the selectivity obsd. can be rationalized by the difference in electrostatic potential between the two isoforms in a given region rather than any specific interaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquHPawgTpp87Vg90H21EOLACvtfcHk0lgB0Hewi9pjzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlGktrvE&md5=4ebed9c985c52238eddc45c6183cf3de</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Fjm2007084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2007084%26sid%3Dliteratum%253Aachs%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DOlivero%26aufirst%3DA.%26aulast%3DStaben%26aufirst%3DS.%2BT.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DDo%26aufirst%3DS.%26aulast%3DDotson%26aufirst%3DJ.%26aulast%3DFolkes%26aufirst%3DA.%2BJ.%26aulast%3DGoldsmith%26aufirst%3DP.%26aulast%3DGoldsmith%26aufirst%3DR.%26aulast%3DGunzner%26aufirst%3DJ.%26aulast%3DLesnick%26aufirst%3DJ.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DMathieu%26aufirst%3DS.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DShuttleworth%26aufirst%3DS.%26aulast%3DSutherlin%26aufirst%3DD.%2BP.%26aulast%3DWan%26aufirst%3DN.%2BC.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DZhu%26aufirst%3DB.-Y.%26atitle%3DRational%2520design%2520of%2520phosphoinositide%25203-kinase%2520%25CE%25B1%2520inhibitors%2520that%2520exhibit%2520selectivity%2520over%2520the%2520phosphoinositide%25203-kinase%2520%25CE%25B2%2520isoform%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7815%26epage%3D7833" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Staben, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blaquiere, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradley, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolesnikov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Do, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heffron, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesnick, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nonomiya, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivero, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salphati, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, P.</span><span> </span><span class="NLM_article-title">Cis-amide isosteric replacement in thienobenzoxepin inhibitors of PI3-kinase</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">897</span><span class="NLM_x">–</span> <span class="NLM_lpage">901</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=897-901&author=S.+T.+Stabenauthor=N.+Blaquiereauthor=E.+Bradleyauthor=A.+Kolesnikovauthor=S.+Doauthor=T.+P.+Heffronauthor=J.+Lesnickauthor=J.+Murrayauthor=J.+Nonomiyaauthor=A.+G.+Oliveroauthor=J.+Pangauthor=L.+Salphatiauthor=B.+Weiauthor=P.+Wu&title=Cis-amide+isosteric+replacement+in+thienobenzoxepin+inhibitors+of+PI3-kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStaben%26aufirst%3DS.%2BT.%26aulast%3DBlaquiere%26aufirst%3DN.%26aulast%3DBradley%26aufirst%3DE.%26aulast%3DKolesnikov%26aufirst%3DA.%26aulast%3DDo%26aufirst%3DS.%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26aulast%3DLesnick%26aufirst%3DJ.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DOlivero%26aufirst%3DA.%2BG.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DWu%26aufirst%3DP.%26atitle%3DCis-amide%2520isosteric%2520replacement%2520in%2520thienobenzoxepin%2520inhibitors%2520of%2520PI3-kinase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D897%26epage%3D901" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Staben, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ndubaku, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blaquiere, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belvin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bull, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dudley, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edgar, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heald, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heffron, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolesnikov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesnick, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLean, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nonomiya, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivero, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ord, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prior, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rouge, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salphati, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sampath, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiesmann, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, P.</span><span> </span><span class="NLM_article-title">Discovery of thiazolobenzoxepin PI3-kinase inhibitors that spare the PI3-kinase β isoform</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">2606</span><span class="NLM_x">–</span> <span class="NLM_lpage">2613</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm4003632&amp;key=10.1016%2Fj.bmcl.2013.02.102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm4003632&amp;key=23540645" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm4003632&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltVenu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=2606-2613&author=S.+T.+Stabenauthor=C.+Ndubakuauthor=N.+Blaquiereauthor=M.+Belvinauthor=R.+J.+Bullauthor=D.+Dudleyauthor=K.+Edgarauthor=D.+Grayauthor=R.+Healdauthor=T.+P.+Heffronauthor=G.+E.+Jonesauthor=M.+Jonesauthor=A.+Kolesnikovauthor=L.+Leeauthor=J.+Lesnickauthor=C.+Lewisauthor=J.+Murrayauthor=N.+J.+McLeanauthor=J.+Nonomiyaauthor=A.+G.+Oliveroauthor=R.+Ordauthor=J.+Pangauthor=S.+Priceauthor=W.+W.+Priorauthor=L.+Rougeauthor=L.+Salphatiauthor=D.+Sampathauthor=J.+Wallinauthor=L.+Wangauthor=B.+Weiauthor=C.+Wiesmannauthor=P.+Wu&title=Discovery+of+thiazolobenzoxepin+PI3-kinase+inhibitors+that+spare+the+PI3-kinase+%CE%B2+isoform"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of thiazolobenzoxepin PI3-kinase inhibitors that spare the PI3-kinase β isoform</span></div><div class="casAuthors">Staben, Steven T.; Ndubaku, Chudi; Blaquiere, Nicole; Belvin, Marcia; Bull, Richard J.; Dudley, Danette; Edgar, Kyle; Gray, Daniel; Heald, Robert; Heffron, Timothy P.; Jones, Graham E.; Jones, Mark; Kolesnikov, Aleks; Lee, Leslie; Lesnick, John; Lewis, Cristina; Murray, Jeremy; McLean, Neville J.; Nonomiya, Jim; Olivero, Alan G.; Ord, Rachel; Pang, Jodie; Price, Stephen; Prior, Wei Wei; Rouge, Lionel; Salphati, Laurent; Sampath, Deepak; Wallin, Jeff; Wang, Lan; Wei, BinQing; Weismann, Christian; Wu, Ping</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2606-2613</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of suitable five-membered heterocyclic alternatives to thiophenes within a thienobenzoxepin class of PI3-kinase (PI3K) inhibitors was discovered.  Specific thiazolobenzoxepin 8-substitution was identified that increased selectivity over PI3Kβ.  PI3Kβ-sparing compd. (I) (PI3Kβ Ki,app/PI3Kα Ki,app = 57) demonstrated dose-dependent knockdown of pAKT, pPRAS40 and pS6RP in vivo as well as differential effects in an in vitro proliferation cell line screen compared to pan PI3K inhibitor GDC-0941.  A new structure-based hypothesis for reducing inhibition of the PI3K β isoform while maintaining activity against α, δ and γ isoforms is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtWjysPIycnbVg90H21EOLACvtfcHk0lgtPrJSVPgU7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltVenu7c%253D&md5=348731ff5afa1e679a901eb228cfe71f</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.02.102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.02.102%26sid%3Dliteratum%253Aachs%26aulast%3DStaben%26aufirst%3DS.%2BT.%26aulast%3DNdubaku%26aufirst%3DC.%26aulast%3DBlaquiere%26aufirst%3DN.%26aulast%3DBelvin%26aufirst%3DM.%26aulast%3DBull%26aufirst%3DR.%2BJ.%26aulast%3DDudley%26aufirst%3DD.%26aulast%3DEdgar%26aufirst%3DK.%26aulast%3DGray%26aufirst%3DD.%26aulast%3DHeald%26aufirst%3DR.%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26aulast%3DJones%26aufirst%3DG.%2BE.%26aulast%3DJones%26aufirst%3DM.%26aulast%3DKolesnikov%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DL.%26aulast%3DLesnick%26aufirst%3DJ.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DMcLean%26aufirst%3DN.%2BJ.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DOlivero%26aufirst%3DA.%2BG.%26aulast%3DOrd%26aufirst%3DR.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DPrice%26aufirst%3DS.%26aulast%3DPrior%26aufirst%3DW.%2BW.%26aulast%3DRouge%26aufirst%3DL.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DWallin%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DP.%26atitle%3DDiscovery%2520of%2520thiazolobenzoxepin%2520PI3-kinase%2520inhibitors%2520that%2520spare%2520the%2520PI3-kinase%2520%25CE%25B2%2520isoform%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D2606%26epage%3D2613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Folkes, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmadi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alderton, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alix, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Box, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chuckowree, I. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Depledge, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eccles, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hancox, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kugendradas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lensun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivero, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pergl-Wilson, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saghir, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salphati, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sohal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ultsch, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valenti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallweber, H. J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiesmann, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Workman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhyvoloup, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zvelebil, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shuttleworth, S. J.</span><span> </span><span class="NLM_article-title">The Identification of 2-(1<i>H</i>-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-<i>d</i>]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">5522</span><span class="NLM_x">–</span> <span class="NLM_lpage">5532</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm800295d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm4003632&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVCmsr7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5522-5532&author=A.+J.+Folkesauthor=K.+Ahmadiauthor=W.+K.+Aldertonauthor=S.+Alixauthor=S.+J.+Bakerauthor=G.+Boxauthor=I.+S.+Chuckowreeauthor=P.+A.+Clarkeauthor=P.+Depledgeauthor=S.+A.+Ecclesauthor=L.+S.+Friedmanauthor=A.+Hayesauthor=T.+C.+Hancoxauthor=A.+Kugendradasauthor=L.+Lensunauthor=P.+Mooreauthor=A.+G.+Oliveroauthor=J.+Pangauthor=S.+Patelauthor=G.+H.+Pergl-Wilsonauthor=F.+I.+Raynaudauthor=A.+Robsonauthor=N.+Saghirauthor=L.+Salphatiauthor=S.+Sohalauthor=M.+H.+Ultschauthor=M.+Valentiauthor=H.+J.+A.+Wallweberauthor=N.+C.+Wanauthor=C.+Wiesmannauthor=P.+Workmanauthor=A.+Zhyvoloupauthor=M.+J.+Zvelebilauthor=S.+J.+Shuttleworth&title=The+Identification+of+2-%281H-Indazol-4-yl%29-6-%284-methanesulfonyl-piperazin-1-ylmethyl%29-4-morpholin-4-yl-thieno%5B3%2C2-d%5Dpyrimidine+%28GDC-0941%29+as+a+potent%2C+selective%2C+orally+bioavailable+inhibitor+of+class+I+PI3+kinase+for+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer</span></div><div class="casAuthors">Folkes, Adrian J.; Ahmadi, Khatereh; Alderton, Wendy K.; Alix, Sonia; Baker, Stewart J.; Box, Gary; Chuckowree, Irina S.; Clarke, Paul A.; Depledge, Paul; Eccles, Suzanne A.; Friedman, Lori S.; Hayes, Angela; Hancox, Timothy C.; Kugendradas, Arumugam; Lensun, Letitia; Moore, Pauline; Olivero, Alan G.; Pang, Jodie; Patel, Sonal; Pergl-Wilson, Giles H.; Raynaud, Florence I.; Robson, Anthony; Saghir, Nahid; Salphati, Laurent; Sohal, Sukhjit; Ultsch, Mark H.; Valenti, Melanie; Wallweber, Heidi J. A.; Wan, Nan Chi; Wiesmann, Christian; Workman, Paul; Zhyvoloup, Alexander; Zvelebil, Marketa J.; Shuttleworth, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5522-5532</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Phosphatidylinositol-3-kinase (PI3K) is an important target in cancer due to the deregulation of the PI3K/Akt signaling pathway in a wide variety of tumors.  A series of thieno[3,2-d]pyrimidine derivs. were prepd. and evaluated as inhibitors of PI3 kinase p110α.  The synthesis, biol. activity, and further profiling of these compds. are described.  This work resulted in the discovery of GDC-0941 (I) which is a potent, selective, orally bioavailable inhibitor of PI3K and is currently being evaluated in human clin. trials for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojkFv29FXqO7Vg90H21EOLACvtfcHk0litRTSNsb8qZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVCmsr7E&md5=742084954685353ceaf18660ab3a0703</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fjm800295d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800295d%26sid%3Dliteratum%253Aachs%26aulast%3DFolkes%26aufirst%3DA.%2BJ.%26aulast%3DAhmadi%26aufirst%3DK.%26aulast%3DAlderton%26aufirst%3DW.%2BK.%26aulast%3DAlix%26aufirst%3DS.%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26aulast%3DBox%26aufirst%3DG.%26aulast%3DChuckowree%26aufirst%3DI.%2BS.%26aulast%3DClarke%26aufirst%3DP.%2BA.%26aulast%3DDepledge%26aufirst%3DP.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DHancox%26aufirst%3DT.%2BC.%26aulast%3DKugendradas%26aufirst%3DA.%26aulast%3DLensun%26aufirst%3DL.%26aulast%3DMoore%26aufirst%3DP.%26aulast%3DOlivero%26aufirst%3DA.%2BG.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DPergl-Wilson%26aufirst%3DG.%2BH.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DRobson%26aufirst%3DA.%26aulast%3DSaghir%26aufirst%3DN.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DSohal%26aufirst%3DS.%26aulast%3DUltsch%26aufirst%3DM.%2BH.%26aulast%3DValenti%26aufirst%3DM.%26aulast%3DWallweber%26aufirst%3DH.%2BJ.%2BA.%26aulast%3DWan%26aufirst%3DN.%2BC.%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DZhyvoloup%26aufirst%3DA.%26aulast%3DZvelebil%26aufirst%3DM.%2BJ.%26aulast%3DShuttleworth%26aufirst%3DS.%2BJ.%26atitle%3DThe%2520Identification%2520of%25202-%25281H-Indazol-4-yl%2529-6-%25284-methanesulfonyl-piperazin-1-ylmethyl%2529-4-morpholin-4-yl-thieno%255B3%252C2-d%255Dpyrimidine%2520%2528GDC-0941%2529%2520as%2520a%2520potent%252C%2520selective%252C%2520orally%2520bioavailable%2520inhibitor%2520of%2520class%2520I%2520PI3%2520kinase%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D5522%26epage%3D5532" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Smith, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerns, E. H.</span><span> </span><span class="NLM_article-title">The effect of plasma protein binding on in vivo efficacy: Misconceptions in drug discovery</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">929</span><span class="NLM_x">–</span> <span class="NLM_lpage">939</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm4003632&amp;key=10.1038%2Fnrd3287" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm4003632&amp;key=21119731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm4003632&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsV2jurfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=929-939&author=D.+A.+Smithauthor=L.+Diauthor=E.+H.+Kerns&title=The+effect+of+plasma+protein+binding+on+in+vivo+efficacy%3A+Misconceptions+in+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery</span></div><div class="casAuthors">Smith, Dennis A.; Di, Li; Kerns, Edward H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">929-939</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Data from in vitro plasma protein binding expts. that det. the fraction of protein-bound drug are frequently used in drug discovery to guide structure design and to prioritize compds. for in vivo studies.  However, we consider that these practices are usually misleading, because in vivo efficacy is detd. by the free (unbound) drug concn. surrounding the therapeutic target, not by the free drug fraction.  These practices yield no enhancement of the in vivo free drug concn.  So, decisions based on free drug fraction could result in the wrong compds. being advanced through drug discovery programs.  This Perspective provides guidance on the application of plasma protein binding information in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOa3ippodhGbVg90H21EOLACvtfcHk0lhdNR57RvKg0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsV2jurfI&md5=a45d00f68ab44580fa38a6acef49493a</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fnrd3287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3287%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DDi%26aufirst%3DL.%26aulast%3DKerns%26aufirst%3DE.%2BH.%26atitle%3DThe%2520effect%2520of%2520plasma%2520protein%2520binding%2520on%2520in%2520vivo%2520efficacy%253A%2520Misconceptions%2520in%2520drug%2520discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2010%26volume%3D9%26spage%3D929%26epage%3D939" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Sutherlin, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berry, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castanedo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chuckowree, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dotson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Folks, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldsmith, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunzner, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heffron, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesnick, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathieu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nonomiya, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pegg, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prior, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rouge, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salphati, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sampath, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsui, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiesmann, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, B.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivero, A.</span><span> </span><span class="NLM_article-title">Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">7579</span><span class="NLM_x">–</span> <span class="NLM_lpage">7587</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm2009327" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm4003632&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1Ort7%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7579-7587&author=D.+P.+Sutherlinauthor=L.+Baoauthor=M.+Berryauthor=G.+Castanedoauthor=I.+Chuckowreeauthor=J.+Dotsonauthor=A.+Folksauthor=L.+Friedmanauthor=R.+Goldsmithauthor=J.+Gunznerauthor=T.+Heffronauthor=J.+Lesnickauthor=C.+Lewisauthor=S.+Mathieuauthor=J.+Murrayauthor=J.+Nonomiyaauthor=J.+Pangauthor=N.+Peggauthor=W.+W.+Priorauthor=L.+Rougeauthor=L.+Salphatiauthor=D.+Sampathauthor=Q.+Tianauthor=V.+Tsuiauthor=N.+C.+Wanauthor=S.+Wangauthor=B.+Weiauthor=C.+Wiesmannauthor=P.+Wuauthor=B.-Y.+Zhuauthor=A.+Olivero&title=Discovery+of+a+potent%2C+selective%2C+and+orally+available+class+I+phosphatidylinositol+3-kinase+%28PI3K%29%2Fmammalian+target+of+rapamycin+%28mTOR%29+kinase+inhibitor+%28GDC-0980%29+for+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent, Selective, and Orally Available Class I Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor (GDC-0980) for the Treatment of Cancer</span></div><div class="casAuthors">Sutherlin, Daniel P.; Bao, Linda; Berry, Megan; Castanedo, Georgette; Chuckowree, Irina; Dotson, Jenna; Folks, Adrian; Friedman, Lori; Goldsmith, Richard; Gunzner, Janet; Heffron, Timothy; Lesnick, John; Lewis, Cristina; Mathieu, Simon; Murray, Jeremy; Nonomiya, Jim; Pang, Jodie; Pegg, Niel; Prior, Wei Wei; Rouge, Lionel; Salphati, Laurent; Sampath, Deepak; Tian, Qingping; Tsui, Vickie; Wan, Nan Chi; Wang, Shumei; Wei, Bin Qing; Wiesmann, Christian; Wu, Ping; Zhu, Bing-Yan; Olivero, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">7579-7587</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of 2 (GDC-0980, I), a class I PI3K and mTOR kinase inhibitor for oncol. indications, is described. mTOR inhibition was added to the class I PI3K inhibitor 1 (GDC-0941) scaffold primarily through the substitution of the indazole in 1 for a 2-aminopyrimidine.  This substitution also increased the microsomal stability and the free fraction of compds. as evidenced through a pairwise comparison of mols. that were otherwise identical.  Highlighted in detail are analogs of an advanced compd. 4 that were designed to improve soly., resulting in 2.  This compd., is potent across PI3K class I isoforms with IC50s of 5, 27, 7, and 14 nM for PI3Kα, β, δ, and γ, resp., inhibits mTOR with a Ki of 17 nM yet is highly selective vs. a large panel of kinases including others in the PIKK family.  On the basis of the cell potency, low clearance in mouse, and high free fraction, 2 demonstrated significant efficacy in mouse xenografts when dosed as low as 1 mg/kg orally and is currently in phase I clin. trials for cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-3-5KDI509bVg90H21EOLACvtfcHk0lh8KP1ixcCU2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1Ort7%252FJ&md5=ba7ede710885b51fffa63977fc64d3f5</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm2009327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2009327%26sid%3Dliteratum%253Aachs%26aulast%3DSutherlin%26aufirst%3DD.%2BP.%26aulast%3DBao%26aufirst%3DL.%26aulast%3DBerry%26aufirst%3DM.%26aulast%3DCastanedo%26aufirst%3DG.%26aulast%3DChuckowree%26aufirst%3DI.%26aulast%3DDotson%26aufirst%3DJ.%26aulast%3DFolks%26aufirst%3DA.%26aulast%3DFriedman%26aufirst%3DL.%26aulast%3DGoldsmith%26aufirst%3DR.%26aulast%3DGunzner%26aufirst%3DJ.%26aulast%3DHeffron%26aufirst%3DT.%26aulast%3DLesnick%26aufirst%3DJ.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DMathieu%26aufirst%3DS.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DPegg%26aufirst%3DN.%26aulast%3DPrior%26aufirst%3DW.%2BW.%26aulast%3DRouge%26aufirst%3DL.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DTian%26aufirst%3DQ.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DWan%26aufirst%3DN.%2BC.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DP.%26aulast%3DZhu%26aufirst%3DB.-Y.%26aulast%3DOlivero%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520a%2520potent%252C%2520selective%252C%2520and%2520orally%2520available%2520class%2520I%2520phosphatidylinositol%25203-kinase%2520%2528PI3K%2529%252Fmammalian%2520target%2520of%2520rapamycin%2520%2528mTOR%2529%2520kinase%2520inhibitor%2520%2528GDC-0980%2529%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7579%26epage%3D7587" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Sutherland, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raymond, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, D. E.</span><span> </span><span class="NLM_article-title">Relating molecular properties and in vitro assay results to in vivo drug disposition and toxicity outcomes</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">6455</span><span class="NLM_x">–</span> <span class="NLM_lpage">6466</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm300684u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm4003632&amp;key=1%3ACAS%3A528%3ADC%252BC38XovFartbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6455-6466&author=J.+J.+Sutherlandauthor=J.+W.+Raymondauthor=J.+L.+Stevensauthor=T.+K.+Bakerauthor=D.+E.+Watson&title=Relating+molecular+properties+and+in+vitro+assay+results+to+in+vivo+drug+disposition+and+toxicity+outcomes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Relating Molecular Properties and in Vitro Assay Results to in Vivo Drug Disposition and Toxicity Outcomes</span></div><div class="casAuthors">Sutherland, Jeffrey J.; Raymond, John W.; Stevens, James L.; Baker, Thomas K.; Watson, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6455-6466</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A primary goal of lead optimization is to identify compds. with improved absorption, distribution, metab., excretion, and toxicity (ADMET) properties.  A no. of reports have linked computed mol. properties to desirable in vivo ADMET outcomes, but a significant limitation of these analyses is the failure to control statistically for possible covariates.  We examine the relationship between mol. properties and in vitro surrogate assays vs in vivo properties within 173 chem. series from a database of 3773 compds. with rodent pharmacokinetic and toxicol. data.  This approach identifies the following pairs of surrogates as most predictive among those examd.: rat primary hepatocyte (RPH) cytolethality/vol. of distribution (Vd) for in vivo toxicol. outcomes, scaled microsome metab./calcd. logP for in vivo unbound clearance, and calcd. logD/kinetic aq. soly. for thermodn. soly.  The impact of common functional group substitutions is examd. and provides insights for compd. design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrg26RzgGVyjbVg90H21EOLACvtfcHk0lh8KP1ixcCU2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XovFartbk%253D&md5=e4465539015fef12c20b59d529b5b5cb</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm300684u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300684u%26sid%3Dliteratum%253Aachs%26aulast%3DSutherland%26aufirst%3DJ.%2BJ.%26aulast%3DRaymond%26aufirst%3DJ.%2BW.%26aulast%3DStevens%26aufirst%3DJ.%2BL.%26aulast%3DBaker%26aufirst%3DT.%2BK.%26aulast%3DWatson%26aufirst%3DD.%2BE.%26atitle%3DRelating%2520molecular%2520properties%2520and%2520in%2520vitro%2520assay%2520results%2520to%2520in%2520vivo%2520drug%2520disposition%2520and%2520toxicity%2520outcomes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6455%26epage%3D6466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="note"><p class="first last">The cLogD<sub>7.4</sub> values were calculated using MoKa software (version 1.1.0, Molecular Discovery).</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Blaquiere, N.; Do, S.; Dudley, D.; Folkes, A. J.; Heald, R.; Heffron, T.; Jones, M.; Kolesnikov, A.; Ndubaku, C.; Olivero, A. G.; Price, S.; Staben, S.; Wang, L.</span><span> </span><span class="NLM_article-title">Benzoxazepin PI3K Inhibitor Compounds and Methods of Use</span>. PCT Int. Appl.<span class="NLM_x"> </span><span class="NLM_year">2011</span><span class="NLM_x">, </span>WO/2011036280/A1.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=N.+Blaquiere&author=S.+Do&author=D.+Dudley&author=A.+J.+Folkes&author=R.+Heald&author=T.+Heffron&author=M.+Jones&author=A.+Kolesnikov&author=C.+Ndubaku&author=A.+G.+Olivero&author=S.+Price&author=S.+Staben&author=L.+Wang&title=Benzoxazepin+PI3K+Inhibitor+Compounds+and+Methods+of+Use"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBlaquiere%26aufirst%3DN.%26atitle%3DBenzoxazepin%2520PI3K%2520Inhibitor%2520Compounds%2520and%2520Methods%2520of%2520Use%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Iddon, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, B. L.</span><span> </span><span class="NLM_article-title">Reactions of 1,2-dimethylimidazole, particularly its metallation</span> <span class="citation_source-journal">J. Chem. Soc., Perkin Trans. 1</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1983</span><span class="NLM_x">, </span> <span class="NLM_fpage">271</span><span class="NLM_x">–</span> <span class="NLM_lpage">277</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1983&pages=271-277&author=B.+Iddonauthor=B.+L.+Lim&title=Reactions+of+1%2C2-dimethylimidazole%2C+particularly+its+metallation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DIddon%26aufirst%3DB.%26aulast%3DLim%26aufirst%3DB.%2BL.%26atitle%3DReactions%2520of%25201%252C2-dimethylimidazole%252C%2520particularly%2520its%2520metallation%26jtitle%3DJ.%2520Chem.%2520Soc.%252C%2520Perkin%2520Trans.%25201%26date%3D1983%26spage%3D271%26epage%3D277" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Bellina, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cauteruccio, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossi, R.</span><span> </span><span class="NLM_article-title">Efficient and practical synthesis of 4(5)-aryl-1<i>H</i>-imidazoles and 2,4(5)-diaryl-1<i>H</i>-imidazoles via highly selective palladium-catalyzed arylation reactions</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">8543</span><span class="NLM_x">–</span> <span class="NLM_lpage">8546</span></span><div class="citationLinks">[<a href="/doi/10.1021/jo701496p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2007&pages=8543-8546&author=F.+Bellinaauthor=S.+Cauteruccioauthor=R.+Rossi&title=Efficient+and+practical+synthesis+of+4%285%29-aryl-1H-imidazoles+and+2%2C4%285%29-diaryl-1H-imidazoles+via+highly+selective+palladium-catalyzed+arylation+reactions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjo701496p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo701496p%26sid%3Dliteratum%253Aachs%26aulast%3DBellina%26aufirst%3DF.%26aulast%3DCauteruccio%26aufirst%3DS.%26aulast%3DRossi%26aufirst%3DR.%26atitle%3DEfficient%2520and%2520practical%2520synthesis%2520of%25204%25285%2529-aryl-1H-imidazoles%2520and%25202%252C4%25285%2529-diaryl-1H-imidazoles%2520via%2520highly%2520selective%2520palladium-catalyzed%2520arylation%2520reactions%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2007%26volume%3D72%26spage%3D8543%26epage%3D8546" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Martinelli, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freckmann, D. M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchwald, S. L.</span><span> </span><span class="NLM_article-title">Convenient method for the preparation of weinreb amides via Pd-catalyzed aminocarbonylation of aryl bromides at atmospheric pressure</span> <span class="citation_source-journal">Org. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">4843</span><span class="NLM_x">–</span> <span class="NLM_lpage">4846</span></span><div class="citationLinks">[<a href="/doi/10.1021/ol061902t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2006&pages=4843-4846&author=J.+R.+Martinelliauthor=D.+M.+M.+Freckmannauthor=S.+L.+Buchwald&title=Convenient+method+for+the+preparation+of+weinreb+amides+via+Pd-catalyzed+aminocarbonylation+of+aryl+bromides+at+atmospheric+pressure"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fol061902t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol061902t%26sid%3Dliteratum%253Aachs%26aulast%3DMartinelli%26aufirst%3DJ.%2BR.%26aulast%3DFreckmann%26aufirst%3DD.%2BM.%2BM.%26aulast%3DBuchwald%26aufirst%3DS.%2BL.%26atitle%3DConvenient%2520method%2520for%2520the%2520preparation%2520of%2520weinreb%2520amides%2520via%2520Pd-catalyzed%2520aminocarbonylation%2520of%2520aryl%2520bromides%2520at%2520atmospheric%2520pressure%26jtitle%3DOrg.%2520Lett.%26date%3D2006%26volume%3D8%26spage%3D4843%26epage%3D4846" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Hammerich, O.</span><span> </span><span class="NLM_article-title">Anodic oxidation of hydrocarbons</span>.  <span class="citation_source-book">Organic Electrochemistry</span>, <span class="NLM_edition">4</span>th ed.; <span class="NLM_contrib-group">Lund, H.; Hammerich, O.</span>, Eds.; <span class="NLM_publisher-name">Marcel Dekker</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2001</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">471</span><span class="NLM_x">–</span> <span class="NLM_lpage">498</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2001&pages=471-498&author=O.+Hammerichauthor=H.+Lund&author=O.+Hammerich&title=Organic+Electrochemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DHammerich%26aufirst%3DO.%26atitle%3DAnodic%2520oxidation%2520of%2520hydrocarbons%26btitle%3DOrganic%2520Electrochemistry%26aulast%3DLund%26aufirst%3DH.%26pub%3DMarcel%2520Dekker%26date%3D2001%26spage%3D471%26epage%3D498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Cruciani, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carosati, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Boeck, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ethirajulu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mackie, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howe, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vianello, R.</span><span> </span><span class="NLM_article-title">MetaSite: Understanding metabolism in human cytochromes from the perspective of the chemist</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">6970</span><span class="NLM_x">–</span> <span class="NLM_lpage">6979</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm050529c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6970-6979&author=G.+Crucianiauthor=E.+Carosatiauthor=B.+De+Boeckauthor=K.+Ethirajuluauthor=C.+Mackieauthor=T.+Howeauthor=R.+Vianello&title=MetaSite%3A+Understanding+metabolism+in+human+cytochromes+from+the+perspective+of+the+chemist"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm050529c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050529c%26sid%3Dliteratum%253Aachs%26aulast%3DCruciani%26aufirst%3DG.%26aulast%3DCarosati%26aufirst%3DE.%26aulast%3DDe%2BBoeck%26aufirst%3DB.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DMackie%26aufirst%3DC.%26aulast%3DHowe%26aufirst%3DT.%26aulast%3DVianello%26aufirst%3DR.%26atitle%3DMetaSite%253A%2520Understanding%2520metabolism%2520in%2520human%2520cytochromes%2520from%2520the%2520perspective%2520of%2520the%2520chemist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D6970%26epage%3D6979" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="note"><p class="first last">Detailed information provided in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="note"><p class="first last">Data from additional pharmacokinetic experiments, human dose predictions, and preclinical safety assessments conducted with <b>11l</b> will be the subject of future reports.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Wallin, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prior, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berry, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belmont, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koeppen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belvin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sampath, D.</span><span> </span><span class="NLM_article-title">GDC-0941, a novel class I selective PI3K inhibitor, enhances the efficacy of docetaxel in human breast cancer models by increasing cell death in vitro and in vivo</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">3901</span><span class="NLM_x">–</span> <span class="NLM_lpage">3911</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Fjm4003632&amp;key=10.1158%2F1078-0432.CCR-11-2088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Fjm4003632&amp;key=22586300" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm4003632&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVelurzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=3901-3911&author=J.+J.+Wallinauthor=J.+Guanauthor=W.+W.+Priorauthor=L.+B.+Leeauthor=L.+Berryauthor=L.+D.+Belmontauthor=H.+Koeppenauthor=M.+Belvinauthor=L.+S.+Friedmanauthor=D.+Sampath&title=GDC-0941%2C+a+novel+class+I+selective+PI3K+inhibitor%2C+enhances+the+efficacy+of+docetaxel+in+human+breast+cancer+models+by+increasing+cell+death+in+vitro+and+in+vivo"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">GDC-0941, a Novel Class I Selective PI3K Inhibitor, Enhances the Efficacy of Docetaxel in Human Breast Cancer Models by Increasing Cell Death In Vitro and In Vivo</span></div><div class="casAuthors">Wallin, Jeffrey J.; Guan, Jane; Prior, Wei Wei; Lee, Leslie B.; Berry, Leanne; Belmont, Lisa D.; Koeppen, Hartmut; Belvin, Marcia; Friedman, Lori S.; Sampath, Deepak</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3901-3911</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Docetaxel is a front-line std.-of-care chemotherapeutic drug for the treatment of breast cancer.  Phosphoinositide 3-kinases (PI3K) are lipid kinases that regulate breast tumor cell growth, migration, and survival.  The current study was intended to det. whether GDC-0941, an orally bioavailable class I selective PI3K inhibitor, enhances the antitumor activity of docetaxel in human breast cancer models in vitro and in vivo.  Exptl. Design: A panel of 25 breast tumor cell lines representing HER2+, luminal, and basal subtypes were treated with GDC-0941, docetaxel, or the combination of both drugs and assayed for cellular viability, modulation of PI3K pathway markers, and apoptosis induction.  Drug combination effects on cellular viability were also assessed in nontransformed MCF10A human mammary epithelial cells.  Human xenografts of breast cancer cell lines and patient-derived tumors were used to assess efficacy of GDC-0941 and docetaxel in vivo.  Results: Combination of GDC-0941 and docetaxel decreased the cellular viability of breast tumor cell lines in vitro but to variable degrees of drug synergy.  Compared with nontransformed MCF10A cells, the addn. of both drugs resulted in stronger synergistic effects in a subset of tumor cell lines that were not predicted by breast cancer subtype.  In xenograft models, GDC-0941 enhanced the antitumor activity of docetaxel with max. combination efficacy obsd. within 1 h of administering both drugs.  GDC-0941 increased the rate of apoptosis in cells arrested in mitosis upon cotreatment with docetaxel.  Conclusion: GDC-0941 augments the efficacy of docetaxel by increasing drug-induced apoptosis in breast cancer models.  Clin Cancer Res; 18(14); 3901-11. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6QHWx5T7bgrVg90H21EOLACvtfcHk0lgFQj6k57Erww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVelurzF&md5=88b5534aade0580d6908710ffed87599</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-2088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-2088%26sid%3Dliteratum%253Aachs%26aulast%3DWallin%26aufirst%3DJ.%2BJ.%26aulast%3DGuan%26aufirst%3DJ.%26aulast%3DPrior%26aufirst%3DW.%2BW.%26aulast%3DLee%26aufirst%3DL.%2BB.%26aulast%3DBerry%26aufirst%3DL.%26aulast%3DBelmont%26aufirst%3DL.%2BD.%26aulast%3DKoeppen%26aufirst%3DH.%26aulast%3DBelvin%26aufirst%3DM.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DSampath%26aufirst%3DD.%26atitle%3DGDC-0941%252C%2520a%2520novel%2520class%2520I%2520selective%2520PI3K%2520inhibitor%252C%2520enhances%2520the%2520efficacy%2520of%2520docetaxel%2520in%2520human%2520breast%2520cancer%2520models%2520by%2520increasing%2520cell%2520death%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D3901%26epage%3D3911" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Wallin, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edgar, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berry, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prior, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesnick, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nonomiya, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salphati, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivero, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutherlin, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spoerke, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lensun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kassees, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lackner, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sampath, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belvin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, L. S.</span><span> </span><span class="NLM_article-title">GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">2426</span><span class="NLM_x">–</span> <span class="NLM_lpage">2436</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm4003632&amp;key=10.1158%2F1535-7163.MCT-11-0446" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Fjm4003632&amp;key=21998291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm4003632&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFylurfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=2426-2436&author=J.+J.+Wallinauthor=K.+A.+Edgarauthor=J.+Guanauthor=M.+Berryauthor=W.+W.+Priorauthor=L.+Leeauthor=J.+D.+Lesnickauthor=C.+Lewisauthor=J.+Nonomiyaauthor=J.+Pangauthor=L.+Salphatiauthor=A.+G.+Oliveroauthor=D.+P.+Sutherlinauthor=C.+O%E2%80%99Brienauthor=J.+M.+Spoerkeauthor=S.+Patelauthor=L.+Lensunauthor=R.+Kasseesauthor=L.+Rossauthor=M.+R.+Lacknerauthor=D.+Sampathauthor=M.+Belvinauthor=L.+S.+Friedman&title=GDC-0980+is+a+novel+class+I+PI3K%2FmTOR+kinase+inhibitor+with+robust+activity+in+cancer+models+driven+by+the+PI3K+pathway"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway</span></div><div class="casAuthors">Wallin, Jeffrey J.; Edgar, Kyle A.; Guan, Jane; Berry, Megan; Prior, Wei Wei; Lee, Leslie; Lesnick, John D.; Lewis, Cristina; Nonomiya, Jim; Pang, Jodie; Salphati, Laurent; Olivero, Alan G.; Sutherlin, Daniel P.; O'Brien, Carol; Spoerke, Jill M.; Patel, Sonal; Lensun, Letitia; Kassees, Robert; Ross, Leanne; Lackner, Mark R.; Sampath, Deepak; Belvin, Marcia; Friedman, Lori S.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2426-2436</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Alterations of the phosphoinositide-3 kinase (PI3K)/Akt signaling pathway occur broadly in cancer via multiple mechanisms including mutation of the PIK3CA gene, loss or mutation of phosphatase and tensin homolog (PTEN), and deregulation of mammalian target of rapamycin (mTOR) complexes.  The dysregulation of this pathway has been implicated in tumor initiation, cell growth and survival, invasion and angiogenesis, thus, PI3K and mTOR are promising therapeutic targets for cancer.  We discovered GDC-0980, a selective, potent, orally bioavailable inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2) with excellent pharmacokinetic and pharmaceutical properties.  GDC-0980 potently inhibits signal transduction downstream of both PI3K and mTOR, as measured by pharmacodynamic (PD) biomarkers, thereby acting upon two key pathway nodes to produce the strongest attainable inhibition of signaling in the pathway.  Correspondingly, GDC-0980 was potent across a broad panel of cancer cell lines, with the greatest potency in breast, prostate, and lung cancers and less activity in melanoma and pancreatic cancers, consistent with KRAS and BRAF acting as resistance markers.  Treatment of cancer cell lines with GDC-0980 resulted in G1 cell-cycle arrest, and in contrast to mTOR inhibitors, GDC-0980 induced apoptosis in certain cancer cell lines, including those with direct pathway activation via PI3K and PTEN.  Low doses of GDC-0980 potently inhibited tumor growth in xenograft models including those with activated PI3K, loss of LKB1 or PTEN, and elicited an exposure-related decrease in PD biomarkers.  These preclin. data show that GDC-0980 is a potent and effective dual PI3K/mTOR inhibitor with promise for the clinic.  Mol Cancer Ther; 10(12); 2426-36.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4yjwxW7TM3bVg90H21EOLACvtfcHk0lgFQj6k57Erww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFylurfJ&md5=756410aaf86377284a63d8ee70ad36ec</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0446&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0446%26sid%3Dliteratum%253Aachs%26aulast%3DWallin%26aufirst%3DJ.%2BJ.%26aulast%3DEdgar%26aufirst%3DK.%2BA.%26aulast%3DGuan%26aufirst%3DJ.%26aulast%3DBerry%26aufirst%3DM.%26aulast%3DPrior%26aufirst%3DW.%2BW.%26aulast%3DLee%26aufirst%3DL.%26aulast%3DLesnick%26aufirst%3DJ.%2BD.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DOlivero%26aufirst%3DA.%2BG.%26aulast%3DSutherlin%26aufirst%3DD.%2BP.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DC.%26aulast%3DSpoerke%26aufirst%3DJ.%2BM.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DLensun%26aufirst%3DL.%26aulast%3DKassees%26aufirst%3DR.%26aulast%3DRoss%26aufirst%3DL.%26aulast%3DLackner%26aufirst%3DM.%2BR.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DBelvin%26aufirst%3DM.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26atitle%3DGDC-0980%2520is%2520a%2520novel%2520class%2520I%2520PI3K%252FmTOR%2520kinase%2520inhibitor%2520with%2520robust%2520activity%2520in%2520cancer%2520models%2520driven%2520by%2520the%2520PI3K%2520pathway%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2011%26volume%3D10%26spage%3D2426%26epage%3D2436" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm4003632&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Fjm4003632%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2013.56.issue-11%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm4003632" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679973459d543c88","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
